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ABSTRACT
‘Activated’ mesangial cells (MC) may play a direct role in mediating glomerular 
inflammation via the generation of inflammatory mediators. The potential of human 
MC to express chemokines, and the molecular mechanisms regulating MC cytokine 
production were investigated. In addition to the neutrophil chemoattractant IL- 8  and 
monocyte chemoattractant MCP-1, cultured MC produce the chemotactic factor for 
CD45RO/CD4+ T lymphocytes, RANTES following stimulation with IL-1 or TNF. The 
kinetics and specificity of RANTES expression was markedly different to that of IL- 8  or 
MCP-1, RANTES was expressed later and TNF was the more potent stimulant. A 
difference in the kinetics of chemokine expression following IL-1 or TNF stimulation 
was also evident.
The intracellular second messenger, cAMP differentially regulated MC cytokine 
production. cAMP-elevating agents upregulated IL-1 induced IL-6 , downregulated 
TNF induced RANTES and had no effect on IL-1 or TNF induced IL- 8  production. The 
regulatory effects of cAMP on IL-1 induced IL- 6  were occurring at the level of gene 
expression. cAMP did not modify IL- 6  mRNA stability indicating the mechanism of 
regulation was at the level of transcription.
Pretreatment of MC with pertussis toxin (PT), an agent widely employed as a 
tool to investigate the role of heterotrimeric Gj/ 0  type proteins in signalling mechanisms, 
resulted in partial inhibition of IL-1 induced IL- 8  and IL- 6  production. The purified B 
oligomer of PT and mutated forms of the toxin however, were equally inhibitory 
indicating the mechanism of PT inhibition was independent of G protein modification 
by ADP-ribosylation.
Inducible nitric oxide synthase (iNOS) mRNA and protein expression was 
observed in human MC after stimulation with a combination of cytokines, IL-1 and 
IFN-y, single cytokines were ineffective. Production of NO however, could not be 
readily detected, indicating complex regulation of iNOS activity. Furthermore, the 
specificity of iNOS induction in human MC indicates NO may not play a role in IL-1 
signalling for chemokine expression.
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1. INTRODUCTION
1.1. GLOMERULONEPHRITIS
Glomerulonephritis (GN), a major cause of renal failure, is a general term applied to a 
spectrum of disorders that may essentially be considered as immunologically mediated 
injury to glomeruli (Couser, 1993). Although the number of patients receiving dialysis 
and transplantation continues to increase by approximately 1 0 % each year, 
understanding of the pathogenesis and treatment of GN remains at best rudimentary 
despite decades of research in this field. Consequently most of the therapies that are 
used are non-specific with major side effects and offer limited therapeutic benefits for 
the patient (Schlondorff et al. 1995).
An initial step in the induction of glomerular injury is the formation of immune 
complexes within the glomeruli. These may be formed by a number of different 
mechanisms, including deposition of circulating immune complexes, trapping of 
circulating free antigen and subsequent immune complex formation in situ or production 
of antibody to normal antigens in the glomerular basement membrane (GBM) or on 
glomerular cell membranes (Couser, 1993). In the majority of patients with immune 
complex mediated GN, the nature of the antigen involved is not known. Exogenous 
antigens may be derived from viruses, bacteria (e.g. post-streptococcal GN), parasites or 
drugs, while endogenous antigens may include host DNA (e.g. systemic lupus 
erythematosus), an antigen in the glomerular basement membrane (e.g. anti-GBM 
nephritis) or the GP330 protein present on the membrane of glomerular epithelial cells 
(e.g. experimental membranous nephropathy). Increasing evidence suggests that many 
more of the antibody-mediated human glomerular diseases are autoimmune in nature 
than previously suspected, thus genetic factors may play a major role in determining the 
incidence and severity of GN (Bums et al. 1991).
Regardless of how the immune deposits form in glomeruli, they can cause injury by two 





Figure 1. Schem atic representation of the glomerulus. This cross section shows the central core o f  
the glomerulus containing mesangial cells (MC) embedded in extracellular matrix (Ma), which contains 
intercellular channels (IC). A single endothelial cell (En) lines each capillary and fenestration (F) o f  
endothelium (En) allows continuity between capillary lumen and intercellular channels. Epithelial cells 
(Ep) are located outside the glomerular basement membrane (GBM), which incompletely surrounds the 
endothelial wall o f  the capillary loops. (RBC = red blood cell) (From Mene et al, 1989).
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A key role for leukocytes in mediating glomerular injury is based on evidence from 
animal models of GN demonstrating that leukocyte depletion prior to the induction of 
GN attenuates renal injury (Schreiner et al 1978; Tucker et al 1985; Lavelle et al 
1981). Furthermore, immunohistochemial analysis employing monoclonal antibodies 
specific for leukocyte antigens haye shown the presence of neutrophils, macrophages 
and T lymphocytes in many human forms of GN (Rovin & Schreiner, 1991), as well as 
in experimental models (Radounikli et al 1995; Main et al 1992). Typically, 
macrophages were found in much greater numbers than T lymphocytes in inflamed 
glomeruli (Rovin & Schreiner, 1991; Main et al 1992). An investigation of the kinetics 
of leukocyte infiltration in rats with accelerated nephrotoxic serum nephritis (NTN), an 
experimental model of anti-glomerular basement membrane nephritis (Schreiner et al 
1978; Unanue & Dixon, 1965) demonstrated a transient infiltration of neutrophils and a 
sustained increase in monocytes using immunohistology and flow cytometry (Tam et al 
1996). Neutrophil influx was maximal 6  hours after disease induction and returned to 
baseline levels by 24 hours, while monocyte influx was maximal at 24 hours and 
persisted thereafter (>96 hours). Similarly, in the anti-Thy-1 model of 
mesangioproliferative GN in rats (Yamamoto & Wilson, 1987), monocyte/macrophage 
infiltration was pronounced within 30 minutes of antibody injection and was maintained 
up to 3 weeks after the induction of GN (Stahl et al 1993). Infiltrating T lymphocytes 
have been observed in glomeruli at 24 hours (Tipping et al 1985) or 10 days 
(Radounikli et al 1995) after induction of immune complex mediated GN in rats.
Once localised in tissue, leukocytes mediate glomerular injury via the local release of 
inflammatory mediators. Neutrophils release oxidants and proteases which directly 
damage the surrounding tissue (Johnson et al 1994), while macrophages are a rich 
source of a variety of inflammatory mediators including oxidants, prostaglandins, 
leukotrienes, cytokines, polypeptide growth factors, complement components and 
coagulation factors (Nathan, 1987). The role of T lymphocytes is less clear. However, 
the T cell influx appears to be predominantly of the T helper cell subset (CD4+) which 
suggests an involvement in both the initiation and progression of the disease via the 
release of inflammatory cytokines such as interferon-y (IFN-y), interleukin-2 (IL-2), IL-
4
4 and granulocyte/macrophage-colony stimulating factor (GM-CSF) that amplify the 
immune response to a specific antigen (Main et al 1992).
1.1.2. Role of cytokines in glomerulonephritis
Cytokines are locally active, inducible polypeptides of molecular weight greater than 5 
kDa which cause specific, receptor mediated effects in target cells and/or in the cytokine 
producing cells themselves. The cell to cell communication via released cytokines is a 
key event in the initiation and development of inflammatory diseases (Sedor, 1992). 
Tissue injury elicits a network of cytokines and growth factors and as most cytokines 
are multifunctional, both redundancy and specificity exists within the network (Akira et 
al 1990a). The resulting tissue response ultimately reflects an integration of the 
molecular mechanisms initiated by cytokine interactions.
The expression of cytokines and/or their specific receptors in glomeruli of animals or 
patients undergoing renal injury has suggested their involvement in the pathogenesis of 
experimental and human glomerular disease (Sedor, 1992). Cytokines are involved in 
both the early and late stages of GN, with proinflammatory cytokines such as IL-1 and 
tumour necrosis factor (TNF) important in initiating the disease, while growth factors 
such as platelet derived growth factor (PDGF) and transforming growth factor P (TGFp) 
may play a role in its progression to sclerosis, characterized by mesangial cell 
proliferation and extracellular matrix expansion (Isaka et al 1993).
1.1.2.1. Interleukin-1 and tumour necrosis factor
IL-1 and TNF are pleiotropic cytokines which are involved in the regulation of the 
immune response, hematopoiesis, and inflammation (Le & Vilcek, 1987). IL-1 is one of 
the most potent and multifunctional activators of cells so far described (O'Neill, 1995), 
and despite being biochemically and immunologically distinct proteins, IL-1 and TNF 
show striking similarity in the broad range of biological activities they induce (Le & 
Vilcek, 1987). Both cause acute inflammation when injected locally in vivo, and have 
similar proinflammatory activities in vitro. Several of the activities of IL-1 and TNF 
are due to the induction of secondary proteins in the target cells.
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EL-1 and TNF are synthesized by monocytes and macrophages, and while these cells are 
thought to be the principle cellular source of TNF, IL-1 production has been 
demonstrated in a wide range of immune and non-immune cells, including epithelial, 
endothelial and mesangial cells (Oppenheim et al 1986). Three forms of IL-1 have 
been identified, IL-1 a, IL-1 (3 and IL-1 receptor antagonist (IL-lra). IL-1 a  and IL-1 (3 
have 26% homology at the amino acid level. Both forms bind to the same cell surface 
receptors and induce similar biological activities (Le & Vilcek, 1987). The principal 
difference between the two forms is that IL-1 a  is membrane bound, while EL-lp, the 
predominant form, is released into the surrounding medium (Abbott et a l 1992). IL-lra 
is structurally related to EL-l a  and EL-1(3, but binds to the IL-1 receptors without 
inducing any discernible biological response and thus functions as a naturally occurring, 
specific receptor antagonist (Arend, 1991). TNF is structurally and functionally related 
to lymphotoxin, a protein produced by activated T lymphocytes, which binds to and 
signals via the TNF receptors (Fiers, 1991). Lymphotoxin is sometimes referred to as 
TNFp, while the ‘original’ TNF is termed TNFa.
A number of studies have implicated an involvement of IL-1 and TNF in the 
pathogenesis of experimental and human glomerular injury (Sedor, 1992; Baud & 
Ardaillou, 1994). Steady state IL-1 and TNF mRNA expression was increased in renal 
cortex from mice with experimental nephritis (Boswell et a l 1988). 
Immunohistochemical analysis demonstrated IL-1 and TNF positive cells within the 
mesangium of glomeruli during acute aminonucleoside nephrosis, which appeared to 
originate mainly from infiltrating macrophages (Diamond & Pesek, 1991). 
Furthermore, glomeruli purified from rat kidneys with experimentally induced nephritis 
have been found to release IL-1 and TNF when incubated ex vivo (Baud & Ardaillou, 
1994; Matsumoto & Hatano, 1995), and cytokine production was dependent on 
macrophage infiltration (Tipping et al 1991). Finally, administration of anti-TNF 
antibody (Mulligan et a l 1993; Hruby et al 1991) or IL-lra (Lan et a l 1993) resulted in 
reduced glomerular injury in experimental anti-GBM nephritis.
6
1.1.2.2. Interleukin-6
IL- 6  is another multifunctional cytokine which has been found to have growth and 
differentiation activities on a wide variety of tissues and cells. The biological activities 
of IL- 6  include stimulation of B-cell differentiation, induction of acute phase proteins in 
liver cells, growth-promotion of myeloma cells and the induction of IL-2 and IL-2 
receptor expression, proliferation and differentiation in T cells. Many cells are able to 
synthesize IL- 6  after appropriate stimulation, and major cellular sources are 
monocytes/macrophages, fibroblast and endothelial cells (Hirano et al. 1990).
IL- 6  has been implicated in the pathogenesis of mesangioproliferative GN (Horii et al
1993). This type of GN is histologically characterized by proliferation of resident 
glomerular MC, suggesting the involvement of a MC growth factor in the pathogenesis 
of the disease. IL- 6  was shown to induce proliferation of cultured rat MC (Horii et al. 
1989; Ruef et al 1990), and may function as an autocrine growth factor, since rat and 
human MC in vitro produce IL- 6  upon appropriate stimulation (Horii et al 1989; Ruef 
et al 1990; Abbott et al 1991; Brown et al 1991a). In vivo evidence comes from 
patients with mesangioproliferative glomerulonephritis showing in 50% of the cases 
significantly elevated urinary IL-6 , which was not detected in healthy volunteers or 
patients with other glomerulopathies (Horii et al 1989). A positive correlation between 
urinary IL- 6  and the severity of the disease was observed in the study. Immunostaining 
of biopsy samples from patients with proliferative GN demonstrated IL- 6  production, 
which was mainly localised in the glomerular mesangium (Horii et al 1989). 
Furthermore, overexpression of IL- 6  in transgenic mice (C57BL/6), produced by fusing 
the human IL- 6  genomic gene with the immunoglobulin heavy chain enhancer (Ep), 
resulted in development of mesangioproliferative GN, along with massive 
plasmacytosis (Suematsu et al 1989).
In addition to IL-6 , a number of other cytokines and growth factors have been 
implicated as MC mitogens, or co-mitogens. These include IL-1, insulin-like growth 
factor 1 (IGF1), basic fibroblast growth factor (bFGF), PDGF and epidermal growth 
factor (EGF) (Kashgarian & Sterzel, 1992). PDGF has been reported to induce the 
proliferation of cultured rat (Shultz et al 1988) and human (Floege et al 1991) MC, and
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platelet depletion prior to the induction of experimental mesangioproliferative GN was 
found to partially reduce proliferation of resident glomerular cells (Johnson et al 1990).
In contrast to the potential pathological role of IL- 6  in mesangioproliferative GN, a 
recent study has suggested IL- 6  may have therapeutic effects in other forms of 
glomerular injury. Pretreatment of rats with IL- 6  did not exacerbate glomerular injury 
in the NTN model of GN, instead it largely abrogated the ability of lipopolysaccharide 
(LPS) to enhance injury (Karkar et al. 1993). An ability of IL- 6  to down-regulate IL-1 
and TNF synthesis by LPS stimulated macrophages in vitro (Aderka et al. 1989; 
Schindler et al. 1990) may explain the anti-inflammatory properties of IL- 6  in this 
model, and IL- 6  treatment was associated with a marked reduction in glomerular IL-1 
and TNF mRNA expression.
1.2. CHEMOKINES
The migration of leukocytes from the circulation to an extravascular site of injury is a 
multi-step process that requires a series of co-ordinated signals, including the expression 
and activation of cellular adhesion molecules and the generation of chemotactic 
gradients by the cells of the extravascular compartment (Adams & Shaw, 1994). Recent 
advances in understanding leukocyte migration have come from the discovery of a 
superfamily of chemotactic factors, collectively known as the chemokines (Lindley et 
al 1993; Baggiolini et al 1994). Members of this family are small (<10 kDa), basic, 
heparin-binding proteins which are structurally related by possessing four conserved 
cysteine residues that form two disulphide bonds and establish the tertiary structure of 
the protein. The chemokines are divided into two sub-families based on the position of 
the first two cysteine residues in the molecule (Fig. 2). In the C-X-C sub-family, the 
first two cysteine residues are separated by an intervening amino-acid and the genes 
encoding this group of proteins are clustered on human chromosome 4. The C-C sub­
family possess adjacent cysteine residues and are clustered on human chromosome 17. 
The key feature of this family is their ability to attract subsets of leukocytes in a 
relatively specific manner. In general the C-X-C chemokines, of which IL- 8  is a
8
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Figure 2. Organisation of the chemokine superfamily. Diagrammatic representation o f  the mature 
protein structures o f  C-X-C and C-C chemokines. The number o f  intervening amino acids between the 
cysteine residues in a typical human chemokine is denoted by the subscript. The designations for the 
m olecules listed are those o f the human chemokines, except for murine CIO and 17 where no human 
molecule has yet been identified. The line connecting CTAP III, 0-TG and NAP-2 to PBP indicates that 
these proteins are thought to be derived from a common precursor. (NAP-4) and (P500) are chemokine 
variants that lack some o f the cysteines in the characteristic four-cysteine motif. In the diagram showing 
the two loop structure o f human chemokines, the amino acids in one letter codes are A=Ala; C=Cys; 
D=Asp; E=Glu; F=Phe; G=Gly; H=His; I=Ile; K=Lys; M=Met; N=Asn; P=Pro; Q=Gln; R=Arg; S=Ser; 
T=Thr; V=Val; W=Trp; Y=Tyr (Modified from Schall et al, 1994, Baggiolini et al, 1994).
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prominent member (Baggiolini et al 1989), attract and activate neutrophils, while the 
C-C molecules, which include monocyte chemotactic protein-1 (MCP-1) and RANTES 
(Regulated on Activation, Normal T cell Expressed and Secreted) preferentially act on 
mononuclear cells (Table 1). MCP-1 is a potent chemoattractant for 
monocytes/macrophages (Leonard & Yoshimura, 1990), and more recently was been 
found to be chemotactic for CD4+ and CD8+ T lymphocytes (Loetscher et al 1994; 
Taub et al 1995). In addition to monocytes, RANTES is a selective chemotactic agent 
for CD45RO/CD4+ T cells (memory T cells) (Schall et al 1990) and eosinophils 
(Kameyoshi et al 1992) (Table 2). Unlike the C-C sub-family, the C-X-C chemokines 
can be further divided into proteins which contain or lack an ELR motif. The ELR 
motif represents three amino acids, Glu-Leu-Arg that immediately precede the first 
cysteine residue in the molecule. This motif is important in receptor/ligand interactions 
on neutrophils, thus chemokines which lack this motif (PF4, IP 10 and Mig) are only 
weak neutrophil chemoattractants. Production of the chemokines is not limited to 
immune cells, with a spectrum of tissue cells (i.e. fibroblasts, endothelial cells and MC) 
capable of expressing these cytokines upon appropriate stimulation (e.g. IL-1, TNF, 
LPS) (Baggiolini et al 1994).
A new class of chemokine, designated the C sub-family has recently been proposed, 
following the discovery of lymphotactin (Kelner et al 1994). Lymphotactin is 
structurally similar to members of both the C-C and C-X-C sub-families, but lacks two 
of the four characteristic cysteine residues (lacks cysteines 1 and 3). Furthermore, the 
gene encoding lymphotactin is located on human chromosome 1. Lymphotactin is 
unique in that it is chemotactic for lymphocytes, but not monocytes or neutrophils, and 
lymphotactin is abundantly produced by CD8+ T cells.
Chemokines participate at several levels of the multi-step process that regulates 
leukocyte migration into injured tissue. The migration process is defined by four 
sequential steps: rolling, triggering, adhesion and migration (Fig. 3) (Adams & Shaw,
1994). Rolling interactions between leukocytes and endothelium cause circulating cells 
to slow their flow and roll along the vessel wall. Rolling is mediated by selectins, 
which are expressed on both leukocytes and endothelium. This initial adhesive
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Neutrophils Monocytes
PF4 (C-X-C) MCP-1 (C-C)
IL-8 (C-X-C) MCP-2 (C-C)
NAP-2 (C-X-C) MCP-3 (C-C)
MGSA/gro-a (C-X-C) RANTES (C-C)
GCP-2 (C-X-C) M IP-la (C-C)




Based on purified recombinant or natural material.
Table 1. Chemokines which are active on neutrophils and monocytes in vitro.
T Cells B Cells Eosinophils Basophils Fibroblasts
PF4 (C-X-C) +
p-TG (C-X-C) +
IL-8 (C-X-C) + -
IP-10 (C-X-C) +
RANTES (C-C) + - + +
MCP-1 (C-C) + +
M IP-la (C-C) + + + ±
M IP-ip (C-C) + - “ “
Table 2. Chemoattractant effects in vitro o f chemokines for cells other than m onocytes and 
neutrophils.
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interaction is transient in nature and functions to allow leukocytes to sample the local 
endothelium for the presence of specific ‘triggering factors’ that activate leukocyte 
integrins and allow the adhesion cascade to continue. In the absence of such factors, 
leukocytes disengage from the endothelium and move on. Chemokines (and other 
cytokines) present on the vessel wall act as triggering factors, converting the 
functionally inactive integrin molecules on the leukocyte to an active, adhesive 
configuration which promote strong adhesion to the endothelium (Tanaka et al 1993). 
During strong adhesion, integrin mediated binding to endothelial cell counter receptors 
results in cessation of movement and flattening of the leukocyte. IL-8 is an important 
example of a neutrophil triggering factor, and is produced either by the endothelium 
itself, or diffuses from the perivascular tissue (Rot, 1992). IL-8 is retained on the vessel 
wall where it acts as an immobilised ligand for the rolling leukocyte. The C-C 
chemokines, MCP-1, macrophage inflammatory protein-la (MIP-la) and RANTES can 
modulate monocyte integrin expression (Vaddi & Newton, 1994), while RANTES and 
MIP-lp activate CD4+ T cell integrins (Gilat et al. 1994). After strong adhesion to the 
endothelium, the leukocytes migrate into tissue along a chemotactic gradient. Many of 
the factors that trigger strong adhesion act as chemoattractants, thus IL-8 and MIP-lp 
induces migration of neutrophils and T cell subsets respectively, maintaining leukocyte 
subset specificity (Adams & Shaw, 1994). Evidence suggests migration may be a result 
of haptotaxis as opposed to chemotaxis (Rot, 1992), thus leukocytes may migrate along 
a gradient of bound substrate, as opposed to a soluble chemotactic gradient that may be 
diluted by flowing blood. The proteoglycan-binding properties of the chemokines may 
be important for their binding to endothelium and extracellular matrix. In addition to 
their chemoattractant capacities, certain chemokines play a role in activation of the 
target cell. Thus IL-8 stimulates the release of lysosomal enzymes, expression of 
complement receptors and increases the formation of leukotriene B4 (LTB4) and 
superoxide by neutrophils (Baggiolini et al 1989).
Recent findings have indicated that chemokines may be involved in systems other than 
leukocyte migration. C-C chemokines have been shown to play a role in T cell 
development and activation, while the C-X-C chemokines are important in angiogenesis 
(Kunkele/tf/. 1995).
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Chemokines bind to an array of shared and specific receptors on blood leukocytes. 
Several chemokine receptors have been cloned and all belong to the family of 
heterotrimeric G protein-coupled receptors, which possess seven transmembrane 
domains (Table 3). Two C-X-C chemokine receptors have been identified, designated 
C-X-C type A (or IL-8R-A) and C-X-C type B (or IL-8R-B) (Holmes et al 1991; 
Murphy & Tiffany, 1991). C-X-C type A is specific for IL-8, while C-X-C type B is a 
shared receptor for the C-X-C chemokines, including IL-8, melanocyte growth 
stimulating activity/gro (MGSA/gro), neutrophil activating protein-2 (NAP-2) and 
epithelial-derived neutrophil attractant-78 (ENA-78). Receptor binding and cross­
desensitisation studies indicate the existence of multiple receptors for C-C chemokines, 
which differ in their pattern of distribution across cell types (Sozzani et al. 1995). To 
date five C-C chemokine receptors have been identified and cloned (Table 3) (Neote et 
al 1993; Charo et al 1994; Myers et al 1995; Combadiere et al 1995a; Power et al 
1995; Hoogewerf et al 1996; Combadiere et al 1995b). The receptors designated C-C 
chemokine receptor 1 (C-C CKR-1) and C-C CKR-2 are the best characterized of these. 
C-C CKR-1 binds MIP-la, RANTES, MIP-ip and MCP-1 with varying affinities, but 
transduces a signal in transfected kidney cells primarily in response to only M IP-la and 
RANTES (Neote et al 1993). C-C CKR-2 is specific for MCP-1 and two forms of the 
receptor exist (type A and B), which have alternatively spliced carboxy terminal tails 
(Charo et al 1994). Furthermore, the Duffy antigen receptor for chemokines (DARC), 
present on human erythrocytes and on endothelial cells lining post-capillary venules in 
the kidney and spleen is a promiscuous receptor, which binds both C-C and C-X-C 
classes, as well as acting as a receptor for the malarial parasite, Plasmodium vivax 
(Hadley et al 1994), The function of the Duffy antigen is not yet clear, however 
expression of this receptor on post-capillary endothelium may play a role in leukocyte 
transmigration by concentrating chemokines at the cell surface for presentation to target 
leukocytes, while the erythrocyte receptor may function as a ‘sink’ that binds and 
inactivates circulating chemokines.
Particular interest in the chemokine family stems from the degree of leukocyte 
specificity they possess, which contrasts with the non-specific action of the classical 
chemotactic factors such as C5a, platelet activating factor (PAF) and LTB4. The
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Basem ent Membrane
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V Chemokines
3. S trong  A dhesion
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Figure 3. Schem atic representation of leukocyte transmigration following activation o f glom erular 
cells.
CH EM O K INE RECEPTORS LIGAND SPECIFICITY
C-X-C type A High affinity for IL-8 
Low affinity for MGSA/gro
C-X-C type B High affinity for IL-8, MGSA/gro, NAP-2, ENA-78
C-C CKR-1 High affinity for M IP-la
Low affinity for RANTES, MCP-1, MCP-3, M IP-lp
C-C CKR-2 Type A and type B: Both high affinity for MCP-1 
Type B also binds MCP-3
C-C CKR-3 Binds eotaxin
C-C CKR-4 Binds M IP-la and RANTES
C-C CKR-5 Binds M IP-la, M IP-ip and RANTES
DARC Promiscuous receptor, binds both C-X-C and C-C (not MIP- 
la )  chemokines
Table 3. C-X-C and C-C chem okine receptors.
14
specificity of the chemokine family may explain in part, the time-dependent 
accumulation of specific leukocyte populations during the course of acute and chronic 
inflammation. Complex interactions between the leukocyte and endothelial cell, 
involving the selective expression of cellular adhesion molecules may also play an 
important role (Adams & Shaw, 1994).
1.2.1. Role of chemokines in glomerulonephritis
A number of studies have implicated a role for chemokines in the pathogenesis of GN. 
Increased expression of MIP-2, MCP-1 and RANTES has been observed in glomeruli 
from rats with experimental mesangioproliferative and anti-GBM disease (Tam et al 
1996; Stahl et al. 1993; Rovin et al 1994b; Thaiss et al 1993). The enhanced 
chemokine expression correlated with the kinetics of leukocyte infiltration (Tam et al 
1996; Stahl et al 1993). More direct evidence comes from a recent report showing 
administration of neutralising antibodies for IL-8 reduced glomerular neutrophil 
infiltration by 40% and completely normalised urinary levels of protein and albumin in 
rabbits with acute immune complex-induced GN (Wada et al 1994a). Similarly, 
administration of anti-MIP-2 or anti-CINC (cytokine-induced neutrophil 
chemoattractant) antiserum to rats with anti-GBM nephritis attenuated neutrophil influx 
and reduced proteinuria (Feng et al 1995; Wu et al 1994).
Evidence of a chemokine involvement in human GN is more limited. Immunostaining 
of patient biopsy samples demonstrated glomerular MCP-1 expression in human 
inflammatory glomerulopathies, but not in glomerular disease lacking a prominent 
monocyte infiltrate (Rovin et al 1994b). Urinary excretion of IL-8 was increased in 
patients with proliferative GN, and this was associated with immunohistological 
detection of IL-8 in diseased glomeruli and the appearance of higher numbers of 
leukocytes (Wada et al 1994b). A role for RANTES in renal inflammation was 
demonstrated by J. Pattison et al (1994), who localised RANTES mRNA and protein in 
infiltrating mononuclear cells and renal tubular epithelium in renal biopsies from 
patients undergoing cell-mediated transplant rejection. Furthermore, increased mRNA 
expression for ENA-78 has been observed during cellular transplant rejection 
(Schmouder et al 1995).
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1.3. NITRIC OXIDE
The free radical nitric oxide (NO) is a labile molecule, which has been identified as 
having important roles in cell communication, cell defence and injury (Moncada et al
1991). NO is synthesized from the terminal guanidino nitrogen of the semi-essential 
amino acid, L-arginine (Fig. 4). This oxidative process is catalysed by a family of 
enzymes termed NO synthases (NOS) (Knowles & Moncada, 1994) and results in the 
formation of NO and L-citrulline. All known isoforms of NOS require reduced 
nicotinamide adenine dinucleotide phosphate (NADPH), flavine dinucleotide (FAD), 
flavine mononucleotide (FMN) and tetrahydrobiopterin (BH4) as cofactors, but vary in 
their dependency for Ca2+ and calmodulin. Three isoforms have been identified, brain 
NOS, endothelial NOS and macrophage NOS, which were cloned from rat cerebellum 
(Bredt et a l 1991), bovine and human vascular endothelial cells (Lamas et a l 1992; 
Janssens et al 1992) and murine macrophages (Lowenstein et al 1992), respectively. 
Brain NOS, which is also present in peripheral neural tissue, and endothelial NOS are 
constitutive enzymes (cNOS) which are calcium and calmodulin dependent. Brain and 
endothelial NOS share -60% homology at the amino acid level, and the cloning of both 
bovine and human endothelial NOS indicates that isoform sequences for the enzyme are 
extremely well conserved between species (-94% homology). Macrophage NOS, which 
is -50% homologous at the amino acid level to endothelial NOS, is calcium and 
calmodulin independent and is not constitutively expressed, but induced (iNOS) by 
certain cytokines and bacterial products (Knowles & Moncada, 1994).
Constitutive and inducible isoforms of NOS differ in their structure and regulation 
(Table 4) (Knowles & Moncada, 1994). Both neuronal and endothelial cNOS enzymes 
are controlled by Ca2+ mobilising agents in a very transient and highly controlled 
fashion. NO production by cNOS is small, nM quantities and short lasting. In marked 
contrast iNOS synthesizes NO in large (pM) amounts and is regulated at the 
transcriptional level (Morris & Billiar, 1994). NO production by iNOS is delayed by 
several hours following stimulation, but once induced, is active for hours and days. 
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Figure 4. Pathways o f L-arginine metabolism via nitric oxide synthase (NOS) and arginase (From 
Cattell and Cook, 1993).
Constitutive Inducible
Both cytosolic (neuronal NOS) and particulate 
(endothelial NOS)
Require NADPH, BH4, FAD, FMN as cofactors
Ca2+/calmodulin dependent
Unaffected by glucocorticoids and inhibitors o f  
DNA transcription/translation
Picomoles o f  NO released (nM concentrations)
Cytosolic
Require NADPH, BH4, FAD, FMN as cofactors
Ca2+/calmodulin independent
Inhibited by glucocorticoids and inhibitors o f  DNA 
transcription/translation
Nanomoles o f NO released (pM concentrations)
Table 4. Comparison of constitutive and inducible NO synthase isoforms.
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such as actinomycin D and cycloheximide (Radomski et al 1990; Pfeilschifter & 
Schwarzenbach, 1990). In addition, glucocorticoids (Radomski et al 1990; 
Pfeilschifter, 1991b) and cytokines such as TGFp (Ding et al 1990), PDGF 
(Pfeilschifter, 1991a), IL-8 (McCall et al 1992) and IL-10 (Cunha et al 1992) have 
been found to inhibit iNOS activity, without affecting cNOS. Constitutive NOS and 
iNOS also show some differences in their affinity for N“-monosubstituted arginine 
analogs, which compete with L-arginine for binding sites in the NO synthase enzymes 
and inhibit their activity (Fig. 5). Constitutive endothelial NOS showed a rank order of 
potency of N 02 > NH2 > CH3 substituted analogs, in comparison to the NH2 > CH3 > 
N 02 order of iNOS (Gross et al 1991; Gross et al 1990). Thus N^-nitro-L-arginine (L- 
NNA) and N“-amino-L-arginine (L-NAA) are more potent inhibitors of cNOS and 
iNOS respectively, while N^-monomethyl-L-arginine (L-NMMA) was found to be an 
effective inhibitor of both NOS isoforms. The L-arginine analogues are selective 
inhibitors of NOS activity, in comparison to other known inhibitors (Table 5) (Knowles 
& Moncada, 1994).
Expression of iNOS has been observed in a diverse range of cell types, including rat 
neutrophils (McCall et al 1989), rat mesangial cells (Pfeilschifter & Schwarzenbach,
1990) and rat renal tubular epithelial cells (Markewitz et al 1993). NOS is induced in 
these cells in response to a number of inflammatory stimuli, including LPS, IFN-y, IL-1 
or TNF, either alone or in combination. At the time of starting this study there was no 
definitive evidence for iNOS expression in human macrophages or any other human cell 
type. The existence of a human iNOS however, was strongly suggested by two lines of 
evidence. Firstly the vasopressor resistant hypotension of septic shock in humans could 
be improved with intravenous administration of the NOS inhibitor, L-NMMA (Petros et 
al 1991). The role of NO as a vasodilator explains these findings. In addition, cancer 
patients receiving cytokine therapy had significantly elevated serum and urine nitrate 
levels, a stable end-product of NO synthesis (Hibbs et al 1992). Metabolic tracer 
studies using L-[guanidino-,5N2}arginine demonstrated the increased nitrate production 
was derived from the terminal guanidino nitrogen atom of L-arginine.
18
L-Arginine N“-M onom ethyl-L -arginine
(L-N M M A )
NH, \
H , N NH
COO
NH,
N “ -A m ino-L-arginine





(L-N N A )
Figure 5. Structure of arginine and the arginine analogues most frequently used as NO synthase 
inhibitors.
Inhibitor type Type of inhibition Comments
Arginine analogues (e.g. L- 
NMMA)
Competitive with arginine Selective
Diphenyleneiodonium Competitive with NADPH Also inhibits some other 
NADPH-enzymes
Calmodulin antagonists (e.g. 
trifluoperazine)
Competitive with calmodulin Only inhibit some NO 
synthases; also inhibit other 
calmodulin-dependent enzymes




NO, CO Not known Probably inhibit by interacting 
with NO synthase haem
Table 5. Types o f NO synthase inhibitors.
NO has numerous physiological and pathophysiological actions (Moncada et al 1991). 
The major roles so far identified are in the control of blood pressure and vascular tone, 
neurotransmission, mediation of macrophage cytotoxicity and inhibition of platelet 
aggregation and adhesion to endothelium. The mechanism for these diverse effects 
involves the local diffusion of NO from generator to target cells, which represents a 
novel signal transduction mechanism between cells. Thus endothelial cNOS can be 
activated by vasodilators such as acetylcholine, bradykinin and ADP, or by shear stress 
forces, all of which result in Ca mobilisation. The NO produced diffuses to 
underlying vascular smooth muscle cells and initiates relaxation by binding to the haem 
moiety of soluble guanylate cyclase, causing enzyme activation and elevation of the 
intracellular second messenger, cyclic guanine-5’-monophosphate (cGMP). Similarly, 
NO generated by endothelial cNOS participates in the regulation of the glomerular 
microcirculation by modifying the tone of the afferent arteriole and mesangial cells 
(Raij & Baylis, 1995). Elevation of intracellular cGMP also mediates the inhibitory 
effects of NO on platelet aggregation, its role as a neurotransmitter in the brain and 
peripheral nervous system and the ability of NO to inhibit leukocyte transmigration and 
adhesion (Moncada et al 1991; Kubes et al. 1991).
NO, when released in large quantities by iNOS activity can inhibit key enzymes by 
nitrosylation of reactive groups, such as iron-sulphur centres (Fe-S) and thiol groups (- 
SH), which are essential for enzyme catalytic function (Molina Y Vedia et al 1992; 
Cattell & Cook, 1993). NO can inhibit enzymes in the mitochondrial electron transport 
chain and citric acid cycle which may account for the cytotoxic and cytostatic effects of 
macrophage-derived NO on tumour cells and micro-organisms. In addition, the anti­
proliferative effects of NO may be due to inhibition of DNA synthesis via inactivation 
of the ribonucleotide reductase enzyme. The cytotoxic activity of NO may play a role in 
tissue injury during inflammatory diseases, and the production of NO can lead to the 
generation of more toxic radicals through its reaction with superoxide, forming 
peroxynitrite, which degrades to form hydroxyl radicals (Beckman et al 1990).
The diverse biological effects of NO therefore depend upon the local concentration of 
NO and the specific location where NO is generated.
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1.3.1. Role of nitric oxide in glomerulonephritis
NO has been associated in the induction and progression of experimental GN. Studies 
have shown glomeruli isolated from rats with immune complex induced GN produce 
increased amounts of nitrite, to micromolar levels when incubated ex vivo (Cattell et al 
1990; Cattell et al 1991). Inducible NOS mRNA expression was elevated in glomeruli 
from rats with accelerated NTN (Cook et al 1994) and iNOS was detected by 
immunohistochemistry in rats with immune complex mediated disease (Jansen et al 
1994). In this latter study, iNOS was detected within the intraglomerular mononuclear 
cells, and the majority of iNOS expressing cells were found to be macrophages. Earlier 
studies by Cattell et al (1991; 1993) have suggested that infiltrating macrophages were 
the major source of glomerular NO during immune injury, since they demonstrated a 
good correlation between nitrite generation and the extent of macrophage infiltration in 
glomeruli from nephritic rats. In addition they found that nitrite was produced by 
macrophages isolated from nephritic glomeruli and that nitrite production was inhibited 
when macrophages were depleted in vivo (Cattell et al 1991; Cattell & Cook, 1993). 
The concomitant participation of intrinsic glomerular cells to increased NO synthesis 
during glomerular inflammation, however cannot be excluded, since iNOS expression 
by rat and bovine mesangial cells in culture has been demonstrated (Pfeilschifter & 
Schwarzenbach, 1990; Marsden & Ballermann, 1990). The relative contribution of 
intrinsic glomerular cells to NO synthesis is difficult to establish since induction of 
NOS in these cells in culture requires cytokines such as IL-1, TNF and IFN-y. Thus 
while primed macrophages may be the main source of NO early during inflammation, 
the release of macrophage-derived cytokines may activate intrinsic glomerular cells to 
synthesise cytokines and express NOS by autocrine and/or paracrine mechanisms. 
Macrophage infiltration may therefore be necessary to trigger iNOS expression in 
intrinsic glomerular cells (Pfeilschifter et al 1993).
The role of NO during glomerular inflammation is unclear, since NO appears to exhibit 
both cytotoxic and cytoprotective effects. The cytotoxic activity of NO has been 
demonstrated in MKL-lpr/lpr mice, which develop glomerulonephritis during the 
course of a spontaneous autoimmune disease. Synthesis of NO is increased in these 
mice and the use of a NOS inhibitor (L-NMMA) attenuated the development of GN
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(Weinberg et al 1994). Studies in the anti-Thy-1 model of mesangioproliferative GN 
showed mesangial cell injury and subsequent accumulation of extracellular matrix were 
both reduced by 90% with NOS inhibition (Narita et al. 1995). In contrast, Waddington 
et al (1996) demonstrated inhibition of iNOS activity using arginase lead to increased 
proteinuria in the NTN model of GN in rats. In the systemic model of the disease, 
administration of arginase also resulted in increased glomerular thrombosis and an 
increase in the severity of histological changes, accompanied by systemic hypertension. 
These later findings suggest NO may have an important role in limiting acute 
glomerular injury in this model of GN.
1.4. GLOMERULAR MESANGIAL CELLS
1.4.1. Cells of the mesangium
The detailed microscopic observation of Zimmerman in 1933 first identified the 
mesangium as the central connective-tissue like space of the glomerular capillary tuft. 
The mesangium is now known to be a highly specialised, branching pericapillary tissue 
which is considered to possess two principal cell populations: a vascular smooth muscle 
type cell called the mesangial cell (MC) that represents the predominant cell type and a 
rare (3 to 7 % of mesangial cell population) bone-marrow derived phagocytic cell. 
Electron microscopy demonstrated MC to be irregular in shape, with numerous 
pseudopods of varying length extending into the surrounding matrix and connected to 
the GBM. A prominent feature of these cells is the presence of numerous bundles of 
small intracellular filaments and associated attachment bodies similar to those found in 
smooth muscle cells. A further similarity between MC and smooth muscle cells is the 
presence of angiotensin II receptors on the plasma membrane (Foidart et al 1980). The 
small subpopulation of resident phagocytic cells, demonstrated in rat glomeruli, display 
many features of monocytes/macrophages, expressing Fc and C3b receptors, the 
common leukocyte antigen and many also bear la determinants (Striker & Striker, 1985; 
Kashgarian & Sterzel, 1992).
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The major function of the MC within the kidney is to control the rate of glomerular 
filtration primarily through the regulation of mesangial cell tone. A secondary function 
of this specialised pericyte is to maintain the integrity of the glomerulus via matrix 
synthesis and provide support for the capillary loops. Furthermore, because of its close 
contact to the glomerular capillary lumen via the fenestrated endothelium, the 
mesangium is constantly perfused by macromolecules and filtration residues. While the 
resident macrophage type cells may play a major role in clearing macromolecules by 
phagocytosis, in vitro evidence suggests MC also have specific uptake mechanisms for 
macromolecules, including immune complexes. Endocytosis of immune complexes by 
MC in culture is mediated by surface Fc receptors, and uptake results in the generation 
of a variety of inflammatory mediators (Schlondorff, 1987).
1.4.2. Inflammatory mediators released by Activated’ mesangial cells
The establishment of MC in culture has increased understanding of the biochemistry 
and physiology of these cells, and shown that MC can serve as both a source and target 
for numerous cytokines, eicosanoids and reactive oxygen intermediates (Mene et al 
1989; Sedor et al. 1993). Both in vitro and in vivo evidence indicates MC do not play a 
bystander role in inflammatory disorders, but instead participate in the initiation and 
maintenance of glomerular inflammation via the release of inflammatory mediators 
(Sedor et al 1993).
Cultured MC provide a good model system for studying the potential of these cells to 
participate in inflammatory events, as these cells express a phenotype in culture which 
may mimic their characteristics within the inflamed glomerulus (Mene et al 1989). In 
the normal in vivo situation, MC are exposed only to plasma, while in culture they are 
exposed to non-autologous serum that contains products produced by platelets and by 
activation of the coagulation system. Furthermore, the initiation of cell culture 
necessitates active and prolonged cellular proliferation, while intrinsic glomerular cells 
in the normal adult have very low replicative rates. This transition to an activated, 
rapidly proliferating state may however be associated with the loss or gain of certain 
phenotypic properties, which need to be considered when interpreting in vitro studies 
(Lovett & Sterzel, 1986).
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1.4.2.1. Mesangial cell-derived cytokines
Cultured MC produce cytokines and growth factors which may act in both an autocrine 
and paracrine manner. Many of the growth factors thought to be mitogenic for MC can 
be produced by the cells themselves, including IL-6, PDGF and IGF-1 (Ruef et al 1990; 
Silver et al 1989; Aron et al 1989). Production of these factors by MC can occur in 
response to each other, and themselves (Abbott et al 1992; Brown et al 1991a; Ruef et 
al 1990; Silver et al 1989), which complicates the interpretation of their specific 
effects in this system.
A number of studies have demonstrated human MC can express IL-1. IL-1 a  and p 
mRNA was detected in human MC treated with serum, PDGF or EGF (Lovett & 
Larsen, 1988), and IL-1 p was found to dose-dependently increase its own expression in 
proliferating cells (Zoja et al 1992). A further study showed both proliferating and 
quiescent human MC in culture expressed IL-1 a  mRNA following cytokine stimulation, 
and the IL-1 protein produced remained cell associated (Abbott et al 1992). Reports 
concerning an ability of human MC to express TNF are limited, and contradictory. 
Schonermark et al (1991) describe TNF production by MC following stimulation with 
IL-1 or the membrane attack complex, C5b-9, while Abbot et al (1992) failed to detect 
TNF mRNA in either proliferating or quiescent MC following IL-lp, TNF or LPS 
stimulation.
1.4.2.2. Mesangial cell-derived chemokines
Glomerular MC in culture produce a number of chemokines upon appropriate 
stimulation. Human MC, when activated by IL-1 or TNF express and secrete IL-8 and 
MCP-1 (Brown et al 1991b; Abbott et al 1991; Kusner et al 1991; Rovin et al 1992; 
Brown et al 1992). Elevated IL-8 and MCP-1 mRNA expression was detected as early 
as 1 hour post-cytokine stimulation (Abbott et al 1991; Rovin et al 1992), and 
quantitation of IL-8 protein production demonstrated levels were still increasing at 24 
hours (Brown et al 1991b). The MC-conditioned media was shown to be chemotactic 
for both neutrophils (Kusner et al 1991) and monocytes (Rovin et al 1992) in vitro, 
and leukocyte migration was inhibited by -60% with anti-IL-8 or by -80% with anti- 
MCP-1 neutralising antibodies, respectively. IL-1 was a more potent stimulant than
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TNF for both IL-8 and MCP-1 production in human MC (Brown et al 1991b; Brown et 
al 1992), and the stimulatory effects of IL-1 were completely inhibited following 
pretreatment with IL-lra (Brown et al 1992). Furthermore, the glucocorticoid, 
dexamethasone was partially effective at reducing both IL-1 and TNF induced IL-8 
production (Brown et al 1991b).
Increased MCP-1 production has also been observed in IFN-y or thrombin stimulated 
human MC (Grandaliano et al 1994b; Grandaliano et al 1994a), and by mouse MC 
stimulated with either IFN-y, TNF or IgG immune complexes (Satriano et al 1993). In 
addition, a recent study performed in a murine mesangial cell line describes RANTES 
expression and production following stimulation with TNF, IL-1 or LPS (Wolf et al 
1993).
Expression of MCP-1 in glomeruli has been demonstrated in the anti-Thy-1 rat model of 
GN (Stahl et al 1993). Immunohistologic staining localised MCP-1 production to the 
mesangium. The correlation between the timing of increases and decreases in 
glomerular MCP-1 expression, with that of mesangioproliferation and mesangiolysis 
during progression of the disease indicated MC may be a major source of MCP-1 in this 
model, not the infiltrating monocytes/macrophages.
1.4.2.3. Mesangial cell-derived prostaglandins
Eicosanoids are metabolites of arachidonic acid, a polyunsaturated long chain fatty acid 
which is stored in cell walls esterified in phospholipids. Arachidonic acid is the 
substrate for both cyclooxygenase and lipoxygenase, and multiple eicosanoid products 
are derived from these two pathways (Fig. 6). Eicosanoids have a wide range of 
biological activities, which contribute to the cellular response to injury (Rola- 
Pleszczynski, 1985; Goodwin & Webb, 1980; Klahr & Harris, 1989). Thromboxane A2 
(TXA2) can cause platelet aggregation and granulocyte adhesion, as well as acting as a 
vasoconstrictor, while the prostaglandins, PGE2 and PGI2 are vasodilatory. The 
peptido-leukotrienes LTC4, LTD4 and LTE4 are vasoconstrictors, LTB4 in comparison 






























Figure 6. Biosynthesis o f prostaglandins and thromboxane. The broken lines indicate the site o f  
action o f  known inhibitors o f this pathway (Abbreviations; HETE=hydroxyeicosatetraenoic acid, 
PG=prostaglandin)
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chemoattractant for leukocytes and inducing other inflammatory mediators, including 
cytokines (Rola-Pleszczynski & Stankova, 1992).
Human mesangial cells in culture were found to constitutively release trace amounts of 
the prostaglandins, PGE2 , PGF2 a and 6-keto-PGFia, the latter being the stable end 
product of prostacyclin (PGI2 ) formation (Mene et al 1989). Both IL-1 and TNF 
increase prostaglandin synthesis by cultured human MC, with PGE2  and 6-keto-PGFia 
being the major prostaglandins produced (Topley et al 1989). Both these cytokines 
induce the expression and activation of secretory and cytosolic forms of the 
phospholipase A2  (PLA2 ) enzyme in rat MC, which results in the release of arachidonic 
acid from membrane phospholipids (Schalkwijk et al 1991; Schalkwijk et al 1992). 
These cytokines also induce de novo expression of the cyclooxygenase enzyme (Topley 
et a l 1989). Increased production of vasodilatory prostaglandins may have a protective 
effect on renal function during chronic renal disease by maintaining glomerular filtration 
rates (Klahr & Harris, 1989). Prostaglandins may also influence local cell proliferation, 
synthesis and breakdown of extracellular matrix and cytokine production (Schlondorff,
1987). In vitro, PGE2  downregulates TNF production by endotoxin stimulated 
monocytes/macrophages via elevation of the intracellular second messenger cyclic 
adenosine-5’-monophosphate (cAMP) (Schade & Schudt, 1993).
1.4.2.4. Production of oxygen radicals by mesangial cells
Release of the oxygen radical, superoxide (O2 ') has been mainly described as a specific 
function of phagocytic leukocytes, where it is required for the killing of bacteria and 
parasites (Jones et a l 1993). However, recent studies have shown human mesangial 
cells also possess a similar plasma membrane-bound NADPH-dependent oxidase, which 
catalyses O2 ’ production (Radeke et al 1991; Jones et al 1993). O2 ’ release has been 
demonstrated in culture human MC following stimulation with IL-1, TNF and the 
calcium ionophore A23187 (Radeke et al 1990). In comparison to neutrophils and 
eosinophils, the rate of 02* release by MC was low (nanomoles/hour) and did not appear 
to be toxic to the MC.
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0 2* generation results in spontaneous or catalysed formation of other reactive oxygen 
intermediates which differ in their toxicity to cells (Fig. 7). Lipids, proteins, nucleic 
acids and carbohydrates are all major targets for oxidative modification that can result in 
tissue injury (Johnson et al 1994). While MC may contribute to the oxygen-radical 
induced damage during GN, together with infiltrating leukocytes, recent reports have 
suggested production of lower concentration of oxygen radicals by non-immune cells 
(e.g. MC, fibroblasts and endothelial cells) may have important regulatory functions, in 
particular in cellular signalling (Jones et al 1993). A role for 0 2’ as a second messenger 
for MCP-1 and RANTES production in cytokine activated mouse MC has recently been 
suggested (Satriano & Schlondorff, 1994a; Satriano & Schlondorff, 1994b).
1.4.2.5. Production of nitric oxide by mesangial cells
Induction of NO synthase activity in cultured rat and bovine glomerular MC was first 
described in 1990, following stimulation with IL-1, TNF or LPS (Pfeilschifter & 
Schwarzenbach, 1990; Marsden & Ballermann, 1990; Shultz et al 1991). Due to the 
labile properties of NO, its production was demonstrated by measuring elevated 
intracellular cGMP levels and the formation of micromolar amounts of extracellular 
nitrite, a stable end-product of NO degradation. The induction of cGMP formation 
required a lag phase of 4-8 hours and was inhibited by actinomycin D and 
cycloheximide, indicating de novo protein synthesis was required (Pfeilschifter & 
Schwarzenbach, 1990; Marsden & Ballermann, 1990). The MC derived NOS was 
characterized as being of the macrophage inducible type, as the L-arginine analogue, L- 
NMMA was more potent than L-NNA in inhibiting cytokine induced cGMP formation
2"Pand enzyme activity appeared independent of Ca and calmodulin (Pfeilschifter et al
1992). Cytokine induction of NOS activity in rat MC was dose-dependently inhibited 
by TGFp (Pfeilschifter & Vosbeck, 1991), glucocorticoids (Pfeilschifter, 1991b) and 
PDGF (Pfeilschifter, 1991a). Furthermore, cAMP-elevating agents alone induced iNOS 
expression and activity above basal levels and when added in combination with IL-1, 
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Figure 7. Formation o f other free radicals from superoxide. Superoxide anions ( 0 2‘ ) are produced 
by the univalent reduction o f oxygen by NADPH oxidase. Dismutation o f  Oz\  either spontaneously or 
catalysed by superoxide dismutase (SOD) yields hydrogen peroxide (H20 2). The H20 2 can react with 
myeloperoxidase and chloride to form hypochlorous acid (H0C1) and chlorine (Cl2), or it can react with 
iron and 0 2' to form hydroxyl radicals ( OH) (Haber-Weiss reaction). Protection from the toxic effects o f  
H20 2 is afforded by catalase and glutathione peroxidase, which degrade H20 2 to water.
In the presence o f  nitric oxide (NO ), 0 2‘ is converted to peroxynitrite ( 0 N 0 0 ‘), which also 
leads to OH generation. The stable end product o f OH formation is nitrate (N 0 3").
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1.5. POTENTIAL SIGNAL TRANSDUCTION MECHANISMS FOR IL-1 OR 
TNF ACTIVATION OF MESANGIAL CELLS
In vitro studies indicate both IL-1 and TNF are important in ‘activating’ MC to express 
a phenotype that contributes to the progression of glomerular inflammation through the 
differential induction of specific genes that can result in altered matrix metabolism, an 
altered cell growth response and secretion of cytokines and inflammatory mediators 
(Sedor et al 1993). Such changes at the cellular level culminate in the histological and 
functional characteristics of renal injury. The molecular mechanisms by which IL-1 and 
TNF activate cells remain unclear and is a controversial area of signal transduction since 
virtually all known signalling systems have been implicated (O'Neill, 1995; Saklatvala 
& Guesdon, 1992). Increasing evidence suggests the IL-1 and TNF signalling 
mechanisms may be cell-specific, and depend upon the particular cellular response 
under investigation (O'Neill, 1995)
1.5.1. IL-1 receptors
Two distinct plasma membrane receptors have been identified for IL-1. The type I 
receptor (80 kDa) is the predominant form, expressed on MC, T lymphocytes, 
fibroblasts, and endothelial cells, while the type II receptor (60 kDa) occurs mainly on B 
cells, monocytes, neutrophils and hepatoma cells (O'Neill, 1995; Zoja et al 1992). The 
type I receptor binds IL-1 a, IL-1 p and IL-lra with equal affinity, while the type II 
receptor bind IL-1 p with greater avidity than IL-1 a  or IL-lra (Arend, 1991). Both types 
of IL-1 receptor have been cloned from mouse and human cell lines (McMahan et al.
1991) and share 28% homology at the amino acid level in the extracellular domain. The 
receptors possess a single membrane spanning domain and belong to the 
immunoglobulin supergene family, to which many growth factor and cytokine receptors 
belong (Taga & Kishimoto, 1992). The cytoplasmic region of the type II IL-1 receptor 
comprises of only 29 amino acids, in comparison to 215 amino acids in this region of 
the type I receptor, and evidence based on antibody blocking studies (Stylianou et al. 
1992; Sims et al. 1993) strongly suggests the type II receptor is not involved in IL-1 
signalling. The type II receptor may function as an extracellular IL-1 inhibitor as it has 
been shown to be shed from cells, thus it may bind IL-1, preventing it from interacting
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with the type I receptor (O'Neill, 1995). The main features of the type I receptor is its 
high affinity for IL-1 and the relatively low number of receptors per cell (200-4000 
receptors/cell) (Saklatvala & Guesdon, 1992). Intriguingly, receptor occupancy studies 
have indicated less than 10 IL-1 receptors per cell need to be occupied to elicit a 
biological response (Stylianou et al 1992; Curtis et al 1989).
1.5.2. TNF receptors
Two distinct cell surface receptors for TNF have been identified, termed TNF receptor 1 
(TNF-R1) and TNF receptor 2 (TNF-R2) (Tartaglia & Goeddel, 1992). These receptors 
are -55 kDa and ~75 kDa respectively and both are expressed on most cell types, with 
the number varying between 100 and 10,000 per cell (Beyaert & Fiers, 1994). Both 
receptors have a single, membrane spanning domain and are 28% homologous in the 
extracellular region. The TNF receptors are members of a growing superfamily of 
receptors that includes the fas antigen, CD40 and gp50, all of which possess four 
extracellular repeats of a cysteine rich domain (Smith et al 1994). The intracellular 
domains of TNF-R1 and TNF-R2 consist of 221 and 174 amino acids respectively, and 
show no detectable similarity in their amino acid sequences which suggests they utilise 
distinct signalling pathway and mediate distinct TNF activities (Lewis et al 1991). 
This latter suggestion has been confirmed in gene-knockout experiments and studies 
using antibodies that act as specific agonists or antagonists of the two receptor types 
(Pfeffer et al 1993; Engelmann et al 1990; Wong et al 1992; Tartaglia et al 1993; 
Kruppa et al 1992). The majority of TNF activities appear to be mediated by TNF-R1 
including cytotoxicity, cytokine induction, activation of the transcription factor nuclear 
factor kB (NF-kB) and prostaglandin synthesis (Engelmann et al 1990; Wong et al 
1992; Kruppa et al 1992; Tartaglia et al 1993). Direct signalling through TNF-R2 
appears to be mainly confined to T lymphocytes, where it is involved in cytokine 
expression and/or proliferation. However, a model of receptor co-operation has been 
proposed, where the R2 facilitates binding of TNF to R1 at low concentrations of TNF, 
since TNF has a higher affinity for R2 than R1 (Tartaglia & Goeddel, 1992). Studies on 
TNF-R1 suggest that crosslinking of the receptors is important in the activation process. 
The native forms of TNF and lymphotoxin have been described as trimers and thus may 
exert their effects by binding to and clustering the TNF receptors (Engelmann et al
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1990; Tartaglia & Goeddel, 1992). Both forms of the TNF receptor may also be shed 
from the cell, which may act to inhibit TNF activity. However, the effect of soluble 
TNF receptors on TNF function needs to be further explored, since the binding of TNF 
in a dissociable form may effect the pharmokinetics and stability of the TNF molecule 
(Fiers, 1991).
1.5.3. Heterotrimeric G proteins
Heterotrimeric G proteins are guanine nucleotide binding proteins which couple 
receptors to effector enzymes and many classes of ion channels (Hepler & Gilman,
1992). G proteins provide a primary means of amplifying a signal, as a single occupied 
receptor can activate many G proteins, which in turn can activate more than one of the 
effectors. Activation of effector enzymes such as adenylyl cyclase or phospholipase C 
(PLC) leads to the generation of second messengers, that ultimately leads to cellular 
responses.
G proteins consist of 3 subunits, a , p and y, which are complexed in their inactive state, 
with GDP bound to the a  subunit (Fig. 8). Receptor activation induces a GDP-GTP 
exchange, upon which the a  subunit dissociates from the Py dimer to interact with the 
appropriate effector system. The cycle is complete, when GTP is hydrolysed by the 
intrinsic GTPase activity of the a-subunit and reassociation with the Py dimer occurs 
(Hepler & Gilman, 1992). Originally, the a  subunit was thought to be solely 
responsible for downstream regulation of effector systems, while the Py dimer 
functioned as a helper protein which facilitated both the activation and deactivation of 
the a  subunit, and its localisation to the membrane. However, recent studies have 
demonstrated the Py dimer can also directly regulate some downstream events, in 
addition to the predominant role of the a-subunits (Clapham & Neer, 1993). A role for 
py dimers in the regulation of the P-sub-family of PLC enzymes and adenylyl cyclase 
has been established (Clapham & Neer, 1993; Ueda & Tang, 1993). To date, at least 20 
different a-subunits have been identified in mammals, along with 5 different p-subunits 
and 12 y-subunits (Neer, 1995). The a-subunits confer the specificity of effector 
interaction (Table 6) and individual cells usually contain at least 4 or 5 types of a  
subunit. Differences between the a-subunits are highlighted by their susceptibility to
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Table 6. Properties o f the more common G protein sub-types. Apparent molecular weights are 
shown. Two long forms and two short forms o f  Gas exist, which are splice variants o f  a single gene. The 
two forms o f  Gao are also splice variants .
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modification by the bacterial toxins, cholera toxin (CT) and pertussis toxin (PT) 
(Milligan, 1988). These toxins are typical A-B toxins, consisting of 5 different 
polypeptide subunits held together by non-covalent interactions. The A subunit (SI 
subunit) catalyses the transfer of ADP-ribose from NAD+ to the a-subunit of relevant G 
protein substrates, with important functional consequences. The B portion of the toxin 
(B oligomer) consists of the subunits S2 to S5, which are arranged as two dimers, S2-S4 
and S3-S4, linked by S5. It functions to bind the toxin to specific cell surface receptors 
and deliver the SI subunit through the target cell membrane (Kaslow & Bums, 1992). 
CT ADP-ribosylates the stimulatory G protein, Gs, which leads to its permanent 
activation through disruption of the intrinsic GTPase activity of the a s subunit. PT 
ADP-ribosylates a distinct group of G proteins, including all the isoforms of Gj and G0, 
leading to their inactivation by preventing receptor-G protein coupling (Milligan, 1988). 
The bacterial toxins have thus proved to be useful tools for investigating signal 
transduction pathways. If the toxins inhibit or stimulate a biological response to a 
hormone, Gj/0 or Gs respectively can be implicated in the signal transduction 
mechanism.
The sites of cholera and pertussis toxin modification in susceptible a-subunits are 
different. PT ADP-ribosylates a conserved cysteine residue located 4 amino acids from 
the C-terminus (Milligan, 1988). This region of the subunit is thought to be important 
for receptor interaction, which is dismpted by ADP-ribosylation, leading to inhibition of 
G protein function, a  subunits that are not substrate for PT lack this cysteine residue in 
the C-terminus (Milligan, 1988). In contrast, CT modifies an arginine residue which is 
postulated to be located close to the guanine-nucleotide binding domain in the tertiary 
structure of the a-subunit. Interestingly, the position of this arginine residue and the 
surrounding region is highly conserved in all G proteins, yet very few serve as 
substrates for CT. It has been proposed that in the non-susceptible G proteins, 
occupancy of the site by a guanine nucleotide may hinder access of CT (Milligan,
1988). This is supported by the observation that PT substrates only become substrate 
for CT in the absence of guanine-nucleotides (Milligan, 1987). A new strategy for 
identifying PT-sensitive G protein coupled receptors has stemmed from these 
observations. In membrane preparations, in the absence of guanine nucleotides,
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receptors which couple to PT-sensitive G proteins produce a specific enhancement of 
CT catalysed ADP-ribosylation of Gi/0 type proteins (Milligan et al 1991; Gierschik & 
Jakobs, 1987; Iiri et al. 1989). This is thought to be due to agonist induced dissociation 
of GDP from the guanine-nucleotide binding domain of the receptor-linked G protein, 
which in the absence of guanine nucleotides remains empty and becomes susceptible to 
CT modification (Milligan e ta l 1991).
A distinct family of receptors which possess the common structural feature of 7 
membrane spanning domains are known to couple to heterotrimeric G proteins (Taga & 
Kishimoto, 1992). However, a number of studies suggest receptors which do not 
possess this configuration may also be G protein coupled, including the receptors for IL- 
1, TNF, colony stimulating factor-1 (CSF-1), IL-2, EGF and TGF|3 (O'Neill et al 1990a; 
Imamura et al 1988; Imamura & Kufe, 1988; Evans et al 1987; Nair et al 1989; Howe 
et al 1990). Much of the evidence indicating an involvement of Gi/0 type proteins in IL- 
1 and TNF signal transduction mechanisms has arisen from studies using PT, which was 
found to inhibit a wide range of IL-1, and some TNF post-receptor responses (Dobson et 
al 1989; Chedid et a l 1989; O'Neill et a l 1990a; Rollins et a l 1991; Imamura et al 
1988; Clark et a l 1988; Brett et a l 1989). PT inhibited IL-1 induced prostaglandin 
release from fibroblasts (Chedid et a l 1989), IL-1 induced IL-2 expression in EL4 cells 
(murine thymoma cell line) (O'Neill et al 1990a; Rollins et al 1991) and TNF induced 
PLA2 activity in endothelial cells (Clark et al 1988). Interestingly however, not all IL-1 
responses were found to be sensitive to PT, with IL-1 induced NF-kB activation, 
collagenase production and phosphorylation of the EGF receptor being unaffected by 
toxin treatment (O'Neill et al 1992). Additional evidence of a role for G proteins in IL- 
1 and TNF signalling mechanisms has come from studies showing both these cytokines 
specifically increase GTPase activity and GTP binding to cell membrane preparations 
(O'Neill et al 1990a; Chedid et al 1989; Imamura et al 1988). The ability of PT to 
inhibit the stimulating effects of IL-1 and TNF in these assays further indicates that the 
IL-1 and TNF receptors are coupling to PT-sensitive G proteins, such as Gj or G0 
isoforms.
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1.5.4. Second messengers and protein kinases
Evidence obtained in human fibroblasts, and also in MC, shows IL-1 and TNF, upon 
receptor binding, stimulate a rapid increase in the phosphorylation of a number of 
cellular proteins, chiefly on serine and threonine residues, indicating the activation of 
kinases and/or inhibition of protein phosphatases specific for these target residues (Guy 
et al 1991; Guy et al 1993; Saklatvala & Guesdon, 1992; Lovett et al 1988). The 
identity of the kinases or phosphates involved remain to be identified (O’Neill, 1995). 
Earlier work investigated the role of known serine/threonine protein kinases, such as 
protein kinase A (PKA) and protein kinase C (PKC) in IL-1 and TNF signalling 
pathways. The findings however, were controversial with some studies implicating an 
involvement of these kinases in IL-1 and TNF signalling events (Mizel, 1990; Zhang et 
al 1988b; Baud et al 1988) while others ruled out any such role (Sedor et al 1992; 
O'Neill et al 1990b; Guy et al 1991). Recent studies have focused on a role for protein 
phosphatases and more novel second messengers and kinases. The sphingomyelin- 
ceramide pathway (Kim et al 1991; Schiitze et al 1992; Ballou et al 1992), the 
mitogen-activated protein (MAP) kinase pathway (Saklatvala et al 1993) and okadaic 
acid-sensitive phosphatases, such as PP1 and PP2A (Guy et al 1992; Guy et al 1993) 
have all been implicated. Furthermore novel kinases, for which the substrate and/or 
upstream regulators have yet to be determined, may play an important role (Freshney et 
al 1994; Guesdon et al 1993; O'Neill, 1995).
I.5.4.I. The cAMPpathway
The ability of IL-1 to activate the adenylyl cyclase / cAMP signal transduction pathway 
(Fig. 9) has been investigated in some detail. IL-1 has been shown to directly induce a 
transient elevation of intracellular cAMP levels in a variety of cell types (Mizel, 1990; 
Chedid et al 1989; Zhang et al 1988b; Schirakawa et al 1988). Furthermore, 
pharmacological agents which elevate intracellular cAMP by a number of different 
mechanisms (Fig. 9) have been shown to mimic several actions of IL-1. cAMP 
analogues and forskolin were found to replace IL-1 in inducing PLA2 secretion in rat 
MC (Pfeilschifter et al 1991), IL-2 receptor expression on YT lymphocytes (human 
natural killer-like T cell line) (Schirakawa et al 1988), idg light chain expression in the 
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Figure 9. The cAM P signal transduction pathway: Site o f action o f cAM P-elevating agents.
Agonist-bound receptor activation o f  the stimulatory G protein, Gs leads to activation o f  adenylyl cyclase, 
the enzyme responsible for the conversion o f ATP to cAMP. Cellular responses are brought about by 
phosphorylation events involving the cAMP-dependent protein kinase (PKA), which is activated by the 
raised cAMP levels.
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(Zhang et al 1988b). In marked contrast, other investigators found no increase in 
cAMP levels following IL-1 activation of cells of both lymphoid and non-lymphoid 
origin (Ray et al 1992; Bomsztyk et al 1990; Rollins et al 1991; Schlegel-Haueter & 
Aebischer, 1990), including rat MC (Pfeilschifter et al 1991), and report an inability of 
cAMP to mimic IL-1 effects (Ray et al 1992; Bomsztyk et al 1990; Rollins et al 1991; 
Schlegel-Haueter & Aebischer, 1990). Furthermore the characteristic increase in 
protein phosphorylation observed after IL-1 stimulation was found to occur 
independently of PKA activity (Guy et al 1991). The reason for these differences at 
present are unclear, however taken together, the findings indicate cAMP is unlikely to 
be a major second messenger in IL-1 signalling events.
Less work has been done on the role of cAMP as a second messenger for TNF 
signalling, but the findings have been similarly contradictory, with some reports 
implicating an involvement of cAMP in mediating TNF effects (Baud et al 1988; 
Zhang et al 1988b), while others rule out any such role (Pfeilschifter et al 1991; Guy et 
al 1991).
Interestingly, a number of studies have indicated cAMP can have important regulatory 
effects on IL-1 activity. Elevation of intracellular cAMP by PGE2 or pharmacological 
agents was found to down regulate IL-1 induced IL-2 production in EL4 cells (Rollins 
et al 1991) and have a dual modulatory effect on IL-1 induced serine esterase activity in 
PC60 cells (cytotoxic T cell hybridoma) (Schlegel-Haueter & Aebischer, 1990). More 
recently, cAMP has been shown to downregulate IL-6 production in IL-1 stimulated 
lung fibroblasts (Zitnik et al 1993) and downregulate IL-1 and TNF induced MCP-1 
production in MC (Rovin & Tan, 1994; Satriano et al 1993).
I.5.4.2. The nitric oxide signalling pathways
NO functions as an important signalling molecule through it’s activation of soluble 
guanylate cyclase, resulting in elevation of the intracellular second messenger cGMP 
and subsequent activation of the cGMP-dependent protein kinase. An involvement of 
this signalling pathway in mediating smooth muscle cell relaxation and 
neurotransmission are well recognised (Moncada et al 1991).
38
Recent studies have indicated a role for NO in regulating the production of certain 
inflammatory mediators. Brown et al (1993b) have demonstrated that IL-1 induced 
production of NO potentiates the secretion of IL-8 in human MC via elevation of 
intracellular cGMP. The NOS inhibitor L-NMMA, L-arginine depletion and known 
inhibitors of guanylate cyclase were all found to inhibit IL-1 induced IL-8 production by 
MC, while the NO donor sodium nitroprusside and cGMP analogues were found to 
enhance IL-8 generation in arginine-depleted cells. NO donors have also been reported 
to cause significant upregulation of both IL-8 promoter activity and IL-8 protein 
secretion in the human melanoma cell line, G361 (Andrew et al 1995). The mechanism 
of NO upregulation of IL-8 gene expression involved, at least in part, activation of the 
transcription factor NF-kB. In addition, the ability of the NOS inhibitor N“-amino-L- 
arginine to reduce TNF stimulated IL-8 promoter activity by >50% indicates NO may 
function as an endogenous regulator of IL-8 expression in G361 cells. Endogenous 
production of NO in LPS and IFN-y stimulated rat kupffer cells was found to inhibit 
subsequent PGE2, TXB2, and IL-6 synthesis by these cells, while IL-1 and TNF 
production was unaffected (Stadler et al 1993). Furthermore, exogenous addition of 
NO increased TNF mRNA expression in HL-60 cells and differentially regulated IL-3 
and IL-2 production by spleen cells from contact-sensitised mice (Marcinkiewicz & 
Chain, 1993). The role of cGMP in mediating the regulatory effects of NO on cytokine 
and eicosanoid production in these latter studies was not determined.
An ability of NO to activate a number of signalling systems via cGMP-independent 
mechanisms has been reported in human peripheral mononuclear cells. Such effects of 
NO include activation of the transcription factor NF-kB (Lander et al 1993a) and direct 
activation of the heterotrimeric G proteins, Gs, Gn and the small molecular weight G 
protein, p21ras (Lander et al 1993b). The ability of NO to directly activate G proteins is 
thought to play a role in its activation of NF-kB, however the mechanism of G protein 
activation by NO remains unknown (Lander et al 1993b). Interestingly NO increases 
the activity of a cytosolic ADP-ribosyltransferase in human platelets and different rat 
tissues by a cGMP independent mechanism (Brune & Lapetina, 1989). NO activation 
of this enzyme resulted in the ADP-ribosylation of a 39 kDa protein in all the tissues 
analysed. However, the protein was not recognised by Gcommon a antiserum, indicating
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the protein is not one of the known heterotrimeric G proteins which have similar 
molecular masses. The importance of the NO induced ADP-ribosylation of the 39 kDa 
protein therefore remains to be elucidated. In addition, NO has been shown to modulate 
protein tyrosine kinase and protein tyrosine phosphatase activity in lymphocytes 
(Lander et al 1993a).
The ability of NO to activate a number of different signalling pathways indicates an 
expanding role for this molecule in signal transduction mechanisms.
1.5.5. Transcription factors
Transcription factors are DNA binding proteins that mediate changes in gene 
expression. They provide the link between post-receptor signalling events and changes 
in transcription. Phosphorylation plays a key role in regulating their activities, and upon 
activation the sequence specific transcription factors bind to particular sites in the 
promoter region of genes and control their transcription. Different families of 
transcription factors have been defined, based upon their protein structure (Karin & 
Smeal, 1992; Peterson & Tupy, 1994).
IL-1 and TNF have been shown to activate several transcription factors, including NF- 
kB, NF-IL6  and AP-1 (O'Neill, 1995; Osbom et al 1989; Mukaida et al 1990; 
Yasumoto et al 1992; Brown et al 1993a). The activation of NFkB by IL-1 and TNF 
appears to be important in mediating a number of their inflammatory effects, including 
induction of IL-8 , IL- 6  and gro gene expression (Mukaida et al 1990; Zhang et al 
1990; Anisowicz et al 1991). The predominant form of NF-kB exists in resting cells in 
the cytosol as a heterodimer of p50 and p65 (relA) polypeptides complexed to an 
inhibitory protein, IkB. Activation of NF-kB requires dissociation from IkB, which 
allows translocation of the heterodimer to the nucleus, while IkB is rapidly degraded. 
The mechanisms that induce dissociation are poorly understood, but may involve 
phosphorylation of IkB (Beg & Baldwin, Jr. 1993). The kinase(s) involved however 
remain to be identified. PKA, PKC and the MAP kinases have all been found to 
activate NFkB in vitro (Shirakawa & Mizel, 1989).
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1.6. AIMS OF THE STUDY
This study is based on the hypothesis that MC play a direct role in the initiation and 
propagation of inflammatory events within the glomerulus via the release of 
inflammatory mediators. Recent studies have demonstrated that human MC in vitro are 
a rich source of the chemokines IL- 8  and MCP-1, and the mesangioproliferative 
cytokine IL- 6  following stimulation with the proinflammatory cytokines IL-1 or TNF 
(Brown et al 1991b; Abbott et al 1991; Rovin et al 1992).
The objectives of this investigation were therefore;
(1) To investigate the potential of human MC to express other members of the 
chemokine superfamily.
(2) To determine the molecular mechanisms that regulate the expression and release
of chemokines and IL- 6  in cytokine activated human MC.
(3) To identify the role of the cAMP signal transduction pathway in the regulation of
IL- 8  and IL- 6  production in IL-1 or TNF stimulated MC.
(4) To investigate the role of pertussis toxin-sensitive heterotrimeric G proteins in
the IL-1 signalling mechanisms for IL- 8  and IL- 6  in MC.
(5) To define the potential role of the L-arginine/nitric oxide signal transduction
pathway in IL-1 induced IL- 8  generation in MC.
Increasing our understanding of the signal transduction pathways that regulate 
chemokine and IL- 6  production in human MC may provide leads for the development of 
novel and effective therapeutic strategies for the prevention of glomerular inflammation.
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2. MATERIALS AND METHODS
Recipes for the buffers used in the following method sections, and specific details 
relating to the storage and handling of drug solutions are contained in appendices I-VI at 
the end of the thesis.
2.1. MESANGIAL CELL ISOLATION AND CULTURE CONDITIONS
Details of the buffers and solutions used for cell culture are given in appendix II. Sterile 
plastics and pastettes were purchased from Biddy Sterilin Ltd (Store, UK) and Scientific 
Laboratory supplies (Nottingham, UK), respectively. All reagents and equipment which
were not purchased sterile were autoclaved at 20 lb/in for 20 min at 121 °C before use.
2
Glassware was autoclaved at 30 lb/in for 30 minutes at 135°C.
All tissue culture plastics (Nunc, Denmark) were coated with 1% gelatin for 1 hour at 
37°C, then washed lx with PBS, prior to the addition of cells.
2.1.1. Mesangial cell isolation
Human mesangial cells (MC) were isolated from macroscopically normal portions of 
renal cortex, obtained from human kidneys immediately after surgical nephrectomy for 
renal carcinoma. Tissue was provided by Dr C. Gallagus (Royal United Hospital, Bath) 
and was collected in 50 ml sterile Hanks balanced salt solution (HBSS), pH 7.4. MC 
were isolated according to the method described by Striker and Striker (1985) and 
Lovett et al (1983). Glomeruli were isolated from renal cortex by differential sieving 
(mesh sizes 250,106 and 75 pm (Fisons)). Slices of cortex in HBSS were transferred to 
the top sieve (250 pM) and gently mashed with the bulb end of a sterile pastette to break 
up the tissue and release the glomeruli, while repeatedly washing with HBSS. 
Glomeruli which collected on the lower two sieves (106 and 75 pm mesh size) were 
transferred to 2 universals and centrifuged for 5 minutes at 200 g at room temperature. 
The supernatant was removed and the glomeruli resuspended in 10 ml of prewarmed
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sterile collagenase solution (type IV) (Sigma), 1 mg/ml in Waymouths medium. The 
glomeruli were incubated at 37°C for 20 minutes with occasional agitation, then 
centrifuged for 5 minutes at 200 g. The supernatant was removed and the glomeruli 
resuspended in 10 ml Waymouths medium containing 10% (v/v) foetal calf serum 
(FCS), and placed in two 80 cm2  tissue culture flasks. Flasks were incubated at 37°C in 
5% C 0 2  and left undisturbed for 5 days, after which the media was changed. Primary 
cultures were established as outgrowths from glomeruli by day 1 0  and reached 
confluency by day 2 0 .
2.1.2. Cell culture conditions
MC were routinely cultured in 80 cm2  tissue culture flasks in Waymouths MB752/1 
medium supplemented with antibiotics and 10% (v/v) FCS (referred to as complete 
medium). Cultures were maintained at 37°C in 5% C 0 2  and 95% air. The medium was 
changed every 4 days.
To subculture, the medium was removed and the cells were washed 3x with 5 ml 
phosphate buffered saline (PBS) (w/o Ca2+ and Mg2+). Cells were then incubated for 
approximately 5 minutes at 37°C in 3 ml of warmed 0.05% trypsin/0.02% EDTA (xl) 
(Gibco) until the cells had detached from the flask. Flasks were firmly tapped to 
encourage cell detachment. The action of the trypsin was inhibited by adding 10 ml of 
complete medium and the cells centrifuged at 200 g for 5 minutes. The cell pellet was 
resuspended in 1 ml of complete medium and the viable cells counted in a Neubauer 
haemocytometer (Weber Scientific International Ltd, Teddington, UK) after mixing 10 
pi of resuspended cells with 40 pi of PBS and 10 pi of 0.4% trypan blue (Sigma). Dead 
cells stained blue, due to the uptake of trypan blue. The concentration of cells was 
calculated using the following equation;
cells / ml = (Number of cells in the centre 25 squares on each side of the 
haemocytometer x 6  x 1 0 4  ) 2
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Cells were seeded into 80 cm2  tissue culture flasks (12 ml/flask), 25 cm2  flasks (4 
ml/flask) or 24 multi-well plates (0.5 ml/well) at a density of 50,000 cells/ml. Plates 
and flasks reached confluency after approximately 3 and 5 days respectively.
n
For storage, cells between passages 0 and 3 were resuspended at 1x10 cells/ml in 
Waymouths medium (no FCS) and mixed 1:1 with a cold solution of 80% FCS / 20% 
dimethylsulphoxide (DMSO) (final concentration = 40% FCS, 10% DMSO). The cell 
suspension was transferred to cryotubes (0.5 ml/tube) (Nunc) and gradually cooled in 
the vapour phase of liquid nitrogen over 6  hours. Cryotubes were then stored in liquid 
nitrogen tanks. When required, the cells were rapidly defrosted at 37°C in a water bath, 
washed in Waymouths medium and resuspended in complete medium. Cells from 1 
cryotube were then plated into an 80 cm flask.
2.1.3. Characterization of cells
MC identity was confirmed by the display of the characteristic hillock structures in 
culture (Sterzel et al 1986) and by the use of a series of cell markers. For cell staining, 
MC were plated into sterile flat-bottomed 96 well plates or 8  well lab-tek chamber 
slides (Nunc) at a density of 25,000 cells/ml (100 and 300 pl/well respectively). Lab- 
tek slides were used if photographs were required. Cells were incubated for 48 hours 
prior to fixing. Sub-confluent cells were used, as the elongation that occurs when cells 
are confluent conceals clear staining of the intermediate filaments.
Cells to be fixed were washed 3x with PBS + 0.05% (w/v) BSA and air dried in a cell 
culture hood for 1 hour. 10% neutral buffered formalin solution (Sigma) was added and 
the cells incubated at 4°C for 1 hour. Cells were washed 3x with PBS + 0.05% BSA 
and left at 4°C prior to staining. Alternatively, cells to be stained for a-smooth-muscle 
specific actin were washed in PBS + 0.05% BSA and immediately fixed by immersing 
the cells for 10 minutes in cold methanol at -20°C.
Primary antibodies or phalloidin were appropriately diluted in PBS + 0.05% BSA and 
incubated with the cells for 1 hour (50 and 150 pi volumes were used in the 96-well 
plates and lab-tek slides respectively). Cells were washed 3x and the unlabelled primary 
antibodies detected by incubating for 1  hour with a 1 : 2 0  dilution of fluorescein
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isothiocynate (FlTC)-conjugated rabbit anti-mouse IgG (F313, Dako Ltd, High 
Wycombe, UK). Cells were washed 3x, and the lab-tek slides were mounted with a 
coverslip in glycergel mounting medium (Dako), which was left overnight to dry. Cells 
were viewed under ultraviolet light using a Nikon fluorescence microscope.
MC cultures stained positive for F-actin (1:100 dilution of phalloidin-FlTC) (Sigma), cx- 
smooth muscle specific actin (1:200 dilution of FTTC-conjugated IgG2a monoclonal) 
(Sigma) (Fig. 10) and for the intermediate filament vimentin (1:25 dilution of IgGlk 
monoclonal) (M0725, Dako). This latter stain denotes cells of mesenchymal origin. 
Cultures at passage 3 to 4 were negative for cytokeratin (1:40 dilution of IgG2a 
monoclonal K8.13, Sigma) and von Willibrand factor antigen (1:25 dilution of IgGlk 
monoclonal, M0616, Dako) excluding contamination with epithelial and endothelial 
cells respectively. Cultures at passage 2 contained some epithelial cell contamination 
(<20%). Phalloidin-FlTC was routinely used to assess the purity of cultures, as this 
reagent stains all the possible contaminating cells (fibroblasts, macrophages, endothelial 
and epithelial cells). MC cultures were first used in experiments at passage 3 or 4, when 
cultures were >95% pure. Cultures were negative when incubated with the same 
dilutions of mouse IgGlk control serum (X093, Dako) instead of the primary antibodies. 
The control serum was directed against Aspergillus niger glucose oxidase, which is not 
present in mammalian tissue. Specificity of the secondary FITC-conjugated antibody 
was demonstrated by omitting addition of the primary antibody on some wells. 
Furthermore, primary cultures of human synovial fibroblasts were used as a negative 
control for a-smooth muscle actin staining, while the epithelial cell line HT-29 was 
used as a positive control for cytokeratin staining. These latter 2 cell types were kindly 
supplied by Dr N. Jordan and Dr G. Kolios (Dept, of Pharmacology, University of 
Bath).
2.1.4. Mycoplasma assay
MC cultures were tested for contamination with the 4 common mycoplasma species (M. 
arginini, M. hyorhinis, A. laidlawii, M. orale) using an enzyme immunoassay kit 
(Boehringer Mannheim). The manufacturers protocol was followed for the detection of 
mycoplasma in culture supernatants, and all the buffers and reagents used were supplied 
with the kit.
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Figure 10. Human MC stained for smooth muscle specific actin. Sub-confluent MC grown in 8 well 
lab-tek chamber slides were methanol fixed prior to staining with a 1:200 dilution o f  FITC-conjugated 
anti-a-smooth muscle specific actin monoclonal antibody. Cells were photographed under a 
magnification o f  x400.
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96 well microtitre plates (Nunc Immuno maxisorb plates) were coated with 125 pi of 
four different antibody solutions directed against the four mycoplasma species. Plates 
were incubated for 2 hours at 37°C. Antibody solutions were removed and non-specific 
binding sites blocked with 125 pi of blocking solution for 30 minutes at 37°C. Plates 
were washed 3x and incubated with either 100 pi of MC culture supernatant, positive 
control solutions or media alone, overnight at 4°C. Plates were washed 3x and 
incubated with 1 0 0  pi of the four corresponding biotin labelled detecting antibodies for 
2 hours at 37°C. Plates were washed 3x and incubated with 100 pi of streptavidin- 
alkaline phosphatase for 1 hour at 37°C. Washed plates were incubated with 100 pi of 
substrate solution for 1 hour at room temperature. Results were evaluated visually and 
confirmed by reading optical densities at 405 nm.
Of 6  cultures tested during this study, 4 cultures were negative for all of the mycoplasma 
species screened for, while 1 culture was positive for M. arginini and another culture 
was faintly positive for M. arginini and M. hyorhinis. These later two cultures, which 
were both approximately 2  years old were discarded.
2.2. EXPERIMENTAL PROTOCOL
MC, between passages 3 to 7 were grown to 80% confluency in 24 multi-well tissue 
culture plates (~5xl04  cells/well), 25 cm2  flasks (~ 8xl05  cells/flask) or 80 cm2  flasks 
(~ 2.5xl06  cells/flask). Twenty-four hours prior to the start of the experiment the cells 
were washed and cultured in serum-free Waymouths medium. MC were then treated 
with fresh serum-free medium and challenged with either drugs, cytokines or vehicle 
controls for the times and doses specified in the results section. Supernatants were 
collected, centrifuged to remove cellular debris and stored at -70°C until assayed for 
extracellular IL-6 , IL-8 , RANTES, PGE2  or nitrite. Total cellular RNA, cell membranes 
or cellular proteins were extracted from cells as described in sections 2.8.1, 2.9.1 and 
2.10.2 respectively. Cell viability was routinely assessed at the end of the experiment by 
phase microscopy and by trypan blue exclusion.
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2.3. PROTEIN ASSAY
Protein was estimated using the Bio-Rad protein assay (Bio-Rad Laboratories Ltd, 
Hemel Hempstead, UK), which is based on the coomassie brilliant blue dye-binding 
method of Bradford (Bradford, 1976).
The protein content of samples was estimated by comparison with a standard curve of 
bovine gamma globulin (Bio-Rad standard 1) ranging from 0-25 pg/ml in PBS. 200 
p 1/well of standard and appropriately diluted sample (e.g. MC membranes, IL- 6  
antibody) were added to a flat-bottomed 96-well microtitre plate in duplicate. 50 pi of 
Bio-Rad dye-binding reagent was added to each well and the samples were mixed using 
a multi-channel pipette. After 20 minutes the absorbance was measured at 595 nm.
2.4. AFFINITY PURIFICATION OF ANTI-IL-6 ANTIBODY
Goat anti-human IL- 6  antiserum (Bleeds G150 B3a and G150 BM) and human 
recombinant IL- 6  (hrIL-6 ) were a gift from Dr Steven Poole (National Institute of 
Biological Standards and Controls (NIBSC), South Mimms, UK). The antiserum was 
affinity purified and biotinylated as previously described (Rafferty et al 1991; Taktak et 
al 1991) for use in an IL- 6  ELISA.
2.4.1. Preparation of column for affinity purification
Human recombinant IL- 6  was immobilised on affigel 15, a matrix of cross-linked 
agarose containing N-hydroxysuccinimide functional groups, which bind amino (-NH2) 
groups in proteins spontaneously via a covalent bond. Affigel 15 solution (Bio-Rad) 
was transferred to a 15 ml sterile conical tube (Falcon, Becton Dickinson, Oxford, UK) 
to give a 1 ml volume of settled gel. The affigel was centrifuged at 180 g for 5 minutes 
and the supernatant removed and discarded. The gel was washed in 3 ml of cold 
double-distilled sterile water and centrifuged. The supernatant was removed and 1 mg 
of hrIL- 6  in 4 ml of cold PBS was added. For optimum coupling, this first part of the 
procedure was performed within 20 minutes. The gel slurry was then agitated on a tube
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rotator for 4 hours at 4°C. After 4 hours, the affigel was centrifuged and the supernatant 
removed and kept to be assayed for unbound hrIL-6 . The affigel was washed twice with 
3 ml double-distilled water and both supernatants were kept to assay for unbound IL-6 . 
The affigel was transferred to a column consisting of a 2 ml sterile syringe body with a 
cotton wool plug and a two-way valve. The column was washed with double-distilled 
water, followed by 20 ml 0.1 M glycine/HCl pH 2.5, the solution to be later used to 
elute the antibodies from the column. Finally, the column was washed with PBS and 
stored at 4°C in PBS + 0.1% sodium azide.
Unbound IL- 6  in wash supernatants was calculated from the absorbance at 280 nm in a 
1 cm light path. The pH of the supernatants were first lowered using HC1, as N- 
hydroxysuccinimide released during coupling adsorbs at neutral or basic pH.
IL- 6  (mg/ml) in supernatant = A280 nm x 10
13.6
Based on the above equation (Harlow & Lane, 1988), only 18% of the hrIL- 6  remained 
unbound.
2.4.2. Purification of IL-6 antibody
The IL- 6  affigel column was washed with 50 ml PBS at room temperature, prior to the 
addition of 1 ml of IL- 6  antiserum. The antiserum was allowed to penetrate completely 
into the gel, before the flow was stopped and PBS added to the top of the gel to prevent 
it drying out. The column was covered with nescofilm and incubated at room 
temperature for 4 hours. The column was washed with 50 ml PBS to remove non­
specific antibodies. Specific anti-IL- 6  antibody was eluted with 10 ml 0.1 M 
glycine/HCl, pH 2.5 and 1 ml fractions were collected in tubes containing 200 pi 1 M 
TRIS, pH 8 . 8  to neutralise the pH of the sample. The column was then washed with a 
further 10 ml glycine/HCl followed by PBS. The column was stored in PBS + 0.1% 
sodium azide at 4°C.
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The protein concentration of each fraction was determined by reading the absorbance at 
280 nm. The first 4 - 6  fractions contained the eluted IL- 6  antibody and were therefore 
pooled. The antibody was dialysed overnight at 4°C against either 3 L of PBS, pH 7.4 
(for ELISA coating antibody) or 100 mM HEPES, pH 8.5 (for detecting antibody). The 
protein concentration of the antibody solutions was measured using a Bio-Rad protein 
assay (see section 2.3). 1 and 1.7 mg of antibody was obtained per ml of serum from 
two separate bleeds. Samples in PBS were then concentrated to 1 mg/ml in an Amicon 
Ultrafiltration cell, under nitrogen gas, using a YM 30 membrane (Diaflo ultrafiltration 
membranes, Amicon Corporation, Danvers, USA) and stored at -20°C. Antibody in 100 
mM HEPES was concentrated to 2 mg/ml ready for biotinylation.
2.4.3. Biotinylation of antibodies
Antibodies (anti-IL- 6  and anti-RANTES) were labelled using a succinimide ester of 
biotin, which covalently couples to the protein via free amino groups. Biotinylated 
antibodies can then be detected using peroxidase labelled streptavidin, which has a very 
high affinity for biotin.
The protein to be biotinylated was dissolved in 100 mM HEPES buffer, pH 8.5 to a 
concentration of 2  - 1 0  mg/ml (e.g. to a 1  ml volume of a 2  mg/ml solution). 
Immediately prior to use, N-hydroxysuccinimidobiotin (Sigma) was dissolved in 
warmed N,N-dimethylformamide (DMF) (Aldrich) to an appropriate concentration (e.g. 
1 0  mg/ml), so that an amount of biotin equivalent to 1 / 1 0  of the weight of protein (e.g. 
0.2 mg biotin) was added in a 20 pi volume to the antibody preparation. The 
preparation was incubated at room temperature for 2  hours with occasional agitation. 
The reaction was stopped by adding 5 pi ethanolamine (Sigma) and the biotinylated 
antibody was dialysed against 3 changes of 2 L of PBS, pH 7.4 to remove unreacted 
biotin. The antibody was stored at -20°C.
50
2.5. ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
Recipes for the buffers used in the following ELISA protocols are given in appendix III. 
Standard curves were run on every plate, and a control standard of recombinant IL-6 , 
IL- 8  or RANTES diluted in wash buffer + 2% FCS (stored frozen, in aliquots at -20°C) 
was included on each plate to monitor both interplate and interassay variability.
2.5.1. IL-6 ELISA
Antigenic IL- 6  peptide in culture supernatants was quantitated using a double-ligand 
ELISA method, as previously described (Taktak et al. 1991). Optimum concentrations 
of antibody for coating and detecting were determined for each batch of antibody 
purified by performing a checkerboard ELISA to compare different coating and 
detecting antibody concentrations (in the range of 0.5 - 1.5 pg/ml). The concentrations 
which produced a steeper standard curve were used. IL- 6  in cell supernatants was 
estimated by comparison with a standard curve of the ‘international standard for IL-6 ’ 
(code 89/548, NIBSC) (Gaines Das & Poole, 1993).
Flat-bottomed 96-well microtitre plates (Nunc Immuno maxisorb plates) were coated 
with 100 p 1/well of affinity purified anti-IL6  antibody in PBS coating buffer. Plates 
were covered and incubated overnight at 4°C. Plates were washed 3x with wash buffer, 
followed by the addition in duplicate of either 100 pi of IL- 6  standard (range 0.008 to 2 
ng/ml) or culture supernatant appropriately diluted in wash buffer + 2% (v/v) FCS, and 
incubated for 2 hours at room temperature. Plates were washed 3x and 100 pi 
biotinylated anti-IL- 6  antibody diluted in wash buffer + 2% FCS was added to all wells 
and incubated for 1 hour at room temperature. Plates were washed 3x and incubated 
with 100 pi streptavidin-peroxidase (Sigma) (0.5 pg/ml) diluted in wash buffer + 2% 
FCS for 15 minutes. Following 3 washes, 100 pi of 0.2 mg/ml o-phenylenediamine 
dihydrochloride (OPD) dissolved in warm 0.1 M citric acid-phosphate buffer containing 
0.4 pl/ml 30% (v/v) H2 0 2  was added to all wells. The substrate solution was prepared 
immediately prior to use. After 15 minutes incubation in the dark at room temperature, 
colour development was stopped with 150 pi 1 M H2 S0 4  and optical density (OD) 
measured at 492 nm. The assay was linear between 0.03 - 2 ng/ml (Fig. 11).
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2.5.2. IL-8 ELISA
Antigenic IL- 8  in culture supernatants was quantitated using a double-ligand ELISA 
method as previously described (Ceska et al. 1989). Mouse monoclonal anti-human IL- 
8  antibody, goat polyclonal anti-human IL- 8  antibody conjugated to alkaline 
phosphatase and human recombinant IL- 8  standard were provided by Dr I. Lindley of 
Sandoz Forschungsinstitut (Vienna, Austria). Antibodies were stored at 4°C.
96 well microtitre plates (Nunc immuno maxisorb plates) were coated with 100 pl/well 
of monoclonal anti-IL- 8  antibody (5 pg/ml) in carbonate coating buffer. Plates were 
covered and incubated overnight at 4°C. Plates were washed 3x with wash buffer, 
followed by the addition in duplicate of 100 pi IL- 8  standard (0.025 to 2 ng/ml) or 
culture supernatant appropriately diluted in wash buffer + 2% (v/v) FCS, and incubated 
for 2 hours at 37°C. Plates were washed 3x and 50 pi alkaline phosphatase-conjugated 
goat anti-IL- 8  antibody (5 pg/ml) in wash buffer + 2% FCS was added for 2 hours at 
37°C. Following 3 washes, plates were incubated with 100 pi of 1 mg/ml/?-nitrophenyl 
phosphate in warmed diethanolamine buffer at room temperature, until the top standard 
read ~1.5 OD. The reaction was terminated with 50 pl/well 3 M NaOH, and the OD 
measured at 405 nm. The assay was linear between 0.05 - 2 ng/ml (Fig. 12).
2.5.3. RANTES ELISA
Antigenic RANTES in culture supernatants was quantitated using a double-ligand 
ELISA method. Mouse monoclonal anti-human RANTES antibody and goat polyclonal 
anti-human RANTES antibody were purchased from R&D systems (Abingdon, UK). 
The polyclonal anti-RANTES antibody was biotinylated according to the method 
described in 2.4.3, and both monoclonal and polyclonal antibodies were stored in 
aliquots at -20°C. Human recombinant RANTES peptide was from PeproTech INC, 
Rocky Hill, NJ.
96 well microtitre plates (Nunc immuno maxisorb plates) were coated with 50 pl/well 
of monoclonal anti-RANTES antibody (1 pg/ml) in carbonate coating buffer, pH 9.6. 
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Figure 11. Standard curve for the IL-6 ELISA. OD values are the means o f  duplicates after 
subtracting the average OD o f blank wells. The graph is plotted on a log-log scale. A 0.5 ng/ml IL-6 
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Figure 12. Standard curve for the IL-8 ELISA. OD values are the means o f  duplicates after 
subtracting the average OD of blank wells. The graph is plotted on a log-log scale. A 0.8 ng/ml IL-8 
control standard had a value o f 0.70 ± 0.01 ng/ml (mean ± SEM) after 11 determinations on different 
days.
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wash buffer, followed by the addition in duplicate of 50 pi of RANTES standard (0.06 
to 2 ng/ml) or culture supernatant diluted in wash buffer + 2% FCS, and incubated for 2 
hours at 37°C. Plates were washed 3x and 50 pi biotinylated polyclonal anti-RANTES 
antibody (1 pg/ml) in wash buffer + 2% FCS added for 2 hours at 37°C. Plates were 
washed 3x and incubated with 50 pi streptavidin-peroxidase (0.5 pg/ml) in wash buffer 
+ 2% FCS for 30 minutes. Following 3 washes, 100 pi of 0.2 mg/ml OPD dissolved in 
warm 0.1 M citric acid-phosphate buffer containing 0.4 pl/ml 30% (v/v) H2 0 2  was 
added. After a 20 minute incubation in the dark, at room temperature, the reaction was 
quenched with 150 pi 1 M H2 S0 4  and the OD at 492 nm was determined. The assay 
was linear between 0.06 - 2 ng/ml (Fig. 13).
2.6. RADIOIMMUNOASSAY FOR MEASUREMENT OF PROSTAGLANDIN
e 2
125PGE2  levels in cells supernatants were quantitated using a commercial PGE2  [ I] 
radioimmunoassay kit (NEN research products, Boston, USA). The basic principle of 
the assay is competitive-binding. The protocol recommended by the manufacturers was 
followed and the detection range of the assay was 2.5 - 250 pg/ml. Briefly, either 
samples or PGE2  standards were incubated overnight at 4°C with a fixed, limiting 
amount of anti-PGE2  rabbit serum and a fixed amount of iodinated analogue of PGE2  as 
a tracer. Antibody-antigen complexes were separated from free antigen by precipitation
125with polyethylene glycol, and the amount of PGE2  [ I] tracer bound was determined 
by counting each sample for 1 minute in a gamma counter. The concentration of PGE2  
in the samples was determined from a standard curve.
2.7. NITRITE ASSAYS
Nitric oxide (NO) production by MC was assessed by measuring nitrite (N02‘ ) and 
nitrate (N03_) levels in culture supernatants. These are the stable end products of NO 
formation in oxygenated solution.
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2.7.1 Griess Reaction
Nitrite levels of culture supernatants were initially quantitated using the Griess reaction 
(Green et al 1982). The assay is based on the reaction of nitrite with Griess reagent 
which forms a purple azo dye, that absorbs at 546 nm.
Griess reagent was made from stock solutions of 0.1% (w/v) naphthylenediamine 
dihydrochloride (Sigma) in milli-Q water and 1% (w/v) sulphanilamide (Sigma) in 5% 
phosphoric acid. The stock solutions were stored in the dark at 4°C for upto 2 months. 
On the day required, the two solutions were mixed 1:1 and warmed to room 
temperature. A standard curve ranging from 0.78 - 100 pM was freshly prepared from 
sodium nitrite (Sigma) diluted in Waymouths medium. 100 pl/well of nitrite standards 
and samples were added in duplicate to a 96 well microtitre plate and mixed with 100 pi 
of Griess reagent. After 10 minutes the OD at 540 nm was determined. The detection 
limit of the assay was 0.8 pM.
Waymouths medium, which contains phenol red did not interfere with the assay (Fig. 
14) and this medium contains no added nitrite or nitrate.
2.7.2. Fluorimetric assay
The fluorimetric nitrite assay is based upon the reaction of 2,3-Diaminonaphthalene 
(DAN) (Lancaster, Morecambe, UK) with nitrite under acidic conditions to form the 
fluorescent product l-(H)-naphthotriazole. The assay was modified for use on a Photon 
Technology International (PTI) spectrofluorimeter from the method of Misko et al 
(1993), which employed a 96 well plate format for a fluorescent plate reader. In 
contrast to the plate reader, the optimum excitation and emission wavelengths for the 
assay could be set on the fluorimeter, thus improving sensitivity. Fluorescent excitation 
and emission spectra for l-(H)-naphthotriazole were obtained as previously described 
(Misko et al 1993), to determine the optimum wavelengths for the assay using our 
system. Nitrite standards made up in milli-Q water were reacted with DAN reagent as 
described below and scanned. The emission wavelength was set at 410 nm to obtain an 


















0.0100 0.1000 1.0000 
RANTES (ng/ml)
10.0000
Figure 13. Standard curve for the RANTES ELISA. OD values are the means o f  duplicates after 
subtracting the average OD of blank wells. The graph is plotted on a log-log scale. A 1.5 ng/ml 




















Figure 14. Standard curve for the Griess reaction in water or W aymouths medium. Sodium nitrite
standards were either diluted in MQ-water (•, ___) or Waymouths medium ( ■ , ------). OD values are the
means o f duplicates after subtracting the average OD of blank wells. The graph is plotted on a log-log  
scale.
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emission spectrum (Fig. 16). The scan speed was 240 nm/min with excitation and 
emission slits set at 10 nm. An excitation wavelength of 365 nm and emission 
wavelength of 405 nm were found to be optimum, which was consistent with previous 
findings (Misko et al 1993).
Milli-Q water and sterile glassware were used to prepare all reagents for the assay to 
keep background levels of nitrite low. A standard curve of sodium nitrite in 
Waymouths medium, ranging from 100 nM to 2 pM was prepared. 2 ml of standard or 
culture supernatant was mixed in a bijoux with 200 pi of freshly prepared DAN reagent 
(0.05 mg/ml DAN in 0.62 M HC1) and incubated at room temperature in the dark. After 
10 minutes the reaction was stopped by the addition of 100 pi 2.8N NaOH. Fluorescent 
intensity of 2  ml volumes of standards and samples was measured on the fluorimeter 
using an excitation wavelength of 365 nm and an emission wavelength of 405 nm.
Waymouths medium, which contains phenol red caused some interference with the 
assay, reducing fluorescence levels compared to water (Fig. 17).
2.7.3. Chemiluminescence assay
Nitrite levels in cell supernatants were also quantitated by chemiluminescence (Garside, 
1982; Menon et al 1991), using a Sievers NOA 270B nitric oxide analyser (Boulder, 
Colorado, USA). The assay was kindly performed by Dr Mark Wilkes (Queen 
Elizabeth hospital, Birmingham), and detects nitrite levels down to the pM range. 
Chemiluminescent measurement is based on the gas phase reaction between NO and 
ozone, which generates light that is detected by a sensitive photomultiplier tube. This 
technique measures NO directly, therefore nitrite levels in culture supernatants were 
first converted back to NO during the assay by the addition of 1% sodium iodide 
solution in glacial acetic acid. An inert gas (nitrogen) is then bubbled through the 
supernatant to push the NO into the gas phase, which is achieved due to the low 
solubility of NO in aqueous solution. Five separate measurements were performed for 
each sample, using 100 pi supernatant per measurement. The assay was calibrated 
using standards of sodium nitrite.
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Figure 15. Excitation spectrum o f the fluorescent product, l-(H )-naphthotriazole. A 5 pM nitrite 
standard was reacted with DAN reagent and scanned using an emission wavelength o f  410 nm. The scan 
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Figure 16. Emission spectrum of l-(H )-naphthotriazole. Nitrite standards (0.5 - 5 pM) were reacted 
with DAN reagent and scanned using an excitation wavelength o f 365 nm. The scan speed was 240 





































0 500 1000 1500 2000
Nitrite (nM)
Figure 17. Standard curve for the fluorimetric nitrite assay in water or Waymouths medium.
Sodium nitrite standards (B=blank, S 1=100 nM, S2=250 nM, S3=500 nM, S4=100 nM, S5=2000 nM) 
were either diluted in MQ-water (•, — ) or Waymouths medium (■, — ). Fluorescence values were read 
o ff  the fluorimeter trace (a) and plotted against nitrite concentrations using a linear scale (b).
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2.7.4. Enzymatic conversion of nitrate to nitrite
Nitrate levels in culture supernatants are not detected by the Griess reaction or 
fluorimetric assay. Nitrate must therefore be reduced to nitrite for measurement. 
Nitrate was reduced to nitrite using the enzyme nitrate reductase from Aspergillus niger, 
as previously described (Misko et al. 1993; Hevel & Marietta, 1994).
Reagents:
B-Nicotinamide adenine dinucleotide phosphate - reduced form (B-NADPH; Sigma) was 
diluted to 0.6 mM in 0.15 M potassium phosphate buffer, pH 7.5 and stored in aliquots 
at -20°C for upto 2 weeks.
Nitrate reductase (NADPH-dependent) (Sigma) was diluted to 4.2 U/ml in 0.15 M 
potassium phosphate buffer and stored in aliquots at -20°C.
Milli-Q water and sterile glassware were used to prepare all buffers to reduce 
background nitrate levels.
Culture supernatants were incubated with 280 mU/ml nitrate reductase and 40 pM 
NADPH for 30 minutes at room temperature. Samples to be measured by the Griess 
reaction were incubated in a final volume of 100 pi, in duplicate, in a 96 well plate. The 
reaction was terminated after 30 minutes by the addition of 100 pi of Griess reagent and 
nitrite levels were estimated against a standard curve of sodium nitrite as described in 
section 2.10.1. Samples to be measured by the fluorimetric assay were incubated in a 
fined volume of 300 pi and the reaction was terminated after 30 minutes by the addition 
of 300 pi of milli-Q water. The samples were then reacted as described in 2.10.2, with 
appropriately adjusted volumes of DAN reagent and 2.8N NaOH (60 pi and 30 pi 
respectively). The fluorescent intensity of 600 pi of converted samples and standards 
were measured in the fluorimeter using a small quartz cuvette (650 pi capacity). The % 
conversion achieved each time was calculated by converting standards of sodium nitrate 
(Sigma) in Waymouths medium in parallel with samples.
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2.8. NORTHERN ANALYSIS
Total cellular RNA was isolated from MC using a modification of the methods of 
Chirgwin et al (1979) and Strieter et al (1989). Buffers and solutions used for northern 
analysis are detailed in appendix IV, and all solvents were ‘analytical reagent’ grade.
2.8.1. RNA isolation
MC, in 25 cm tissue culture flasks, were scraped into 3 ml nucleic acid extraction 
buffer and frozen at -70°C in 15 ml sterile polypropylene conical tubes (Falcon) for at 
least 1 hour. RNA was separated from DNA and protein using phenol-chloroform and 
isoamyl alcohol-chloroform. The tubes were kept on ice during the following steps. 
The cell mixture was homogenised by pipetting up and down 25x using a sterile 
pastette. 1.5 ml of phenol extraction buffer and 1.5 ml of a 1:1 solution of water- 
saturated phenol (Rathbum chemicals Ltd, Walkerbum, UK):chloroform was added and 
each tube vortexed vigorously for 2 minutes. Tubes were centrifuged at 3000 g for 10 
minutes at 4°C. Using a sterile glass pipette, the upper aqueous layer was transferred to 
a fresh 15 ml tube and 1.5 ml phenol : chloroform added. The tubes were vortexed and 
centrifuged as before. The upper aqueous layer was transferred to a fresh 15 ml tube 
and 2.5 ml of a 1:25 solution of isoamyl alcohol : chloroform added. The tubes were 
vortexed and centrifuged at 3000 g for 7 minutes. The upper aqueous layer was 
transferred to a fresh 15 ml tube and mixed with 300 pi 3 M sodium acetate and 3 ml 
propan-2-ol. Tubes were kept at -70°C for at least 1 hour to allow RNA to precipitate. 
The contents were then transferred to a 16 x 76 mm polyallomer ultra centrifuge tube 
(Beckman Instruments Ltd, Buckinghamshire, UK) which had been DEPC-treated and 
autoclaved. The tubes were centrifuged at 30,000 g for 75 minutes at 4°C. The 
supernatant was removed and the RNA pellet transferred to an eppendorf tube in 1.5 ml 
75% ethanol solution. The RNA pellets were frozen at -70°C for at least 1 hour.
2.8.2. Sample preparation
RNA samples were centrifuged at 12,000 g for 15 minutes at 4°C. The supernatant was 
removed and 1.5 ml 75% ethanol added to the RNA pellet. The samples were 
centrifuged and the wash step repeated. The supernatant was removed and the pellets
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air dried in a fume cupboard for 1 hour. RNA pellets were resuspended in 25 pi diethyl 
pyrocarbonate (DEPC) treated water and kept on ice. RNA was quantitated by 
measuring the absorbance of 2 pi RNA in 1 ml 0.1 M NaOH at 260 nm. The amount of 
RNA present in the sample (in pg) was calculated by;
OD2 6 0  nm x dilution factor (500) x 40 x volume of remaining RNA solution in ml (0.023)
ODs were also read at 280 nm and 230 nm to assess the purity of the RNA. A value of 
less than 2 for the OD26o • OD28o ratio indicates protein contamination. A low (<2) 
O D 26o : OD230 ratio indicated guanidine contamination.
33 pi of RNA sample buffer was added to 10 pg RNA and the samples were vortex 
mixed and heated for 15-30 minutes at 80°C. The samples were cooled on ice and 2.5 
pi of bromophenol blue solution added. Samples were mixed and briefly centrifuged (5 
seconds) prior to loading on to agarose gels.
2.8.3. Gel preparation and transblotting
A 1% agarose gel was prepared by dissolving 3 g agarose (Boehringer Mannheim) in 
230 ml DEPC-treated water. The solution was heated until the agarose dissolved. 15 
ml 20x 3-[N-morpholino]propane-sulphonic acid (MOPS) buffer and 54 ml 
formaldehyde were added and the gel solution allowed to cool to ~60°C before pouring. 
The gel was set with two 15 lane combs using tanks purchased from Hoefer Scientific 
Instruments (Newcastle, UK). After 40 minutes, the gel was transferred to a submarine 
tank (Hoefer), which was surrounded with ice, and covered with 1 L of cold lx MOPS 
running buffer. 10 pg RNA per lane was loaded and the gel run at a constant current of 
100 mA, until the bromophenol blue band had migrated 1.5 inches (~2 hours). The gel 
was observed under UV light and the ethidium-bromide stained 18S and 28S ribosomal 
RNA bands used to assess equal loading. The gel was photographed using a polaroid 
CU5 88-46 land camera (Genetic research instrumentation Ltd) and type 55 polaroid 
film (Sigma), before being agitated in DEPC-water for 30 - 60 minutes to remove the 
formaldehyde, prior to transblotting.
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The blotting tank consisted of a glass plate suspended in a sandwich box, which was 
half filled with 20x SSC buffer. A wide strip of filter paper placed over the glass plate 
and reaching down into the buffer solution at each end acted as a wick. The gel was 
placed upside down on the filter paper and covered with a piece of positively charged 
nylon membrane (Boehringer Mannheim), which had been briefly soaked in 20x SSC. 
All air bubbles were removed before covering the membrane with 3 pieces of similar 
size filter paper and a stack of paper towels. A glass plate and 500 g weight were placed 
on top, and left overnight to allow the RNA to transfer by capillary action. The RNA 
was fixed onto the nylon membrane by baking at 120°C for 20 minutes. The membrane 
was sealed in a plastic bag and stored at room temperature prior to hybridisation.
2.8.4. Hybridisation and detection using the non-radioactive DIG-labelling system
The DIG detection system is based on the labelling of nucleic acid probes with a steroid 
hapten, digoxigenin. The DIG-labelled probes are hybridised to membrane-bound 
RNA. Specific hybridisation is immuno-detected with an alkaline phosphatase 
conjugated anti-digoxigenin antibody and visualised with the chemiluminescent 
substrate, CSPD (see Abbreviations, p.viii), using X-ray film.
All reagents used for the detection of DIG-labelled probes were purchased from 
Boehringer Mannheim. DIG-labelled cocktails of oligonucleotide probes to IL-8, MCP- 
1, RANTES, IL-6, iNOS and B-actin were purchased from R&D systems. Hybridisation 
of membranes and detection of bound probes was performed essentially as described in 
the Boehringer Mannheim protocols. Hybridisation temperatures were optimised for 
each probe. IL-8, MCP-1, RANTES, IL-6 and B-actin probes were all hybridised at 
42°C, while the iNOS probe required a temperature of 60°C. All probes were used at a 
final concentration of 10 ng/ml.
The volumes specified are for a 100 cm membrane and pre-hybridisation, hybridisation 
and stringency wash steps were all performed at the appropriate hybridisation 
temperature. The membrane was pre-hybridised by incubating with 20 ml hybridisation 
solution for 1 hour in a sealed plastic bag. The solution was discarded and 2.5 ml of 
probe diluted to 10 ng/ml in hybridisation solution added. All air bubbles were
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removed and the bag resealed and incubated overnight. The membrane was transferred 
to a small sandwich box and stringency washes performed. The membrane was washed 
twice for 5 minutes in 2x SSC + 0.1% SDS solution followed by 2x 5 minutes in 0.1 x 
SSC + 0.1% SDS solution. The following steps were then performed at room 
temperature on a shaking waterbath. Membranes were washed for 5 minutes in wash 
buffer, prior to blocking for 30 minutes with 100 ml buffer 2. Membranes were 
incubated for 30 minutes with 20 ml alkaline phosphatase conjugated anti-DIG antibody 
diluted 1:10,000 in buffer 2, washed 2x15 minutes in wash buffer and equilibrated for 2- 
5 minutes in buffer 3. The membrane was drained and incubated for 5 minutes between 
2 plastic sheets with 1 ml CSPD substrate diluted 1:100 in buffer 3. The membrane was 
drained, sealed in a plastic bag and incubated at 37°C for 15 - 30 minutes. The 
membrane was then exposed to Kodak omat AR5 X-ray film (Sigma) for 1 to 2 hours at 
room temperature.
2.8.5. Stripping and reprobing membranes
In some experiments the probe was removed from northern blots which had been 
developed as described in 2.8.4, and the membranes were reprobed with the house 
keeping gene p-actin to determine equal loading and assess specificity of drug 
treatments.
Membranes were rinsed thoroughly in DEPC-water and incubated for 2 x 30 minutes in 
50% N,N-dimethylformamide, 1% SDS, 50 mM TRIS-HC1, pH 8.0 at 68°C. 
Membranes were rinsed in DEPC-water, then in 2x SSC and prehybridized and 
hybridized as described above.
2.9. ADP-RIBOSYLATION EXPERIMENTS
2.9.1. Preparation of cell membranes
Cell membranes were extracted from MC grown in 80 cm tissue culture flasks for use 
in the ADP-ribosylation experiments. MC used in the toxin time course experiments 
described in 2.9.2.1 were pretreated with either CT (100 ng/ml) or PT (1 pg/ml) for 0 - 6
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hours prior to membrane extraction. 2 flasks per time point were used. After toxin 
treatment, cells were washed 2x with PBS and trypsinised off the flasks, as detailed in
2.1.2. The pellet of cells was washed 2x with PBS to remove traces of medium and 
FCS added to inhibit the action of trypsin.
Membranes were extracted from untreated MC for use in the agonist-dependent cholera 
toxin ribosylation experiment described in 2.9.2.2. Cells were washed 3x in PBS and 
scraped off the flasks into 6 ml PBS containing a cocktail of protease inhibitors 
(pepstatin A, aprotinin and leupeptin at 10 pg/ml, phenylmethylsulfonyl fluoride 
(PMSF) at 174 pg/ml (Sigma)). Cells were scraped from the flasks to ensure cell 
receptors remained intact. Cells were pelleted by centrifuging at 500 g for 10 minutes at 
4°C.
Cell membranes were then extracted as previously described (O'Neill et al 1990a). 
Cells were resuspended in 1 ml hypotonic buffer (10 mM Tris, 1 mM MgCl2, pH 7.2) 
containing a cocktail of protease inhibitors (as above), and mixed with 4 volumes of 
sucrose buffer (0.25 M sucrose dissolved in hypotonic buffer). Membranes were 
homogenised by 50 strokes in a ‘tight’ dounce pestle and centrifuged at 500 g  for 5 
minutes at 4°C to remove nuclei and unbroken cells. A membrane enriched fraction 
was obtained by centrifuging the supernatant at 25,000 g for 30 minutes at 4°C. The 
resulting membrane pellets were resuspended in 1 ml PBS containing 1 mM PMSF. 
The protein content of samples was determined as described in section 2.3. Membranes 
were stored at -70°C for use in the toxin time course experiments, or overnight at 4°C 
for use in the agonist-dependent ribosylation experiments.
2.9.2. ADP-ribosylation assay
Stock solutions fo r ADP-ribosylation assay: All solutions were prepared fresh on the 
day in double-distilled water, except for 50 mM MgCl2, which was stored.
100 mM thymidine (Sigma)
30 mM ATP (disodium salt, grade I) (Sigma)
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10 mM GTP (sodium salt, type III) (Sigma)
10 pM (3-NAD (Sigma)
1 M dithiothreitol (DTT) (Gibco)
50 mM MgCl2
1 M Arginine-hydrochloride (Sigma)
2.9.2.1. Cholera and pertussis toxin time course experiments
Extracted membranes were exposed to either cholera toxin, cholera toxin B oligomer,
32pertussis toxin or pertussis toxin B oligomer in the presence of a [ PJ-NAD label (NEN 
research products) and the level of ribosylation determined as previously described 
(O'Neill et al. 1992). All toxins were pre-activated immediately prior to use by 
incubating with 10 mM dithiothreitol for 20 minutes at 30°C to release the SI subunit, 
then kept on ice. Cell membranes were washed with 0.15 M potassium phosphate 
buffer, pH 7.5 and collected by centrifuging at 10,000 g  for 5 minutes. 60 pg of 
membrane protein was incubated with 50 pg/ml of pre-activated CT or CT-B, or with 
10 pg/ml pre-activated PT or 100 pg/ml pre-activated PT-B in 0.15 mM potassium 
phosphate, 10 mM thymidine, 0.5 mM ATP, 50 pM GTP, 10 pM [32P]-NAD+ (50 - 100 
pCi/ml) in a final volume of 100 pi. After incubating for 15 minutes at 30°C, the 
reaction was stopped by the addition of 1 ml of cold 0.15 M potassium phosphate buffer 
and membranes were collected by centrifuging at 10,000 g for 5 minutes at 4°C. 
Membranes were resuspended in 30 pi lx electrophoresis sample buffer and proteins 
were separated by SDS-PAGE.
2.9.2.2. Agonist-dependent cholera toxin ribosylation of a Gi/o type protein
Membranes extracted from untreated cells were CT ribosylated in the absence of 
guanine nucleotide as previously described (Milligan et al 1991; Iiri et al 1989). Cell 
membranes were washed with 0.15 M potassium phosphate buffer and collected by 
centrifugation at 10,000 g for 5 minutes. 60 pg membrane protein was incubated with 
50 pg/ml CT in 0.25 mM potassium phosphate buffer, 20 mM thymidine, 1 mM ATP, 
20 mM arginine-HCl, 3 pM [32P]-NAD (50 - 100 pCi/ml) with and without the presence 
of IL-la (1 or 10 pg/ml), TNFa (1 or 10 pg/ml) or endothelin-1 (3 pM), in a final 
volume of 100 pi. The inclusion of 2.5 mM MgCl2 in the reaction mixture was also
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tried. After incubating for 1 hour at 30°C, the reaction was terminated as above and the 
proteins separated by SDS-PAGE.
2.10. SODIUM DODECYL SULPHATE-POLYACYRLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE)
Proteins were analysed by one dimensional gel electrophoresis, which under reducing 
conditions separates proteins based on molecular size. SDS-PAGE was carried out 
essentially as described by Laemmli (1970). Buffers used for SDS-PAGE are detailed 
in appendix V.
2.10.1. Separation of membrane proteins after ADP-ribosylation
Membrane proteins were separated by SDS-PAGE using the Protean II xi gel system 
(Bio-Rad). Each 20 cm x 16 cm x 1 mm gel was prepared from stock solutions as 
described below;
12.5% (w/v) acrylamide resolving gel;
Protogel (30% (w/v) acrylamide and 0.8% (w/v) Bisacrylamide) 12.5 ml
(National Diagnostics, Aylesbury, UK)
1.5 M TRIS-HC1, pH 8.8 7.2 ml
10% SDS solution 0.3 ml
10% ammonium persulphate 150 pi
double-distilled water 9.85 ml
N, N, N \ N’, tetramethylethylene-diamine (TEMED) (Sigma) 15 pi
5% (w/v) acrylamide stacking gel
Protogel 1.6 ml
0.5 M TRIS-HC1, pH 6.8 2.5 ml
10% SDS solution 0.1 ml
10% ammonium persulphate 50 pi
double-distilled water 5.75 ml
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TEMED 10 nl
The resolving gel was poured and overlaid with a layer of 50% methanol in distilled 
water. After 1 hour the methanol was removed and the top of the gel rinsed with water. 
The stacking gel was poured on top of the resolving gel and set with a 15 lane comb. 
The stacking gel was left 1 hour to polymerise.
Membrane samples were solubilized by boiling for 5 minutes in 30 pi of lx sample 
buffer, which contained 2-mercaptoethanol to reduce protein disulphide bonds. Samples 
were left to cool prior to loading. A prestained molecular weight standard (Gibco) was 
included on each gel. Samples and standard were not loaded in the outer two wells of 
any gel and all empty wells were loaded with an equivalent volume of lx sample buffer 
to ensure that the samples ran straight. Gels were run overnight (13 hours) at a constant 
current of 10 mA per gel using a Bio-Rad powerpack at room temperature and tap water 
was circulated through the cooling system during the run to prevent overheating of the 
gels. The electrophoresis buffer was stirred throughout by placing the tank on a 
magnetic stirrer.
Gels were stained for protein by gently agitating in 0.1% coomassie blue stain for 1 
hour at room temperature. Gels was then transferred into destain solution, which was 
changed regularly until the blue bands of protein were visible on a clear background of 
gel. The sensitivity of coomassie blue staining is 0.3 - 1 pg protein/band. Gels were 
stained to assess equal loading of protein across the lanes. After staining, the gels were 
placed between a sheet of filter paper and a sheet of clear cellophane and dried for 2 
hours at 80°C using a Bio-Rad gel dryer. The dried gels were exposed to Kodak x-omat 
x-ray film for approximately 2 days at -70°C with intensifying screens.
2.10.2. Separation of cell proteins for iNOS detection
MC in 25 cm flasks were extracted for iNOS protein by scraping the cell monolayer 
into 0.5 ml of lx sample buffer containing 20 mM EDTA and 5 pg/ml carboxypeptidase 
inhibitor (Sigma). Samples were immediately boiled for 5 minutes, then stored in 100 
pi aliquots at -20°C until required.
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Two 10 cm x 8 cm x 1 mm minigels were prepared from the following stock solutions;
7% (w/v) acrylamide 5% (w/v) acrylamide
resolving gel: stacking gel:
Protogel (30% acrylamide, 0.8% bisacrylamide) 3.5 ml 1.67 ml
1.5 M TRIS-HC1, pH 8.8 5.6 ml -
0.5 M TRIS-HC1, pH 6.8 - 1.25 ml
10% SDS solution 0.15 ml 0.1 ml
10% ammonium persulphate 0.1 ml 0.05 ml
double-distilled water 5.85 ml 6 ml
TEMED 10 pi 10 pi
Samples were thawed and centrifuged at 12,000 g  for 2 minutes prior to loading. 20 pi 
of sample was loaded per lane (-20 pg) and a prestained molecular weight marker was 
included on each gel. Gels were run at room temperature at 100 volts, until the 
bromophenol blue tracking dye entered the resolving gel. The voltage was then 
increased to 150 volts. Gels were run until the bromophenol blue band had reached the 
bottom of the resolving gel. Gels were then placed into transfer buffer in preparation for 
western blotting.
2.11. WESTERN BLOTTING
2.11.1. Electrophoretic transfer of proteins to nitrocellulose
Proteins separated on 7% polyacrylamide gels were transferred to nitrocellulose paper 
using a wet transfer method. The polyacrylamide gel was soaked for 15 minutes in 
transfer buffer and the lanes of the stacking gel removed. Two pieces of filter paper, a 
piece of nitrocellulose paper and two nylon pads were also soaked in transfer buffer. 
The gel was overlaid with a piece of wet nitrocellulose membrane (Protran BA 85) 
(Schleicher and Schuell, Dassel, Germany) and surrounded on each side by a layer of
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filter paper and a nylon pad. The gel ‘sandwich’ was enclosed in a cassette and placed 
in the transfer tank (Bio-Rad) with the nitrocellulose nearest the anode. The tank was 
filled with cold (4°C) transfer buffer and placed on a magnetic stirrer. Electrophoretic 
transfer was carried out for 35 minutes at 75 volts.
2.11.2. Immunoblotting of nitrocellulose-bound protein
Western blot analysis of iNOS protein was performed according to the method of Dr J. 
Weidner, MERCK research laboratories, Rahway, NJ (personal communication). N053 
rabbit antisera directed against the C-terminal sequence of human iNOS and control 
N054 blocking peptide were gifts from MERCK. Antisera was diluted 1:1 in glycerol 
and stored at -20°C for daily use.
Nitrocellulose membranes were incubated for 30 minutes in 3% milk protein (Sigma) in 
PBS. Membranes were washed once with PBS-T (PBS + 0.05% tween) for 10 minutes, 
and incubated for 1 hour with a 1:40,000 dilution of iNOS antisera diluted in PBS-T. 
Membranes were washed 3 x 10 minutes with PBS-T and incubated for 1 hour with 
sheep polyclonal anti-rabbit IgG antibody conjugated to alkaline phosphatase (Sigma, 
A-0407) diluted 1:1000 in PBS-T. Membranes were washed 3 x 10 minutes with PBS, 
then incubated for 3 - 10 minutes with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium (BCIP/NBT) substrate (2 x 0.2 g tablets diluted in 20 ml distilled water 
immediately prior to use) (Sigma, B-5655). When the desired development of bands 
was reached, the reaction was stopped by transferring the membrane into 4 mM EDTA 
in PBS, pH 7.4 and incubating for 3-5 minutes. To avoid carryover, all incubations 
except the wash steps were performed in separate containers.
Specificity of the iNOS antisera was confirmed by adding 50 nM of a blocking peptide, 
to the working dilution of antisera. The blocking peptide corresponded to the C- 
terminal sequence of human iNOS, against which the antibody was directed.
Separation of MC samples by SDS-PAGE for analysis of iNOS protein and Western 




Nuclear extracts were prepared from MC for analysis of NF-kB activity. Quiescent MC 
grown in 25 cm flasks were pretreated with dibutyryl-cAMP (db-cAMP) (100 pM) or 
media alone for 5 hours, prior to the addition of IL-la (3 ng/ml) to the media for 30 
minutes, 1, 2 or 6  hours. Supernatants were removed and nuclear extracts prepared as 
previously described (Stylianou et al 1992). All buffers used for the nuclear extraction 
contained 0.5 mM PMSF. Cells were briefly washed in hypotonic buffer (10 mM 
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KC1, 0.5 mM DTT) and lysed by incubating in
1.5 ml hypotonic buffer containing 0.1% Nonidet P-40 for 10 minutes on ice. Cells 
were scraped from the flasks and transferred to 1.5 ml eppendorfs. Lysates were 
centrifuged at 10,000 g for 10 minutes at 4°C and the supernatant discarded. The 
pelleted nuclei were resuspended in 45 pi of lysis buffer (20 mM HEPES, pH 7.9, 420 
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% (v/v) glycerol) and incubated at 4°C 
for 15 minutes. Lysed nuclei were vortexed and centrifuged at 10,000 g  for 10 minutes 
at 4°C. The supernatant was removed and mixed with 105 pi of storage buffer (20 mM 
HEPES, pH 7.9, 100 mM KC1, 0.2 mM EDTA, 20% (v/v) glycerol, 0.5 mM DTT). 
Pellets were discarded. The protein content of the samples was estimated, as described 
in section 2.3. and samples were frozen at -70°C.
2.13. ELECTROPHORETIC MOBILITY SHIFT ASSAY
MC nuclear extracts were analysed for NF-kB activity by electrophoresis, as previously 
described (O'Neill et al 1992). 4 pg of nuclear extract protein was incubated for 30
3 32minutes at room temperature with 2x10  cpm P-labelled DNA fragment derived from 
the 5 flanking region of the human serum amyloid A gene (SAA), genomic clone 
SAAg9, which contains the NF-kB binding site. All reactions were performed in the 
presence of 3 pg of poly(dl-dC) as nonspecific competitor DNA. Protein-DNA 
complexes were separated by electrophoresis in 4% acrylamide gels and detected by 
autoradiography.
Gel mobility shift assays were kindly performed by Dr Luke O’Neill (Trinity College, 
Dublin).
2.14. STATISTICAL ANALYSIS
The n number for each experiment is given in the respective figure legend and refers to 
the number of MC cultures tested, which were derived from different donors.
Statistical analysis was performed on peptide data which had been log1 0  transformed to 
make the data more normally distributed. The distribution of data around the normal 
was checked before and after transformation using the homogeneity of variance test. 
Groups of data were then analysed by two-way analysis of variance (ANOVA) to 
determine if any statistical differences existed within the data group. Data which was 
significantly different at the p<0.05 level was further compared using Dunnetts t-test for 
the comparison of multiple groups to a control (Dunnett, 1964). This latter test 
identified which treatments within the group were significantly different from the 
control. The levels of significance achieved using Dunnetts t-test are denoted by * = 
p<0.05 and ** = p<0.01.
Two-way ANOVA and homogeneity of variance tests were performed using the 
software package, Mini-tab for windows.
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3. CHARACTERIZATION OF THE KINETICS AND SPECIFICITY OF IL-6. 
IL-8. MCP-1 AND RANTES EXPRESSION AND PRODUCTION IN 
HUMAN MESANGIAL CELLS
3.1. RATIONALE FOR STUDY
It has been previously shown that human mesangial cells in culture have the potential to 
secrete IL-6 , IL- 8  and MCP-1 following IL-1 or TNF stimulation (Brown et al. 1991b; 
Abbott et al. 1991; Brown et al 1992; Rovin et al. 1992). To investigate the regulation 
of these cytokines in MC, initial experiments were carried out to determine the time 
courses of gene expression following IL-1 or TNF activation, and the corresponding 
dose-response curves. This enabled appropriate stimulation times and sub-maximal 
doses of agonist to be selected in later experiments. Furthermore the potential of human 
MC to express the C-C chemokine RANTES, the selective chemotactic factor for 
CD45RO/CD4+ T cells and monocytes was investigated.
3.2. RESULTS
In the following results section, representative figures have been used to demonstrate the 
profiles of IL-6 , IL-8 , MCP-1 and RANTES mRNA expression and peptide production 
in IL-1 a  or TNFa activated MC. While the profiles of peptide generation were found to 
be similar across MC isolated from different donors, some variation in the levels of 
peptide production were observed (in general, up to 5 fold differences). Unless 
otherwise stated, all experiments were carried out on growth-arrested MC, in the 
absence of FCS. Cells were growth-arrested for 24 hours prior to the start of the 
experiments.
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3.2.1. IL-6 mRNA expression and peptide production by cytokine activated 
mesangial cells
MC incubated with media alone for 5, 24 or 48 hours did not express detectable IL- 6  
mRNA transcripts. Stimulation of MC with IL-1 a  (3 ng/ml) resulted in time-dependent 
IL- 6  mRNA expression (Fig. 18). Transcripts were first detected 1 to 2 hours post­
stimulation, maximal expression occurred between 8  and 16 hours and mRNA levels 
had declined to 25 ± 8 % (mean ± SEM, n=4) of the peak levels by 48 hours.
IL- 6  peptide was not detected in culture supernatants from MC incubated with media 
alone for 5, 24 or 48 hours (<0.03 ng/ml). IL- 6  peptide was first detected in culture 
supernatants 8  hours after IL-1 a  stimulation (0.1 ± 0.02 ng/ml (mean ± SEM)) and 
levels were still increasing at 48 hours (Fig. 19). Production of IL- 6  at 48 hours was 24 
± 1 ng/ml (mean ± SEM). Dose-response studies demonstrate stimulation with 3 ng/ml 
IL-1 a  resulted in sub-maximal release of IL- 6  peptide after 18 hours (Fig. 20a). This 
dose of IL-1 a  was used in future experiments.
In comparison to IL-1 a, TNFa was found to be a very poor stimulus for IL- 6  
production in MC. Stimulation with 30 ng/ml TNFa resulted in IL- 6  peptide levels of 
0.09 ± 0.03 ng/ml (mean ± SEM) after 18 hours (Fig. 20b). This compares to 6 . 6  ±0.1 
ng/ml (mean ± SEM) of IL- 6  peptide measured after stimulation with 30 ng/ml IL-1 a  
for 18 hours (Fig. 20a). The time course of TNFa stimulated IL- 6  mRNA expression 
and peptide production were not investigated during this study, as TNFa was such an 
ineffective stimulus for IL- 6  production under the experimental conditions employed. 
Interestingly, the TNFa response could be improved if the experimental culture 
conditions were changed. To enable the experiments to be performed in a ‘defined’ 
system, all studies were carried out in the absence of serum, on quiescent MC which had 
been pre-incubated in serum-free media for 24 hours prior to the start of the experiment. 
A 4 fold increase in IL- 6  peptide production after 48 hours was however observed if 
MC were not growth-arrested prior to TNFa stimulation, and a 13 fold increase in IL- 6  
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Figure 18. Time-dependent 
expression of IL-6 mRNA in IL-1 
activated MC. MC cultured in 25 
cm2 flasks were stimulated with 3 
ng/ml IL-1 a  for the times 
indicated. Control cells (C) were 
treated with media alone for 24 
hours. Total cellular RNA was 
extracted and northern analysis 
carried out. Autoradiographs (i) 
were analysed by densitometry and 
the results plotted using the 
absorbance units (ii). The 
ethidium bromide stained gels 
showing the 18S and 28S 
ribosomal RNA were used to 
assess equal loading (iii). 
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Figure 19. Time course of IL-6 peptide production by IL-1 stimulated MC. MC cultured in 24 
multi-well plates were stimulated with 1 ml o f  3 ng/ml IL -la  for the times indicated. Control wells (C) 
were treated with media alone for 5 to 48 hours. Cell supernatants were quantitated for extracellular IL- 
6 peptide by ELISA. Results are the mean ± SEM o f  duplicate samples from a representative 
experiment, similar results were obtained in 4 other experiments.
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Figure 20. Dose-dependent production of IL-6 peptide by IL-1 or TNF treated MC. MC cultured in 
24 multi-well plates were stimulated with increasing doses o f  IL-1 a  (a) or TNFa (b) for 18 hours. 
Control wells (C) were treated with media alone for 18 hours. Cell supernatants were quantitated for 
extracellular IL-6 peptide by ELISA. Results are the mean ± SEM o f  duplicate samples from a 
representative experiment, similar results were obtained in 4 other experiments.
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Figure 21. Effect o f different culture conditions on TNF induced IL-6 peptide production by MC. 
MC cultured in 24 multi-well plates were either preincubated in serum free medium for 24 hours, or left in 
'complete’ Waymouths medium prior to stimulation with 300 ng/ml o f TNFa for 18 hours, in both the 
absence and presence o f  2% FCS. IL-6 peptide levels o f cell supernatants were quantitated by ELISA. 
Results are the mean ± SEM o f  duplicate samples, n = l.
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3.2.2. IL-8 mRNA expression and peptide production by cytokine activated 
mesangial cells
MC incubated in media alone for 5, 24 or 48 hours did not express detectable IL- 8  
mRNA transcripts. Stimulation with IL-1 a  (3 ng/ml) resulted in IL- 8  mRNA 
expression which was detected 1 hour post-stimulation (Fig. 22a), maximal expression 
occurred at 8  hours and mRNA levels had declined to 20 ± 8 % (mean ± SEM, n=3) of 
the peak levels by 48 hours. Similarly, stimulation with TNFa (300 ng/ml) induced IL- 
8  mRNA expression which was detected 1 hour post-stimulation and maximal 
expression had occurred at 8  hours (Fig. 22b). However, in contrast to IL-la, the TNFa 
response was more sustained, as mRNA levels remained elevated at 58 ± 20% (mean ± 
SEM, n=3) of the peak levels at 72 hours.
IL- 8  peptide was not detected in culture supernatants from MC incubated with media 
alone for 5, 24 or 48 hours (<0.05 ng/ml). IL- 8  peptide was first detected in culture 
supernatants 4 hours after IL-la stimulation (3.5 ± 0.3 ng/ml (mean ± SEM)) and 
continued to increase upto 24 hours where levels stabilized (Fig. 23). Mean levels of 
IL- 8  at 24 hours were 69 ± 1 ng/ml (mean ± SEM). Previous work carried out in this 
laboratory showed the time course of TNFa induced IL- 8  production was similar to IL- 
la , when measured upto 24 hours post-stimulation (Brown et al 1991b).
Dose-response studies demonstrated IL- 8  peptide production was dose-related over the 
concentration range of IL-la (0.3 - 30 ng/ml) and TNFa (30 - 300 ng/ml) employed 
(Fig. 24a and b). Sub-optimal doses of IL-la (3 ng/ml) and TNFa (300 ng/ml) were 
used in all further experiments. TNFa was found to be approximately 300 fold less 
potent than IL-la in inducing IL- 8  peptide production after 18 hours.
3.2.3. MCP-1 mRNA expression by cytokine activated mesangial cells
MC incubated in media alone for 5, 24, 48 or 72 hours did not express detectable MCP- 
1 mRNA transcripts. Stimulation of MC with IL-la (3 ng/ml) resulted in MCP-1 
mRNA expression which was detected 1 hour post-stimulation, maximal expression 
occurred at 8  hours and mRNA levels declined to 30 ± 15% (mean ± SEM, n=4) of the 
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Figure 22. Time-dependent 
expression o f IL-8 mRNA by IL- 
1 or TNF treated MC. MC
culture in 25 cm2 flasks were 
stimulated with either 3 ng/ml IL- 
l a  (a) or 300 ng/ml TNFa (b) for 
the times indicated. Total cellular 
RNA was extracted and northern 
analysis carried out. Autoradio­
graphs (i) were analysed by 
densitometry and the results 
plotted using the absorbance units 
(ii). The ethidium bromide stained 
gels showing the 18S and 28S 
ribosomal RNA were used to 
assess equal loading (iii). 
Representative blots are shown, 
n=3. Similar results were obtained 
in 2 other experiments.
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Figure 23. Time course o f IL-8 peptide production by IL-1 activated MC. MC cultured in 24 multi­
well plates were stimulated with 1 ml o f 3 ng/ml IL -la  for the times indicated. Cell supernatants were 
quantitated for extracellular IL-8 peptide by ELISA. Results are the mean ± SEM o f  duplicate samples 
from a representative experiment, similar results were obtained in 1 other experiment.
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Figure 24. Dose-dependent production o f IL-8 peptide by IL-1 or TNF stim ulated MC. MC
cultured in 24 multi-well plates were stimulated with increasing doses o f  either IL -la  (a) or TNFa (b) 
for 18 hours. IL-8 peptide levels o f  cell supernatants were quantitated by ELISA. Results are the mean 
± SEM o f  duplicate samples from a representative experiment, similar results were obtained in 5 other 
experiments.
1 mRNA expression with similar kinetics to that observed following IL -la stimulation 
over the first 8  hours (Fig. 25b). Interestingly however, the TNFa induced MCP-1 
mRNA expression was far more sustained than the IL-la response, with mRNA levels 
remaining elevated at near maximal levels for upto 72 hours. MCP-1 mRNA expression 
was 8 6  ± 7% (mean ± SEM, n=3) of the peak levels at 72 hours.
3.2.4. RANTES mRNA expression and peptide production by cytokine activated 
mesangial cells
In addition to IL- 8  and MCP-1, cytokine activated MC have the ability to secrete 
RANTES, another member of the C-C chemokine family. The gene expression and 
production of RANTES was investigated following either IL-la, TNFa or LPS 
activation of MC.
MC incubated in media alone for 4, 24, 48 or 72 hours did not express detectable 
RANTES mRNA transcripts. Stimulation of MC with either IL-la (3 ng/ml) or TNFa 
(300 ng/ml) induced time-dependent RANTES mRNA expression. IL-la induced 
RANTES mRNA transcripts by 2 hours post-stimulation, expression was maximal at 24 
hours and declined to 28 ± 6% (mean ± SEM, n=4) of the peak levels at 72 hours (Fig. 
26a). In marked contrast, TNFa induced a later time course of RANTES mRNA 
expression and the response was more sustained. mRNA transcripts were first detected 
4-6 hours post-stimulation, maximal increase in gene expression occurred at 48 hours 
and levels remained elevated at 72 hours (90 ± 7% (mean ± SEM, n=4) of the peak 
levels) (Fig. 26b).
Supernatants from MC incubated with media alone for 4, 24, 48, or 72 hours contained 
no detectable RANTES peptide (<0.06 ng/ml). Stimulation with IL-la (3 ng/ml) 
induced production of RANTES peptide which was first detected in culture supernatants 
8  hours post-stimulation (0.6 ±0.1 ng/ml (mean ± SEM)) and continued to rise upto 48 
hours, where levels stabilized (Fig. 27a). Peak levels of RANTES produced at 48 hours 
were 1.4 ± 0.3 ng/ml (mean ± SEM). In comparison, TNFa induced detectable levels of 
RANTES peptide by 16 hours post-stimulation (1.0 ± 0.2 ng/ml (mean ± SEM)) and
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Figure 25. Time-dependent 
expression o f MCP-1 mRNA by 
IL-1 or TNF activated MC. MC
cultured in 25 cm2 flasks were 
stimulated with either 3 ng/ml IL- 
l a  (a) or 300 ng/ml TNFa (b) for 
the times indicated. Total cellular 
RNA was extracted and northern 
analysis carried out. Autoradio­
graphs (i) were analysed by 
densitometry and the results 
plotted using the absorbance units 
(ii). The ethidium bromide stained 
gels showing the 18S and 28S 
ribosomal RNA were used to 
assess equal loading (iii). 
Representative blots are shown, 
n=4 and 3 for the IL -la  (a) and 
TNFa (b) data respectively.
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Figure 26. Time-dependent 
expression o f RANTES mRNA  
by IL-1 or TNF activated MC.
MC cultured in 25 cm2 flasks were 
stimulated with either 3 ng/ml IL- 
la  (a) or 300 ng/ml TNFa (b) for 
the times indicated. Total cellular 
RNA was extracted and northern 
analysis carried out. Autoradio­
graphs (i) were analysed by 
densitometry and the results 
plotted using the absorbance units 
(ii). The ethidium bromide stained 
gels showing the 18S and 28S 
ribosomal RNA were used to 
assess equal loading (iii). 






levels were still increasing at 96 hours (Fig. 27b). Mean production of RANTES at 96 
hours was 8 6  ± 10 ng/ml (mean ± SEM). Dose-response studies demonstrate that 
stimulation with 3 ng/ml IL-la resulted in maximal release of RANTES peptide, no 
further increase in production was observed at the higher doses of IL-la (Fig. 28a). In 
contrast, TNFa stimulated RANTES peptide production was dose-related between 30 - 
1000 ng/ml, the concentration range investigated (Fig. 28b). Concentrations of 1 ng/ml 
IL-la and 50 ng/ml TNFa were used in later experiments, when sub-optimal doses 
were required. The time course and dose-response data on RANTES peptide production 
indicate that in marked contrast to TNFa, IL-la is a poor stimulus for RANTES 
production in MC.
Stimulation of MC with LPS (0.1 - 10 pg/ml) resulted in undetectable (<0.06 ng/ml) 
levels of RANTES peptide in culture supernatants after 48 hours (n=2, data not shown).
3.2.5. Investigation of a secondary protein involvement in IL-1 or TNF induced 
chemokine gene expression
Comparison of the kinetics of RANTES, IL- 8  and MCP-1 gene expression in MC shows 
the time course of induction of RANTES mRNA following either IL-la or TNFa 
stimulation was much later than IL- 8  or MCP-1 (Fig. 29). Both IL- 8  and MCP-1 were 
maximally expressed 8  hours post stimulation, while RANTES mRNA expression was 
only maximal 1 and 2 days after IL-la and TNFa stimulation respectively.
To investigate whether the IL-la or TNFa regulation of RANTES mRNA expression 
was dependent on de novo protein synthesis, MC were pretreated for 1 hour with the 
protein synthesis inhibitor cycloheximide (CHX) (5 pg/ml) prior to cytokine 
stimulation. CHX treatment resulted in superinduction of IL -la (3 ng/ml) induced 
RANTES mRNA transcripts after 8  and 24 hours (Fig. 30a), indicating the IL-la 
response was not protein synthesis dependent. In marked contrast, CHX inhibited 
TNFa (300 ng/ml) induced RANTES mRNA expression by 79.4 ± 6.4% (mean ± SEM, 
n=4) at 48 hours (Fig. 30b). The inhibitory effect of CHX on the TNFa response was 
not due to a toxic effect of the drug treatment as cell viability, assessed by trypan blue 
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Figure 27. Time course o f RANTES peptide production by IL-1 or TNF activated MC. MC
cultured in 24 multi-well plates were stimulated with either 3 ng/ml IL -la  (a) or 300 ng/ml TNFa (b) for 
the times indicated. Cell supernatants were quantitated for extracellular RANTES peptide by ELISA. 
Results are the mean ± SEM o f  duplicate samples from a representative experiment, similar results were 
obtained in 4 other experiments.
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Figure 28. Dose-dependent production of RANTES peptide by IL-1 or TNF activated MC. MC
cultured in 24 multi-well plates were stimulated with increasing doses o f either IL -la  for 24 hours (a) 
or TNFa for 48 hours (b). Cell supernatants were quantitated for extracellular RANTES peptide by 
ELISA. Results are the mean ± SEM o f duplicate samples from a representative experiment, similar 
results were obtained in 4 other experiments.
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Figure 29. Summary figure o f the kinetics o f IL-1 and TNF induced chem okine mRNA expression in MC. MC cultured in 25 cm" 
flasks were stimulated with either 3 ng/ml IL -la  or 300 ng/ml TNFa for the times indicated. Total cellular RNA was extracted and 
northern analysis carried out. Autoradiographs were analysed by densitometry and the results plotted as % o f  maximal expression. 
Representative data is shown, n>3.
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Figure 30. Effect o f cyclohexim ide on either IL-1 or TNF induced RANTES mRNA expression.
MC were pretreated with CHX (5pg/ml) for 1 hour prior to stimulation with either 3 ng/ml IL -la  for 8 
and 24 hours (a), or stimulation with 300 ng/ml TNFa for 24 and 48 hours (b). Total cellular RNA 
was extracted and northern analysis carried out. Autoradiographs o f RANTES probed membranes (i) 
were analysed by densitometry and the results plotted using the absorbance units (ii). Identical 
membranes were probed with the house-keeping gene P-actin (iii) to assess equal loading, along with 
the ethidium bromide stained gels (iv). Representative blots are shown, n=4.
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observed when lower doses of CHX (2.5 qg/ml) and TNFa (50 ng/ml) were employed 
(Fig. 31). The inhibitory effect of CHX indicates the TNFa induction of RANTES 
mRNA requires de-novo protein synthesis and therefore may involve secondary 
proteins. Preincubation with 5 pg/ml CHX resulted in >90% inhibition of IL-la and 
TNFa induced MC protein synthesis, assessed by measuring RANTES peptide levels in 
cell supernatants (data not shown).
An involvement of secondary proteins in IL-la or TNFa induced IL- 8  and MCP-1 
mRNA expression was also investigated. Preliminary data showed CHX (5 pg/ml) 
treatment resulted in superinduction of IL-la (3 ng/ml) induced IL- 8  (Fig. 32a) and 
MCP-1 (Fig. 33a) mRNA expression after 24 hours. These results are consistent with 
previous findings in human MC (Dr Z. Brown, personal communication). Similarly, 
CHX treatment resulted in superinduction of TNFa induced IL- 8  mRNA expression 
(Fig. 32b). In contrast, only minor potentiation was observed for TNFa induced MCP-1 
mRNA expression after 24 hours (Fig. 33b). Together the results indicate that both the 
IL-la and TNFa induction of IL- 8  and MCP-1 gene expression were not protein 
synthesis dependent.
CHX treatment had no effect on basal levels of RANTES, IL- 8  or MCP-1 mRNA 
expression (Fig. 30 - 33).
3.2.6. Role of endogenous IL-1 in RANTES peptide production by TNF activated 
mesangial cells
Cycloheximide treatment inhibited TNFa induced RANTES gene expression indicating 
the TNFa response requires de novo protein synthesis and may involve secondary 
proteins. Expression of IL-la by TNFa activated human MC has been previously 
reported (Abbott et al. 1992). To establish if endogenous production of IL-1 played a 
role in the TNFa induction of RANTES peptide, MC were pretreated for 15 minutes 
with human recombinant IL-1 receptor antagonist (IL-lra, 30 to 300 ng/ml) prior to the 
addition of IL-la or TNFa for 48 hours. Treatment of MC with IL-lra at >100 ng/ml 
resulted in complete inhibition of IL-la induced RANTES peptide production (Fig. 34).
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Figure 31. Effect of low doses of cycloheximide and TNF on RANTES mRNA expression. MC
were pretreated with 2.5 pg/ml CHX for 1 hours prior to the addition o f  50 ng/ml TNFa to the drug- 
containing media. Total cellular RNA was extracted and northern analysis carried out. Autoradiographs 
o f the RANTES probed membranes (i) were analysed by densitometry and the results plotted using the 
absorbance units (ii). Identical membranes were probed with the house-keeping gene P-actin (iii) to 
































Figure 32. Effect o f cycloheximide on IL-1 or TNF induced IL-8 mRNA expression. MC were 
pretreated with CHX (5 fig/ml) for 1 hour prior to stimulation with either 3 ng/ml IL -la  (a) or 100 ng/ml 
TNFa for 24 hours (b). Total cellular RNA was extracted and northern analysis carried out. 
Autoradiographs (i) were analysed by densitometry and the results plotted using the absorbance units 
(ii). The ethidium bromide stained gels showing the 18S and 28S ribosomal RNA were used to assess 






Figure 33. Effect of cyclohexim ide on IL-1 Or TNF induced MCP-1 mRNA expression. MC
were pretreated with CHX (5 pg/ml) for 1 hour prior to stimulation with either 3 ng/ml IL -la  (a) or 
100 ng/ml TNFa for 24 hours (b). Total cellular RNA was extracted and northern analysis carried 
out. Autoradiographs (i) were analysed by densitometry and the results plotted using the absorbance 
units (ii). The ethidium bromide stained gels showing the 18S and 28S ribosomal RNA were used to 
assess equal loading (iv). Representative blots are shown, n=l and 2 for the IL -la  (a) and TNFa (b) 
data respectively.
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In contrast, IL-lra had no effect on TNFa induced RANTES peptide production (Fig. 
34).
3.2.7. Role of secondary protein(s) in the TNF induction of RANTES
To establish if TNFa activation of MC resulted in secretion of secondary protein(s) 
which were responsible for the induction of RANTES production in the absence of 
exogenously added TNFa, neutralising antibody experiments were undertaken. MC 
grown in 24 multi-well tissue culture plates were stimulated for 24 hours with 50 ng/ml 
of TNFa. Supernatants were collected and premixed for 30 minutes at 37°C with a 1:50 
dilution of sheep anti-TNF serum or normal sheep serum. Supernatants were then 
transferred to fresh cells and incubated for a further 48 hours. Table 7 (a) shows that 
stimulation of MC for 24 hours with 50 ng/ml of TNFa resulted in 4.8 ± 3.2 ng/ml 
(mean ± SEM, n=4) of RANTES peptide production. Incubation of fresh MC for 48 
hours with supernatants from TNFa stimulated cells in the presence of neutralising 
amounts of anti-TNF antibody resulted in unaltered RANTES peptide levels (Table 7
(b)), compared with supernatants in the presence of control antibody (normal sheep 
serum) which resulted in increased production of RANTES to 12.8 ±3.7 ng/ml (Table 7
(c)). Thus secondary proteins secreted by TNFa stimulated MC were unable to induce 
RANTES peptide production in the absence of ‘active’ TNF. The specificity and 
neutralising ability of the anti-TNF antibody was confirmed by stimulating the cells 
with TNFa (50 ng/ml) either in the presence of a 1/50 dilution of anti-TNF serum or 
normal sheep serum (Table 7 (d ), (e)). Anti-TNF antibody resulted in 100% inhibition 
of 50 ng/ml TNF activity (Table 7 (d)).
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Figure 34. Effect o f [L -l receptor antagonist on IL-1 or TNF stimulated RANTES peptide 
production. MC cultured in 24 multi-well plates were pretreated with IL-lra (30 - 300 ng/ml) for 15 
minutes prior to the addition o f IL -la  (3 ng/ml) or TNFa (300 ng/ml) to the drug-containing media for 
48 hours. Cell supernatants were quantitated for extracellular RANTES peptide by ELISA. Results are 
expressed as a % o f the IL- la  or TNFa control and are the mean ± SEM o f n=3.
Table 7. Effect of secondary proteins 
on RANTES peptide production. MC 
cultured in 24 multi-well plates were 
stimulated for 24 hours with 50 ng/ml 
TNFa (A). Cell supernatants were
removed, premixed for 30 minutes with 
neutralising amounts o f  anti-TNFa serum, 
or normal sheep serum and transferred to 
fresh MC for a further 48 hours (B and C 
respectively). The ability o f  a 1:50
dilution o f  anti-TNFa serum to 
completely neutralise the activity o f  50 
ng/ml TNFa was confirmed by 
stimulating the cells with TNFa premixed 
with anti-TNFa serum (D) or normal 
sheep serum (E) for 48 hours. Cell 
supernatants were quantitated for
extracellular RANTES peptide by ELISA. 
Results are the mean ± SEM o f n=4.
TREATMENT RANTES (ng/ml) 
(mean ± SEM)
(A) TNF (50 ng/ml), 24 hr 4.8 ±3 .2
(B) 24 hr supernatant
+ anti-TNF serum, 48 hr
4.4 ±3 .2
(C) 24 hr supernatant 
+ NSS, 48 hr
12.8 ± 3 . 7
(D) TNF (50 ng/ml)
+ anti-TNF serum, 48 hr
<0.06 ± 0
(E) TNF (50 ng/ml) 




The molecular mechanisms controlling leukocyte migration to a site of tissue injury are 
multistep, and chemokine production by cells of the extravascular site is thought to play 
an important role in mediating the accumulation of specific leukocyte populations at 
different phases of the inflammatory response. A number of studies have demonstrated 
cultured human MC, when activated by cytokines, are a rich source of the neutrophil 
chemoattractant, IL- 8  and the monocyte chemotactic factor, MCP-1 (Brown et al 
1991b; Abbott et al 1991; Kusner et al 1991; Brown et al 1992; Rovin et al 1992). 
This has lead to the proposal that MC may play a key role in the initiation and 
propagation of inflammatory events within the glomerulus. The results presented in this 
chapter support this hypothesis and demonstrate that in addition to IL- 8  and MCP-1, 
cytokine-activated human mesangial cells have the ability to secrete RANTES and 
therefore have the potential to induce the selective attraction of CD45RO/CD4+ T cells 
into the inflamed glomerulus. The production of these three chemokines by MC was 
found to be differentially regulated at several levels.
The profile of RANTES mRNA expression induced by IL-1 and TNF was different. 
TNF induced a later time course of RANTES expression and the signal was more 
sustained than that observed after IL-1 stimulation. Maximal RANTES mRNA 
expression was observed 24 and 48 hours post stimulation with either IL-1 or TNF 
respectively, and while the IL-1 response had declined by 72 hours, TNF induced 
RANTES mRNA levels remained maximally elevated at 72 hours. Similar time course 
differences were observed at the level of protein production. IL-1 and TNF also differed 
in their efficiency for RANTES generation with TNF being the more potent stimulant, 
IL-1 in comparison was a poor agonist. Similar findings on the specificity of RANTES 
regulation by IL-1 and TNF have been reported in human synovial fibroblasts 
(Rathanaswami et al 1993), human umbilical vein endothelial cells (Marfaing-Koka et 
al 1995) and a mouse MC cell line (Wolf et al 1993).
The kinetics and specificity of RANTES induction in human MC is clearly different to 
that of IL- 8  and MCP-1, which are expressed much earlier (maximal 4-8 hours) and
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have a similar time course of expression over the first 8  hours following induction by 
either IL-1 or TNF. IL-1 was the more potent stimulant for IL- 8  peptide production, 
while previous studies show IL-1 and TNF have similar efficacy for MCP-1 production 
in human MC, measured after 18 hours (Brown et al 1991b; Brown et al 1992). 
Relatively late induction of RANTES mRNA expression has been previously reported 
in mitogen and antigen stimulated peripheral blood T cells, which express RANTES 3 
to 5 days after activation, in comparison to the rapid (4-6 hours) upregulation of other 
C-C chemokines (Nelson et al. 1993). Late induction of RANTES expression was also 
observed in human synovial fibroblasts and mouse MC, as mRNA levels peaked 24 
hours after TNF stimulation (Rathanaswami et al. 1993; Wolf et al 1993). Both these 
studies lend support to my observations.
Interestingly, a similar sustained time course for MCP-1 mRNA expression, and to a 
lesser extent for IL- 8  mRNA expression was observed following TNF stimulation of 
MC, in comparison to IL-1. To my knowledge, this difference in the kinetics of IL-1 
and TNF induced chemokine expression has not been previously reported in MC or 
other cell types. The results demonstrate that chemokine regulation by IL-1 and TNF in 
MC may differ not only in the potency of these stimuli, but also in the kinetics of 
production. Some differences must therefore exist between the signal transduction 
pathways employed by these two inflammatory cytokines, which is of interest as IL-1 
and TNF are thought to induce similar post-receptor signal transduction pathways, as 
they share many biological responses (Le & Vilcek, 1987). The nature of the signalling 
pathways employed remains to be fully elucidated (O'Neill, 1995).
The observed difference in kinetics of chemokine induction in cultured human MC, 
with the early induction of IL- 8  and MCP-1, the delayed induction of RANTES and the 
markedly sustained expression of TNF induced MCP-1 and RANTES, correlates well 
with the reported kinetics of leukocyte infiltration into inflamed glomeruli in rat models 
of glomerulonephritis (Tam et al 1996; Stahl et al 1993). Tam et al (1996) 
demonstrated a rapid, but transient infiltration of neutrophils and a sustained increase of 
monocytes in anti-GBM nephritis in rats, while a rapid and sustained influx of 
monocytes was observed in experimental mesangioproliferative GN (Stahl et al 1993).
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Induction of disease in these models resulted in enhanced glomerular expression of the 
chemokines MCP-1 and MIP-2, which correlated with the kinetics of leukocyte 
infiltration (Tam et al 1996; Stahl et al 1993). These findings support an important 
role for MC-derived chemokines in the progression of renal inflammation.
The protein synthesis inhibitor cycloheximide had disparate effects on IL-1 and TNF 
induced RANTES gene expression. CHX treatment resulted in superinduction of IL-1 
induced RANTES mRNA levels, indicating secondary protein(s) were not required for 
the IL-1 response. Superinduction may result from inhibition of the synthesis of 
negative regulatory elements (nucleases, repressors) that are co-induced (Baggiolini et 
al 1994). In marked contrast, CHX treatment inhibited TNF induced RANTES 
expression in MC, indicating the TNF induction of RANTES mRNA transcripts was 
protein synthesis dependent and thus secondary proteins may be involved. These 
observations are supported by similar findings in human synovial fibroblasts where 
TNF, but not IL-1 induced RANTES gene expression was inhibited by CHX 
(Rathanaswami et al 1993). The identity of the secondary protein(s) involved in the 
TNF response in MC and their mechanism of action remains to be fully defined. 
However, my experiments to date demonstrate that endogenous production of IL-1 by 
TNF activated MC does not play a role in the TNF induction of RANTES, since 
pretreatment of MC with IL-lra had no effect on the TNF response at concentrations 
which completely inhibited IL-1 stimulated RANTES production. Furthermore, results 
from the TNF neutralising antibody experiments indicate that the secondary protein(s) 
produced in TNF activated MC were unable to stimulate RANTES production in the 
absence of active TNF. The secondary protein(s) may therefore act to modulate the 
TNF response, causing upregulation of RANTES mRNA expression. The sustained 
time course of RANTES expression observed after TNF stimulation, in contrast to IL-1, 
lends to speculation that the secondary protein(s) may be involved at the level of mRNA 
stability. Interestingly, a recent report by A.Walz et a l demonstrated that CHX 
inhibited IL-1 induced ENA-78 mRNA expression, while superinducing IL-1 induced 
IL- 8  expression in human monocytes (Walz et al 1993). On analysing the time courses 
of ENA-78 and IL- 8  mRNA expression, both chemokines were found to be induced 
initially with similar kinetics by IL-1. However, ENA-78 expression was more
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sustained and remained elevated for over 72 hours, while IL- 8  expression declined. 
Together these findings suggest a link between the involvement of secondary protein(s) 
in cytokine induced chemokine expression and a sustained time course of chemokine 
expression.
Preliminary studies show that CHX treatment resulted in superinduction of both IL-1 
and TNF induced IL- 8  mRNA expression in MC. CHX treatment also resulted in 
superinduction of IL-1 induced MCP-1 mRNA transcripts, while causing only a small 
potentiation of TNF induced MCP-1 mRNA levels. Superinduction of IL-1 and TNF 
induced IL- 8  and MCP-1 expression has been previously reported in several human cell 
types, including endothelial cells (Dixit et al. 1990), smooth muscle cells (Colotta et al. 
1992) and fibroblasts (Rathanaswami et al. 1993). These results indicate that secondary 
proteins are not involved in either IL-1 or TNF induced IL- 8  or MCP-1 expression. 
These latter findings do not support my earlier suggestion that the role of secondary 
proteins in the TNF induction of RANTES mRNA expression may be at the level of 
mRNA stabilization, since secondary proteins were not involved in the TNF induction 
of IL- 8  or MCP-1 mRNA transcripts in MC, yet a sustained time course of IL- 8  and 
MCP-1 gene expression was observed following TNF stimulation. The role of 
secondary proteins in TNF induced RANTES expression therefore requires further 
investigation.
LPS has been shown to induce chemokine production in a variety of cell types, 
including human monocytes (Yoshimura et al. 1987), endothelial cells (Schroder & 
Christophers, 1989) and chondrocytes (Baggiolini et al. 1994). In the present study 
stimulation of MC with LPS failed to induce IL- 8  or RANTES peptide production. An 
inability of LPS to stimulate IL- 8  expression or production in human MC has been 
previously reported by Brown et al (1991b). In contrast, Kusner et al (1991) 
demonstrated significant IL- 8  production by human MC after treatment with similar 
doses of LPS. Such discrepancies may be due to the use of different culture conditions, 
since only the latter study was performed in the presence of FCS, which is known to 
contain LPS-binding proteins that enhance LPS activity (Gallay et al. 1993).
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Cultured human MC also express and secrete the mesangioproliferative cytokine IL- 6  
following IL-1 or TNF treatment, but not in response to LPS stimulation. In comparison 
to IL-1, TNF was a very poor stimulus for IL- 6  production when experiments were 
performed on quiescent MC, which had been growth-arrested for 24 hours. Stimulation 
of the cells with TNF in the presence of 2% FCS however, caused a marked potentiation 
of the IL- 6  response. Furthermore, serum itself induced IL- 6  production, in the absence 
of any cytokine stimulation. The presence of a serum response element in the human 
IL- 6  promoter may explain these findings (Ray et al. 1989). The latter work highlights 
the fact FCS contains a number of cytokines and growth factors (e.g. PDGF, bFGF) 
which may influence the cellular response during an experiment. The studies described 
in the subsequent chapters of this thesis were therefore carried out in the absence of 
serum, on growth-arrested MC in order to eliminate the effects of serum-derived factors. 
By performing the experiments in a more ‘defined’ system (i.e. in the absence of FCS or 
added growth factors) the ability of agents to modulate specifically IL-1 or TNF 
signalling mechanisms for IL-6 , IL- 8  or RANTES could be assessed, and conclusions 
about their signal transduction pathways drawn. MC were growth arrested in serum free 
medium for 24 hours to allow any effects of serum factors to diminish prior to the start 
of the experiment.
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4. ROLE OF cAMP IN THE REGULATION OF IL-6. IL-8 AND RANTES 
PRODUCTION IN IL-1 OR TNF ACTIVATED HUMAN MESANGIAL
CELLS
4.1. RATIONALE FOR STUDY
Little is known about the regulatory effects of cAMP on cytokine production in MC. 
This section of work was designed, therefore, to examine the role of cAMP in the 
regulation of IL- 6  and IL- 8  gene expression and peptide production in IL-1 stimulated 
human MC. During the course of this study, the ability of cAMP to modulate TNF 
induced IL- 8  and RANTES peptide production was also assessed. The regulatory 
effects of cAMP on cytokine production were determined pharmacologically by utilising 
agents which elevate intracellular cAMP, including dibutyryl cAMP (db-cAMP), 
forskolin, 3 -isobutyl-1-methyl-xanthine (IBMX ) and cholera toxin (CT), an agent 
which elevates cAMP via ribosylation and activation of the stimulatory G protein, Gs.
4.2. RESULTS
4.2.1. Effect of cholera toxin or the purified B oligomer on cytokine induced IL-6 
and IL-8 production by human mesangial cells
Pretreatment of MC with CT (10 - 250 ng/ml) for 5 hours prior to the addition of IL-la 
resulted in a dose-dependent and significant (p<0.05) increase in IL- 6  (Fig. 35a) and IL- 
8  (Fig. 35b) production, compared to cells treated with IL-la alone. 250 ng/ml CT 
enhanced IL- 6  and IL- 8  production by 297 ± 56% and 106 ± 24% (mean ± SEM, n=5) 
respectively compared with the IL-la control. Thus CT was 3 times more effective at 
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Figure 35. Cholera toxin potentiates IL-1 induced IL-6 and IL-8 peptide production by MC. MC
cultured in 24 multi-well plates were pretreated with CT (10 - 250 ng/ml) for 5 hours prior to the 
addition o f  a sub-maximal dose o f  IL -la  (3 ng/ml) to the drug containing media for 18 hours. Control 
wells (C) were treated with media alone for 23 hours. Cell supernatants were quantitated for 
extracellular IL-6 (a) and IL-8 (b) peptide by ELISA. Results are expressed as a % o f the IL -la  
control, where cells were stimulated with IL -la  alone for 18 hours, and are the mean ± SEM o f  n=5.
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To assess whether the mechanism of CT potentiation was through activation of Gs by 
ADP-ribosylation and subsequent elevation of intracellular cAMP, the effects of the 
purified B oligomer of cholera toxin (CT-B) on IL-la induced IL- 6  and IL- 8  peptide 
generation was investigated. CT-B can bind to the cell surface, but cannot modify Gs to 
activate the cAMP pathway due to the absence of SI subunit, which is present in the 
holotoxin (CT). Surprisingly, pretreatment with CT-B resulted in enhanced IL- 6  (Fig. 
36a) and IL- 8  (Fig. 36b) peptide production of 144 ± 27% and 8 8  ± 21% (mean ± SEM, 
n=4) respectively at 250 ng/ml, compared to the IL-la control. The potentiation of IL- 
la  induced IL- 6  production by CT-B was not dose-related across the concentration 
range employed (10 - 250 ng/ml), while CT-B had no significant effect on IL-la 
induced IL- 8  release between 10 and 100 ng/ml.
MC treated with CT or CT-B (250 ng/ml) alone for 23 hours showed no induction of IL- 
6  or IL- 8  peptide above media control levels (Fig. 35 and 36).
4.2.2. Ability of cholera toxin and the purified B oligomer to ADP-ribosylate 
mesangial cell membrane proteins
ADP-ribosylation studies were performed to confirm CT was able to modify Gs proteins 
in the MC membrane within a 5 hour incubation with intact cells, and to check the CT-B 
preparation for contamination with SI subunit. MC membranes treated with CT 
contained radiolabelled proteins of ~45 kDa and ~52 kDa (Fig. 37, lane 2). These 
correspond to the molecular weight of two known forms of Gs protein (Hepler & 
Gilman, 1992). To determine the time required for CT modification of the membrane 
pool of Gs cells were treated with for 0, 0.5, 2 and 4 hours with CT (100 ng/ml). 
Membranes were then prepared and a second exposure of 15 minutes to CT in the
32presence of [ P]-NAD was carried out. Figure 37 (lane 4) shows that after 2 hours 
contact of cells with CT all of the Gs protein was ADP-ribosylated. It was therefore 
concluded that the conditions in which the CT enhanced IL- 6  and IL- 8  production (5 
hour preincubation) would have resulted in a near-total ADP-ribosylation and activation 
of Gs. In contrast, treatment of MC membranes with 50 pg/ml B oligomer instead of 
CT failed to generate the ~45 kDa and ~52 kDa bands (Fig. 37, lane 1) indicating no 
contamination of the CT-B preparation with SI subunit.
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Figure 36. Effect of cholera toxin B oligomer on IL-1 induced IL-6 and IL-8 peptide production.
MC were pretreated with CT-B (10 - 250ng/ml) for 5 hours prior to addition o f  IL -la  (3 ng/ml) to the 
drug containing media for 18 hours. Cell supernatants were quantitated for extracellular IL-6 (a) and 
IL-8 (b) peptide by ELISA. Results are expressed as a % o f the IL -la  control, where cells were 
stimulated with IL -la  alone for 18 hours, and are the mean ± SEM o f  n=4.
LanesMW Markers
Figure 37. G proteins modified by cholera toxin or the B oligom er in MC membranes and time 
course o f activation o f Gs. MC cultured in 80 cm2 flasks were pretreated with media alone (lanes 1, 2) 
or 100 ng/ml CT for 30 mins (lane 3), 2 hours (lane 4), or 4 hours (lane 5). Membranes were then 
extracted and 60 pg o f membrane protein re-exposed to 50 pg/ml o f  pre-activated CT-B (lane 1) or CT 
(lanes 2-5) in the presence o f  [32P]NAD for 15 mins at 30°C. Membrane proteins were resolved in a 
12.5% SDS-polyacrylamide gel and autoradiographed. In lanes 3-5, the degree o f Gs ribosylation that 
occurred on the initial exposure o f intact cells to CT is inversely related to the amount o f  ribosylation 
observed on the autorad, which occurred during the second exposure o f  the cell membranes to CT in the 
presence o f  a [32P]NAD label. The relevant part o f  the autorad is shown and is representative o f  3 
separate experiments carried out on MC isolated from 2 donor kidneys.
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4.2.3. Ability of other cAMP-elevating agents to modulate cytokine induced IL-6 
and IL-8 peptide production
The effect of agents that act via different mechanisms to elevate cAMP were 
investigated to clarify the role of cAMP in potentiating IL-la induced IL- 6  and IL- 8  
production. Db-cAMP is a membrane permeable, hydrolysis resistant cAMP analogue 
(Postemak et al 1962), while forskolin activates the catalytic subunit of the adenylyl 
cyclase enzyme to cause increases in intracellular cAMP levels (Seaman & Daly, 1986). 
IBMX is a non-specific phosphodiesterase (PDE) inhibitor which prevents breakdown 
of cAMP within the cell (Nicholson et al 1991).
Pretreatment of MC for 5 hours with forskolin (1-30 pM) or Db-cAMP (10 - 100 pM) 
resulted in a dose-dependent increase in IL-la induced IL- 6  peptide compared with IL- 
la  control (Fig. 38a). Maximal potentiation of IL- 6  induced by either forskolin (10 
pM) or by Db-cAMP (100 pM) was 125 ± 7% and 103 ± 10% (mean ± SEM, n=4) 
respectively compared to IL-la alone. Similarly, a dose-dependent increase in IL-la 
induced IL- 6  was observed following a 1 hour IBMX pretreatment, 300 pM IBMX 
resulted in a 133 ± 43% (mean ± SEM, n=3) increase in IL- 6  production (Fig. 38b). 
None of the c AMP-elevating agents employed enhanced IL-la induced IL- 6  production 
to the same extent as cholera toxin. In marked contrast, Db-cAMP, forskolin or IBMX 
pretreatment did not modify IL-la induced IL- 8  production (Fig. 39a and b).
The ability of cAMP to modify IL-la induced serine esterase activity in PC60 cells was 
reported to be dependent upon the timing of cAMP elevation in relation to agonist 
stimulation, simultaneous addition of cAMP-elevating agents with IL-la resulting in 
potentiation of IL-1 effects, while pretreatment with cAMP-elevating agents lead to 
inhibition (Schlegel-Haueter & Aebischer, 1990). The effect of timing of cAMP 
elevation upon IL-la induced IL- 6  and IL- 8  production in MC was therefore 
investigated. Addition of Db-cAMP (30, 100 pM) simultaneously with IL -la (Fig. 
40a), or 5 hours after IL-la stimulation (Fig. 40b) resulted in similar potentiation of IL- 
6  peptide production. Simultaneous addition of Db-cAMP with IL -la had no 
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Figure 38. Effect o f cAM P-elevating agents on IL-1 induced IL-6 peptide release by MC.
Cells cultured in 24 multi-well plates were pretreated with either forskolin ( 1 - 3 0  pM), Db- 
cAMP (10 - 100 pM) (a) or IBMX (1 - 300 pM) (b) for 5 hours before addition o f  IL -la  (3 
ng/ml) to the drug-containing media for 18 hours. The vehicle control (Veh) was 0.03% DMSO, 
which corresponds to the percentage DMSO present in the top concentration o f  forskolin used. 
Antigenic IL-6 levels in culture supernatants were quantitated by ELISA. Results are expressed 
as % o f  IL -la  controls and are the mean ± SEM o f  n=4 and n=3 respectively for the 
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Figure 39. Effect o f cAM P-elevating agents on IL-1 induced IL-8 peptide release by MC. Cells 
were pretreated with forskolin ( 1 - 3 0  pM), Db-cAMP (10 - 100 pM) (a) or IBMX (1 - 300 pM) (b) for 
5 hours before addition o f  IL -la  (3 ng/ml) to the drug-containing media for 18 hours. The vehicle 
control (Veh) was 0.03% DMSO, which corresponds to the percentage DMSO present in the top 
concentration o f forskolin used. Antigenic IL-8 levels in culture supernatants were quantitated by 
ELISA. Results are expressed as % o f  IL -la  controls and are the mean ± SEM o f  n=4 and n=3 
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upregulates IL-1 induced IL-6 
peptide production indep­
endently o f the timing o f
addition o f the agents. Db- 
cAMP (30, 100 pM) was added 
to MC either simultaneously with 
IL -la  (3 ng/ml) for 18 hours (a), 
or 5 hours after IL -la  addition 
for a further 13 hours (b). Cell 
supernatants were quantitated for 
extracellular IL-6 peptide by 
ELISA. Result in ftg. 40(a) and 
(b) are expressed as % o f IL -la  
control and are the mean ± SEM 
o f  n=7 and n=l respectively.
Simultaneous addition of aaents
Figure 41. Effect o f the 
simultaneous addition o f Db- 
cAM P with IL-1 on IL-8 peptide 
production. MC were stimulated 
with Db-cAMP (30, 100 pM) and 
IL -la  (3 ng/ml) for 18 hours. Cell 
supernatants were quantitated for 
extracellular IL-8 peptide by 
ELISA. Results are expressed as 
% o f IL -la  control and are the 





Investigation of the effects of elevated intracellular cAMP on TNFa induced IL- 8  
production showed pretreatment with Db-cAMP (10 - 100 pM), forskolin ( 1 -3 0  pM) 
or IBMX (1 - 300 pM) for 1 hour did not modify TNFa induced IL- 8  generation (Fig. 
42a and b). Simultaneous addition of Db-cAMP (30, 100 pM) with TNFa also had no 
effect on IL- 8  production (Data not shown). In comparison to IL-8 , preliminary findings 
indicate Db-cAMP (30 - 100 pM) and forskolin ( 1 -30  pM) potentiate TNFa induced 
IL- 6  production (Data not shown).
None of the agents, when added alone to the cells for the duration of the experiment 
caused any induction of IL- 6  or IL- 8  peptide above media control levels (Fig. 38 - 42).
4.2.4. Effect of a specific type IV phosphodiesterase inhibitor, RO 20-1724 on IL-1 
induced IL-6 and IL-8 production
Five families of phosphodiesterases (PDE) are known to exist (I to V), each composed 
of several isoforms and having different tissue distributions. RO 20-1724 is a selective 
inhibitor of the type IV, cAMP-specific PDE, which represents more than 90% of the 
total cAMP phosphodiesterase activity in kidney tissue (Nicholson et al. 1991; Hoey & 
Houslay, 1990). To determine whether RO 20-1724 is an effective inhibitor of cAMP- 
specific PDE in MC, the effect of RO 20-1724 on IL-la induced IL- 6  and IL- 8  
production was assessed. Surprisingly, pretreatment of MC with RO 20-1724 (10 to 
300 pM) for 1 hour had no effect on IL-la induced IL- 6  or IL- 8  peptide production 
(Fig. 43a and b). These findings may be due to the existence of isoforms of type IV 
PDE which show a 5-15 fold difference in their sensitivity to this inhibitor (Nicholson et 
al. 1991; Hoey & Houslay, 1990), MC may possess the more resistant isoform(s).
4.2.5. Effect of agents that elevate cAMP on IL-1 induced IL-6 and IL-8 mRNA 
expression
Agents which elevate cAMP potentiated IL-la induced IL- 6  peptide production, but 
were without effect on IL- 8  production in MC. To determine if the enhancement of IL- 6  
was occurring at the level of gene expression, the effect of these agents on IL- 6  and IL- 8  
mRNA expression was assessed. Figure 44 (a and b) shows that pretreatment with Db- 
cAMP (100 pM), forskolin (30 pM), CT (100 ng/ml) or CT-B (100 ng/ml) for 5
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Figure 42. Effect of cAMP-elevating agents on TNF induced IL-8 peptide release. MC were 
pretreated with Db-cAMP (10 - 100 pM), forskolin (1 - 30 pM) (a) or IBMX (1 - 300 pM) (b) for 5 
hours before addition o f  TNFa (300 ng/ml) to the drug-containing media for 18 hours. The vehicle 
control (Veh) was 0.03% DMSO, which corresponds to the percentage DMSO present in the top 
concentration o f  forskolin used. Cell supernatants were quantitated for extracellular IL-8 peptide by 
ELISA. Results are expressed as % o f TNFa controls and are the mean ± SEM o f n=4 and n=3 
respectively for the forskolin/Db-cAMP (a) and IBMX (b) data.
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Figure 43. Effect of the type IV PDE inhibitor, RO 20-1724 on IL-1 induced IL-6 and IL-8 peptide 
production. MC were pretreated with RO 20-1724 (10 - 300 pM) for 1 hour prior to addition o f  IL -la  
(3 ng/ml) to the drug containing media for 18 hours. Cell supernatants were quantitated for extracellular 
IL-6 (a) and IL-8 (b) peptide by ELISA. Results are expressed as % o f the IL -la  control and are the 
mean ± SEM o f n=3.
112
hours, or IBMX (300 pM) for 1 hour enhanced IL-la induced IL- 6  mRNA levels, 
compared to cells treated with IL-la alone.
In comparison, figure 45 demonstrates that pretreatment with IBMX (300 pM) or CT-B 
(100 ng/ml) had no effect on IL-la induced IL- 8  mRNA levels compared with the IL- 
la  control, while pretreatment with either Db-cAMP (100 pM), forskolin (30 pM) or 
CT (100 ng/ml) resulted in a small potentiation of IL-la induced IL- 8  mRNA 
transcripts.
None of the cAMP-elevating agents alone induced either IL- 6  or IL- 8  gene expression 
(Fig. 44 and 45).
4.2.6. Effect of Db-cAMP on IL-1 induced IL-6 mRNA stability
Messenger RNA degradation studies were carried out to determine if cAMP elevation 
was increasing IL-la induced IL- 6  expression by stabilization of IL- 6  gene transcripts. 
MC were pretreated for 5 hours with media alone or Db-cAMP (100 pM) prior to the 
addition of IL-la for 8  hours. Transcription was then arrested by the addition of 
actinomycin D (AcD) (5 pg/ml) and cultures were incubated for a further 0, 1,2, 4, 8 , 
12 or 24 hours. Total cellular RNA was extracted at the end of each time point. Figure 
46 shows IL- 6  mRNA degradation in the presence of AcD was similar after stimulation 
of the cells with either IL-la alone or Db-cAMP + IL-la, indicating that the increase in 
IL- 6  mRNA expression observed following treatment with agents that elevate cAMP 
was not due to an increase in IL- 6  mRNA stability.
Addition of AcD for 24 hours resulted in a non-specific decrease in mRNA levels of the 
house-keeping gene, p-actin (Fig. 46).
4.2.7. Effect of Db-cAMP on IL-1 induced NF-kB activation in human mesangial 
cells
There is no constitutive activity of the transcription factor NF-kB in MC, however 
treatment with IL-la results in marked NF-kB activation (Brown et al. 1993a). NF-kB 
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Figure 44. Effect o f agents that 
elevate cAM P on IL-1 induced 
IL-6 mRNA expression, (a) MC
cultured in 25 cm2 flasks were 
pretreated for 5 hours with media 
alone, 100 pM Db-cAMP (Db), 30 
|iM forskolin (Fsk), 0.03% DMSO 
vehicle (Veh), 100 ng/ml CT or 
100 ng/ml CT-B, before the 
addition o f  IL -la  (3 ng/ml) to the 
drug containing media, (b) MC 
were pretreated with media alone 
or 300 pM IBMX for 1 hour 
before addition o f  IL -la . Control 
cells (C) were treated with media 
alone for the duration o f  the 
experiment.
After a 5 hour IL -la  
stimulation, total cellular RNA was 
extracted and northern analysis 
carried out. Auto-radiographs (i) 
were analysed by densitometry and 
the results plotted using the 
absorbance units (ii). The 
ethidium bromide stained gels 
showing the 18S and 28S 
ribosomal RNA were used to 
assess equal loading (iii). 






Figure 45. Effect o f agents that elevate cAM P on IL-1 induced IL-8 mRNA expression. MC were 
pretreated for 5 hours with media alone, 100 pM Db-cAMP (Db), 30 pM forskolin (Fsk), 0.03% DMSO 
vehicle (Veh), 100 ng/ml CT, 100 ng/ml CT-B or for 1 hour with 300 pM IBMX. IL -la  (3 ng/ml) was 
then added to the drug containing media for 5 hours. Total cellular RNA was extracted and northern 
analysis carried out. Autoradiographs (i) were analysed by densitometry and the results plotted using the 
absorbance units (ii). The ethidium bromide stained gels showing the 18S and 28S ribosomal RNA were 
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Figure 46. Effect o f Db-cAMP on IL-1 induced IL-6 mRNA stability. MC culture in 25 cm2 flasks 
were pretreated with media alone or 100 pM Db-cAMP for 5 hours prior to stimulation with IL -la  (3 
ng/ml) for 8 hours. Actinomycin D (AcD) was then added to the drug containing media for 0, 1 ,2 , 4, 8, 
12 or 24 hours. Total cellular RNA was extracted and northern analysis carried out. Autoradiographs o f  
IL-6 probed membranes (i) were analysed by densitometry and the results plotted using the absorbance 
units (ii). Identical membranes were probed for the house-keeping gene (3-actin (iii) to assess equal 
loading, along with the ethidium bromide stained gels showing the 18S and 28S ribosomal RNA (iv). 
Representative blots are shown, and similar results were obtained in 2 other experiments.
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genes, and NF-kB has been shown to play a role in their induction by IL-la (Zhang et 
al 1990; Shimizu et al 1990; Mukaida et al 1990). In addition, an involvement of NF- 
kB in mediating the cAMP activation of the IL- 6  gene in a murine monocytic cell line 
has been demonstrated (Dendorfer et al 1994). The effect of Db-cAMP on IL-la 
induced NF-kB activation in MC was assessed to determine if the potentiation of IL- 6  
gene expression and production by cAMP was due to an increase in NF-kB activity. 
MC were pretreated with media alone or Db-cAMP (100 pM) for 5 hours prior to the 
addition of IL-la for 0.5, 1, 2 or 6  hours, and nuclear extracts were prepared. Figure 47 
shows pretreatment with Db-cAMP for 5 hours had no effect on NF-kB activation after 
stimulation with IL-la for 0.5 or 6  hours, compared to the corresponding controls 
treated with IL-la alone. Interestingly, Db-cAMP pretreatment resulted in partial 
inhibition of NF-kB activity after stimulation with IL-la for 1 and 3 hours (Fig. 47). 
NF-kB activity was not observed in cells treated with media or Db-cAMP (100 pM) 
alone (data not shown). The results indicate that the potentiating effect of agents that 
elevate cAMP on IL-la induced IL- 6  mRNA expression is not occurring at the level of 
NF-kB activation.
4.2.8. Effect of indomethacin on IL-1 induced IL-6 and IL-8 production in 
mesangial cells
Cytokine activated human MC in culture are known to synthesize prostaglandins, in 
particular PGE2  production is significantly increased above basal levels following IL-la 
stimulation (Topley et al 1989). MC respond to PGE2  which upon receptor binding 
causes activation of Gs and elevation of intracellular cAMP (Friedlander et al 1983). 
To investigate if endogenous PGE2  production plays a role in the IL -la induction of IL- 
6 , MC were incubated with the cyclooxygenase inhibitor, indomethacin (0.1 - 10 pM) 
for 1 hour prior to stimulation with IL-la. Figure 48 (a) shows that treatment with 
indomethacin resulted in almost complete inhibition of IL-la induced PGE2  production 
(IL-la control = 473 ± 263 pg/ml PGE2  after 18 hours (mean ± SEM, n=3)). Greater 
than 97% of PGE2  production was inhibited at a concentration of 10 pM indomethacin, 
while a 37 ± 6 % (mean ± SEM) reduction in IL- 6  production was observed at the same 
concentration of indomethacin (Fig. 48b). In contrast, indomethacin treatment had no 
inhibitory effect on IL-la induced IL- 8  generation (Fig. 48c). The inhibitory effect of
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Figure 47. Effect o f Db-cAMP on IL-1 induced NF-kB activation in MC. Cells culture in 25 cm 
flasks were pretreated with media alone or 100 pM Db-cAMP for 5 hours prior to the addition o f  IL -la  
for 0.5, 1, 2 or 6 hours. Nuclear extracts were prepared and gel shift assays performed. Autoradiographs 
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Figure 48. Effect of indomethacin on IL-1 stimulated PGE2, IL-6 and IL-8 production by MC.
Cells cultured in 24 multi-well plates were pretreated with indomethacin (0.1 - 10 pM) for 1 hour prior 
to stimulation with IL -la  (3 ng/ml) for 18 hours. The vehicle control (Veh) consisted o f  0.036%  
ethanol, which corresponds to the percentage ethanol present in the top concentration o f indomethacin 
used. The concentration o f  PGE2 in cell supernatants was determined by RIA (a), while extracellular 
IL-6 (b) and IL-8 (c) peptide levels in cell supernatants were quantitated by ELISA. Results are 
expressed as %  o f  the IL -la  control and are the mean ± SEM o f n>3.
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indomethacin on PGE2  and IL- 6  production was not due to a toxic effect of the drug 
treatment, as cell viability as assessed by trypan blue exclusion was >90%. These 
results indicate that IL- 6  production in MC following IL-la stimulation may be 
potentiated by synthesis of PGE2, probably acting via stimulation of adenylyl cyclase.
4.2.9. Regulatory effect of cAMP-elevating agents on RANTES production
The ability of cAMP to regulate RANTES peptide production in cytokine activated MC 
was investigated. Pretreatment of MC for 1 hour with either forskolin ( 1 -3 0  pM) or 
Db-cAMP (10 - 100 pM) had no effect on IL-la induced RANTES production (Fig. 
49a). In contrast, both agents resulted in significant (p<0.05) inhibition of TNFa 
induced RANTES production, 57 ± 7% and 29 ± 6 % (mean ± SEM, n=5) inhibition 




Figure 49. Effect of cAMP-elevating agents on IL-1 and TNF induced RANTES peptide 
production. MC were pretreated with forskolin ( 1 - 3 0  pM) or Db-cAMP (10 - 100 pM) for 1 hour 
prior to the addition o f sub-maximal doses o f  IL -la  (1 ng/ml) (a) or TNFa (50 ng/ml) (b) to the drug 
containing media for 48 hours. The vehicle control (Veh) was 0.03% DMSO, which corresponds to 
the percentage DMSO present in the top concentration o f  forskolin used. Antigenic RANTES levels in 
culture supernatants were quantitated by ELISA. Results are expressed as % o f  the IL -la  (a) or TNFa 
(b) controls and are the mean ± SEM o f  n=5.
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4.3. DISCUSSION
This area of work investigated the role of cAMP in the regulation of cytokine induced IL- 
6 , IL- 8  and RANTES production in MC. The results show that agents that elevate cAMP 
(db-cAMP, forskolin and IBMX) significantly potentiated expression of IL- 6  gene 
transcripts and peptide production in response to IL-1, while having little or no effect on 
IL- 8  gene expression and peptide production. In marked contrast, cAMP elevation 
markedly inhibited TNF stimulated RANTES production.
The bacterial toxin, cholera toxin (CT) was unique in that it was found to cause significant 
enhancement of both IL- 6  and IL- 8  peptide generation in response to IL-1. CT produced a 
marked enhancement of IL- 6  transcripts, but caused only a minor, if any increase in IL- 8  
transcripts indicating that enhanced IL- 8  peptide levels may result from post- 
transcriptional effects of CT. The data indicates that the effect observed with CT cannot 
solely be attributed to elevation of cAMP via Gs activation, since pretreatment of the cells 
with the purified B oligomer of CT (CT-B), which is devoid of ADP-ribosyltransferase 
activity, also resulted in significant potentiation of IL-1 induced IL- 6  and IL- 8  peptide 
production suggesting that cAMP-independent mechanisms may be involved. The flat 
dose-response of IL- 6  upregulation by CT-B (50 - 500 ng/ml) may reflect saturation. The 
molecular weight of CT-B (-59 kDa) is less than 2 fold lower than the molecular weight 
of the holotoxin ( - 8 6  kDa) (Mekalanos, 1988) and thus similar amounts of CT-B are 
present in corresponding doses of the two agents. This implies the larger fold increase 
observed in EL- 6  production following pretreatment with holotoxin compared to CT-B 
may be due to the presence of S 1  subunit and consequently suggests some involvement of 
cAMP-dependent mechanisms in the CT upregulation of IL-6 . In comparison, CT-B and 
holotoxin (at 250 ng/ml) induced similar fold increases in IL- 8  generation suggesting 
cAMP independent mechanisms are involved. This latter suggestion is supported by the 
inability of cAMP-elevating agents which act via different mechanisms to CT, to 
potentiate IL-1 induced IL- 8  production. CT-B is known to bind to a specific cell surface 
receptor, the sialic acid-containing glycosphingolipid, GM1. An ability of the CT-B / 
GM1 pathway to modulate cell growth, differentiation or T cell IL-2 expression via 
cAMP-independent mechanisms has been previously described, although the signalling
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pathways involved remain unclear (Bremer et al 1986; Lycke, 1993; Gouy et al 1994; 
Woogen et al 1993). Interestingly, the binding of CT-B to GM1 has been reported to 
increase intracellular calcium levels in neurones (Milani & Minozzi, 1992), the human 
Jurkat T cell line (Gouy et al 1994), Swiss 3T3 fibroblasts (Spiegel & Panagiotopoulos, 
1988) and rat thymocytes (Jeffrey Dixon et al 1987). The Ca2+ response in Jurkat cells 
was shown to involve both an influx of extracellular Ca2+ and the release of Ca2+ from 
inositol 1,4,5-triphosphate-sensitive intracellular stores, suggesting the activation of 
plasma membrane Ca2+ channels and phospholipase C respectively by CT-B (Gouy et al 
1994). However, the induction of detectable Ca2+ responses in all these studies required 
the use of pg/ml doses of CT-B or the use of anti-CT-B crosslinking antibodies following 
pretreatment with >250 ng/ml CT-B (Milani & Minozzi, 1992; Gouy et al 1994; Spiegel 
& Panagiotopoulos, 1988; Jeffrey Dixon et al 1987). The contrasting dose-response 
curves for the CT-B upregulation of IL-1 induced IL- 8  and IL- 6  production in MC 
indicates Ca2+ responses may not be involved. Other pathways have been implicated in 
mediating CT-B actions. Recent findings have shown various gangliosides, including 
GM1 can modulate in vitro calmodulin-dependent enzyme activity (Higashi & Yamagata,
1992), and GM1, when bound and cross-linked by CT-B may interact with the 
cytoskeleton (Kellie et al 1983). In addition, GM1 may mediate effects by interacting 
with integral membrane proteins and modulating their activity, inhibition of PDGF and 
EGF induced receptor phosphorylation by GM1 has been shown (Bremer et al 1986). 
Studies have also indicated that CT may interfere with signalling pathways other than the 
cAMP pathway, an ability which is dependent on the ADP-ribosylating activity of the 
toxin (Imboden et al 1986). Such action by CT is thought to account for expression of JE, 
the mouse monocyte chemokine in 3T3 cells (Qureshi et al 1991). Thus the ability of CT 
to modulate a number of different signalling pathways through properties of both the S 1  
subunit and B oligomer may account for its potentiating effects on IL-1 induced IL- 8  
generation and explain the large increases seen in IL- 6  generation, which could not be 
mimicked fully by the other cAMP agonists.
Studies in human FS-4 fibroblasts have shown an induction of IL- 6  mRNA expression on 
stimulation with cAMP-elevating agents alone (Zhang et al 1988a). Furthermore, cAMP 
was found to activate IL- 6  transcription by a reporter gene assay in HeLa cells (Ray et al
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1988) and the murine monocytic cell line PU5-1.8 (Dendorfer et al 1994). This contrasts 
with the present findings in human MC. The inability of cAMP-elevating agents alone to 
cause any induction of IL- 6  mRNA or peptide could be linked to the fact the experiments 
were undertaken on quiescent MC, growth-arrested in serum-free medium for 24 hours 
before use. Serum itself is known to induce IL- 6  expression (Ray et al. 1988) and the 
presence of serum immediately prior to agonist stimulation can result in pronounced 
increases in cAMP accumulation (Kreps et al 1993). However, other studies undertaken 
on human lung fibroblasts which were not growth-arrested (Zitnik et al 1993) or on 
human astrocytoma cells which were stimulated in the presence of low serum 
concentrations (Kasahara et al 1990) also describe an inability of cAMP-elevating agents 
to stimulate IL- 6  expression. This indicates that cell specific differences exist in IL- 6  gene 
regulation, which cannot be explained solely by differences in culture conditions.
The ability of cAMP to enhance IL- 6  generation in the presence of cytokines has been 
previously reported in a human astrocytoma cell line (Kasahara et al 1990) and rat 
intestinal epithelial cell line (McGee et al 1993). In contrast Zitnik et al (Zitnik et al
1993) have shown cAMP to significantly inhibit IL-1 induced IL- 6  mRNA and peptide 
production in a human lung fibroblast cell line. Furthermore, cAMP-elevating agents have 
been shown to down-regulate endotoxin induced IL- 6  in Kupffer cells (Goss et al 1993) 
and to have no effect on IL- 6  generation in endotoxin stimulated mononuclear cells 
(Waage et al 1990). The reason for the variations in the ability of cAMP to modulate IL- 6  
production is not clear, and is likely to involve cell specific differences. In addition, these 
findings may reflect an ability of factors such as the timing of cAMP elevation in relation 
to agonist stimulation (Schlegel-Haueter & Aebischer, 1990), the dose of cAMP-elevating 
agent employed (Renz et al 1988), the agonist used (Hurme, 1990) and the activation state 
of the cell (Renz et al 1988) to affect the type of regulation observed. In the present 
study, addition of db-cAMP simultaneously with IL-1, or 5 hours after IL-1 stimulation 
resulted in a similar potentiation of IL-1 induced IL- 6  peptide production, as described 
with a 5 hour pretreatment of MC.
In vivo, prostaglandins are one of the main mediators known to exert modulatory effects 
on inflammatory events via activation of the cAMP pathway. Increased PGE2  synthesis in
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response to IL-1 in cultured MC has been shown previously (Topley et al 1989). The 
present work extends these findings by demonstrating inhibition of IL-1 induced PGE2  
generation with indomethacin leads to a significant inhibition of IL- 6  production, but is 
without effect on the IL- 8  production. This suggests that endogenous PGE2  generation in 
IL-1 stimulated MC operates via a positive feedback loop to upregulate IL- 6  production, 
probably through elevation of intracellular cAMP. This hypothesis is supported by the 
lack of effect of indomethacin on IL-1 induced IL- 8  generation, further supporting the data 
that IL- 8  production in MC is not modulated by cAMP-elevating agents such as PGE2 .
From the results of this study, certain insights into the IL-1 signalling mechanisms for IL- 
6  and IL- 8  can be drawn. In MC, the lack of induction of either IL- 6  or IL- 8  gene 
expression or production in the presence of cAMP-elevating agents alone indicates an 
inability of cAMP to mimic the actions of IL-1. The potentiating effect of cAMP on IL- 6  
production by IL-1 however does indicate that the IL-1 signalling pathway for IL- 6  and 
the cAMP pathway interact. The ability of agents that elevate cAMP to potentiate IL- 6  
mRNA gene transcripts, as well as peptide production indicates that this cross-talk 
between the pathways is occurring at the level of gene expression. mRNA degradation 
studies showed the time course of IL-1 induced IL- 6  mRNA degradation was the same in 
both the presence or absence of db-cAMP, indicating cAMP elevation was not increasing 
IL- 6  expression by stabilization of IL- 6  mRNA transcripts. The potentiating effect of 
cAMP on IL-1 induced IL- 6  expression may therefore be occurring at the level of 
transcription. Nuclear run-on assays would need to be performed to confirm this. 
Previous studies have indicated the transcription factor NF-kB may play an important role 
in mediating IL-1 induction of IL- 6  gene expression (Zhang et al 1990; Shimizu et al 
1990), while reporter gene assays performed in the murine monocytic cell line PU5-1.8 
demonstrated an involvement of NF-kB in the cAMP activation of the IL- 6  gene 
(Dendorfer et al 1994). In these studies mutations in the NF-kB binding site of the IL- 6  
promoter, which impaired the binding of NF-kB, markedly reduced the induction of IL- 6  
by IL-1 or cAMP-elevating agents. Preliminary experiments in MC however indicate the 
mechanism of cAMP potentiation of IL-1 induced IL- 6  expression is not at the level of 
NF-kB activation, as db-cAMP did not upregulate IL-1 induced NF-kB activity. 
Furthermore, treatment of MC with db-cAMP alone caused no detectable induction of NF-
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kB activity. Other transcription factors, such as NF-IL-6 , which are implicated in both the 
IL-1 and cAMP induction of IL- 6  gene expression may be involved (Dendorfer et al 
1994; Akira et al 1990b).
The inability of cAMP to modulate IL-1 stimulated IL- 8  generation highlights differences 
between the regulation of IL- 6  and IL- 8  in human MC. In addition, the lack of effect of 
cAMP on IL- 8  production in response to TNF indicates both the IL-1 and TNF signalling 
pathway(s) for IL- 8  are independent of the cAMP pathway. An inability of cAMP to 
regulate IL- 8  production has been previously demonstrated in LPS stimulated 
neutrophils (Wertheim et al 1993). In contrast, cAMP was found to inhibit IL- 8  
production in LPS stimulated monocytes (Standiford et al 1992). These findings 
suggest the cAMP regulation of IL- 8  production may be both cell and stimulus specific.
In the present study, the regulatory effects of cAMP on RANTES production in MC was 
also investigated. Treatment of MC with either forskolin or db-cAMP significantly 
inhibited RANTES peptide production (p<0.01) in response to TNF, but had no effect 
on the IL-1 induced response for this chemokine. The poor induction of RANTES by 
IL-1 may account for the inability of cAMP to modulate this response in MC, 
alternatively differences between the IL-1 and TNF signalling pathways for RANTES 
generation may be involved. The regulatory effects of cAMP on TNF induced 
RANTES production are in agreement with the recent observations of Satriano et al 
(1993) who found that increasing cAMP suppressed TNF induced MCP-1 expression at 
the transcriptional level in mouse MC. Similar results have also been reported by 
Rovin and Tan (1994) for MCP-1 in human MC, except in this case it was the IL-1 
induced response which was attenuated. More recently both groups have demonstrated 
that raising intracellular cAMP reduced IL-1 or TNF stimulated NF-kB activation in 
MC as well as decreasing MCP-1 mRNA expression (Rovin et al 1994a; Satriano & 
Schlondorff, 1994b). As aoNF-KB binding site has been identified in the 5’-promoter 
region of the MCP-1 gene (Shyy et al 1990), these results suggest that NF-kB may play 
a role in the IL-1 and TNF induction of MCP-1, and furthermore, NF-kB may be the 
molecular target for the inhibitory action of cAMP on MCP-1 expression. This latter 
suggestion is supported by a recent study in T lymphocytes which showed that mutation
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of the NF-kB binding site in the promoter region of the IL-2 gene, that prevented NF-kB 
binding, resulted in the loss of cAMP-mediated suppression of EL-2 induction 
(Neumann et al. 1995). An NF-kB binding site has also been identified in the 5'- 
promoter region of the RANTES gene (Nelson et al. 1993), lending to speculation that 
the mechanism of cAMP regulation of TNF induced RANTES production in human MC 
may occur through inhibition of NF-kB activity. However, modification of NF-kB 
activity by cAMP is unlikely to account fully for the regulatory effects of cAMP on 
chemokine production since studies have shown NF-kB was essential for IL-1 or TNF 
induced IL- 8  expression in more than 6  different cell lines examined (Mukaida et al.
1994), while IL- 8  production was unaffected by elevation of intracellular cAMP in MC. 
Further studies are therefore necessary to determine the mechanism of cAMP regulation 
and to identify the factor(s) required to confer cytokine and chemokine responsiveness 
to cAMP regulation.
127
5. INVESTIGATION OF THE ROLE OF PERTUSSIS TOXIN-SENSITIVE G
PROTEINS IN IL-1 SIGNALLING FOR IL-8 AND IL-6 IN HUMAN
MESANGIAL CELLS
5.1. RATIONALE FOR STUDY
The molecular mechanisms by which IL-1 activates cells are not clear and remain one of 
the major challenges of immunology (O'Neill, 1995). A major amplification in signal is 
thought to occur following IL-1 binding to its’ receptor as receptor occupancy studies 
have indicated less than 10 IL-1 receptors per cell need to be activated in order to elicit a 
biological response (Stylianou et al. 1992; Curtis et al 1989). Amplification of 
hormonal signalling is classically known to occur through coupling of receptors to 
heterotrimeric G proteins, with the subsequent generation of second messengers. 
Several groups have published evidence for a G protein involvement in both IL-1 and 
TNF signalling. Much of this is based upon the inhibitory effects of the bacterial 
pertussis toxin (PT) on post-receptor events triggered by either IL-1 or TNF (Dobson et 
al. 1989; Chedid et al. 1989; O'Neill et al. 1990a; Rollins et al. 1991; Imamura et al. 
1988; Brett et al. 1989; Clark et al. 1988). The aim of this section of work was to 
investigate the role of PT-sensitive G proteins in the IL-1 signalling for IL- 8  and IL- 6  in 
human MC.
5.2. RESULTS
5.2.1. Ability of pertussis toxin or the purified B oligomer to modulate IL-1 
induced IL-8 and IL-6 production in human mesangial cells
The effect of pertussis toxin on IL-la induced IL- 8  and IL- 6  peptide production was 
assessed to determine whether PT-sensitive G proteins play a role in IL-la signalling 
events in human MC. Pretreatment of MC with 50 to 500 ng/ml of PT for 5 hours prior
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to the addition of IL-la resulted in significant (p<0.05) inhibition of IL-8 (Fig. 50a) and 
IL-6 production (Fig. 50b), compared to cells treated with IL-la alone. A 40 ± 11% 
(mean ± SEM, n=5) and 27 ± 4% (mean ± SEM, n=5) decrease in IL-la induced IL-8 
and IL-6 production respectively was observed after pretreatment with 50 ng/ml PT. 
The inhibition observed following PT treatment was not dose-dependent in the 
concentration range of 50 to 500 ng/ml, PT at the higher dose of 1000 ng/ml had no 
significant effect on IL-8 or IL-6 production.
To assess whether the mechanism of PT inhibition was through ADP-ribosylation of 
PT-sensitive G proteins and subsequent inhibition of G protein activity, the effects of 
the purified B oligomer of pertussis toxin (PT-B) on IL-la induced IL-8 and IL-6 
peptide production was investigated. PT-B can bind to the cell surface, but cannot 
modify G proteins due to the absence of SI subunit which is present in the holotoxin 
(PT). Surprisingly, pretreatment with PT-B resulted in similar inhibition of IL-la 
induced IL-8 production to that observed with the holotoxin, a 39 ± 10% (mean ± SEM, 
n=5) decrease in IL-la induced IL-8 production was observed with 50 ng/ml PT-B (Fig. 
51a). The inhibition was not dose-related in the concentration range of 50 to 500 ng/ml 
and at a 1000 ng/ml PT-B had no significant effect. Inhibition of IL -la induced IL-6 
production was also observed following PT-B treatment, at 50 ng/ml PT-B decreased 
IL-6 production by 18 ± 3% (mean + SEM, n=5) (Fig. 51b). The effect of PT-B on IL-6 
production was significant (p<0.01) using ANOVA analysis, but did not reach statistical 
significance when further assessed using Dunnetts t-test. The inhibitory effects of PT 
and PT-B on IL-8 and IL-6 production were not due to a toxic effect of drug treatment, 
as cell viability assessed by trypan blue exclusion was >90%. Furthermore PT and PT- 
B did not interfere with either IL-8 or IL-6 antigenic detection by ELISA as addition of 
100 ng/ml PT or PT-B to known standards of IL-8 and IL-6 had no effect on the ELISA 
results (data not shown).
Treatment of MC with PT or PT-B (500 ng/ml) alone for the duration of the experiment 
had no effect on basal IL-8 or IL-6 production (Fig. 50 and 51).
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Figure 50. Pertussis toxin inhibits IL-1 induced IL-8 and IL-6 peptide production by MC. Cells 
cultured in 24 multi-well plates were pretreated with PT (50 - 1000 ng/ml) for 5 hours prior to the 
addition o f  a sub-maximal dose o f  IL -la  (3 ng/ml) to the drug containing media for 18 hours. 
Control wells (C) were treated with media alone for 23 hours. Cell supernatants were quantitated for 
extracellular IL-8 (a) and IL-6 (b) peptide by ELISA. Results are expressed as a % o f  the IL -la  
control, where cells were stimulated with IL -la  alone for 18 hours, and are the mean ±  SEM o f  n=5.
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Figure 51. Effect of pertussis toxin B oligomer on IL-1 induced IL-8 and IL-6 peptide 
production. MC were pretreated with PT-B (50 - 1000 ng/ml) for 5 hours prior to the addition o f  IL- 
la  (3 ng/ml) to the drug containing media for 18 hours. Cell supernatants were quantitated for 
extracellular IL-8 (a) and IL-6 (b) peptide by ELISA. Results are expressed as a % o f the IL -la  
control, where cells were stimulated with IL -la  alone for 18 hours, and are the mean ±  SEM o f  n=5.
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It was unexpected to find that such a marked biological effect for IL- 8  was due to the 
binding subunit (PT-B), and was unconnected with the ADP-ribosyltransferase function 
of the toxin.
5.2.2. Ability of pertussis toxin and the B oligomer to ADP-ribosylate mesangial 
cell membrane proteins
ADP-ribosylation studies were therefore performed to confirm that PT was able to 
modify G protein substrates in MC membranes and to check that the preparation of PT- 
B used was infact devoid of ADP-ribosyltransferase activity. Membranes extracted 
from untreated MC, and treated with 10 pg/ml PT resulted in radiolabelled proteins of 
-40 kDa (Fig. 52, lane 2). This correlates with the molecular weight of known isoforms 
of Gj (40 - 41 kDa) and G0  (39 kDa) proteins (Milligan, 1988). The -40 kDa band of 
radiolabelled proteins may consist of more than one type of PT-sensitive G protein 
which were not individually resolved using a 12.5% polyacrylamide gel. The -26 kDa 
radiolabelled band (Fig. 52, lane 2) is non-specific, and due to auto-ribosylation of the 
SI subunit (Kaslow & Bums, 1992). In comparison, incubation of MC membranes with 
100 fig/ml PT-B instead of PT failed to generate radiolabelled bands (Fig. 52, lane 3), 
indicating that the PT-B preparation contained no detectable contamination with SI 
subunit, and thus was devoid of ADP-ribosyltransferase activity.
To determine the time required for PT modification of the membrane pool of G protein 
substrates, cells were treated for 0, 1, 2 or 6  hours with PT (500 ng/ml). Membranes
32were then prepared and a second exposure of 15 minutes to PT in the presence of [ P]- 
NAD was carried out. The intensity of the labelling by [ P], visualised by 
autoradiography, would therefore be inversely related to the amount ADP-ribosylated 
during the initial incubation of the cells with the toxin. Figure 53 shows that after 1 
hours incubation of cells with PT (lane 3), 39 ± 10% (mean ± SEM, n=3) of the 
membrane pool of PT-sensitive G proteins had been ADP-ribosylated, with 100% 
ribosylation observed at 6  hours (lane 5). It was therefore concluded that the conditions 
used to determine the effect of PT on IL-la induced IL- 8  and IL- 6  production (5 hour 
pretreatment) would result in near total ribosylation, and inhibition of PT-sensitive G 
proteins.
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Figure 52. ADP-ribosylation of
proteins in MC membranes by
pertussis toxin or the B
oligomer. Membranes were
extracted from untreated MC
cultured in 80 cm2 flasks. 60 jig
o f membrane protein was 
- - 4 0  kDa protein exposed t0 PBS (lane 1)? 10
Hg/ml o f  pre-activated PT (lane 
2) or 100 pg/ml pre-activated PT- 
B (lane 3) in the presence o f  
[32P]- NAD for 15 mins at 30°C. 
Membrane proteins were resolved 
by electrophoresis in a 12.5% 
SDS-polyacrylamide gel and 
autoradiographed. The relevant 
part o f  the autorad is shown, n=2.
Lanes
MW markers 1 2 3 4 5
43,200 -
28,500 -
Figure 53. Time course of G protein modfication by pertussis toxin in MC. MC cultured in 80 
cm2 flasks were treated with media alone (lams 1 and 2) or 500 ng/ml PT for 1 hour (lane 3), 2 hours 
(lane 4) or 6 hours (lane 5). Membranes wjre then extracted and 60 p.g o f  membrane protein re­
exposed to 10 pg/ml ° f  pre-activated PT (lane 2-5) in the presence o f [32P] NAD for 15 mins at 30°C. 
Untreated membranes were also exposed to [,2P]-NAD in the absence o f  toxin (lane 1). Membrane 
proteins were resolved in a 12.5% SDS-polyicrylamide gel and autoradiographed. In lanes 3-5, the 
degree o f  G protein ribosylation that occurrec on the initial exposure o f intact cells to PT is inversely 
related to the amount o f ribosylation observed on the autorad, which occurred during the second 
exposure o f  the cell membranes to PT in the Dresence o f  a [j2P]-NAD label. The relevant part o f  the 







5.2.3. Effect of pertussis toxin mutants on IL-1 induced IL-8 and IL-6 production
As both PT and PT-B were equally inhibitory for IL-la induced IL- 8  production, 
studies were carried out using mutants of PT to ascertain the relevant subunits of PT 
which were responsible for the inhibition. PT cross reactant mutants, PTR^E and 
PTR9 ENK, were employed. PTR9 E contains point mutations in the SI subunit and 
exhibits undetectable ADP-ribosylating activity, while PTR9 ENK contains point 
mutations in both the SI and B oligomer subunits and has impaired ADP-ribosylating 
and binding activity (Lobet et al 1993; Pizza et al. 1989; Loosemore et al. 1990).
Preliminary data indicated that pretreatment of MC with PTRgE (50 to 1000 ng/ml) for 
5 hours prior to the addition of IL-la resulted in partial inhibition of IL- 8  production, 
31 ± 0.3% (mean ± SEM, n=l) inhibition was observed with 50 ng/ml PTR9 E (Fig. 
54a). The inhibitory effect of PTR9 E on IL-la induced IL- 8  production was not dose- 
related between 50 and 500 ng/ml, the higher dose of 1000 ng/ml had no inhibitory 
effect. In contrast, PTR9 E (50 to 1000 ng/ml) had no clear effect on IL -la induced IL- 6  
peptide production (Fig. 54b). These results imply that the ADP-ribosyltransferase 
activity of PT is not involved in the inhibitory effects of the toxin on IL- 8  production.
Interestingly PTR9 ENK, which has both reduced ADP-ribosylating and binding activity 
resulted in inhibition of IL-la induced IL- 8  and IL- 6  production at 50 to 500 ng/ml, and 
this was not dose related (Fig 55 a and b). 50 ng/ml of PTR9 ENK decreased IL- 8  and 
IL- 6  production by 32 ± 6 % and 33 ± 1.4% (mean ± SEM, n=l) respectively, in 
response to IL-la. No inhibition of IL- 8  or IL- 6  production was observed when a 
higher dose of PTR9 ENK was used.
Treatment of MC with PTR9 E or PTR9 ENK (500 ng/ml) for the duration of the 
experiment had no effect on basal IL- 6  or IL- 8  production (Fig. 54 and 55).
These latter results indicate that neither the binding of PT-B to specific cell surface 
receptors nor the ADP-ribosyltransferase activity are required for the pertussis toxin 
inhibition of IL-la induced IL- 8  or IL- 6  production in MC.
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Figure 54. Effect of pertussis toxin mutant, PTR,E (SI subunit mutations) on IL-1 induced IL-8 
and IL-6 peptide production. MC cultured in 24 multi-well plates were pretreated with PTR9E (50 - 
1000 ng/ml) for 5 hours prior to the addition o f  IL-la (3 ng/ml) to the drug containing media for 18 
hours. Cell supernatants were quantitated for extracellular IL-8 (a) and IL-6 (b) peptide by ELISA. 
Results are the mean ± SEM o f duplicate samples o f  n=l.
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Figure 55. Effect of pertussis toxin mutant, PTI^ENK (SI and B oligom er m utations) on IL-1 
induced IL-8 and IL-6 peptide production. MC cultured in 24 multi-well plates were pretreated 
with PTRGENK (50 - 1000 ng/ml) for 5 hours prior to the addition o f  IL -la  (3 ng/ml) to the drug 
containing media for 18 hours. Cell supernatants were quantitated for extracellular IL-8 (a) and IL-6 
(b) peptide by ELISA. Results are the mean ± SEM o f  duplicate samples from n = l.
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5.2.4. Effect of recombinant pertussis toxin B oligomer on IL-1 induced IL-8 and 
IL-6 production
To further clarify the mechanism of PT and PT-B inhibition of IL-la signalling for IL- 8  
and IL- 6  production, a recombinant form of PT-B was employed. Recombinant PT-B is 
devoid of SI subunit, and any other contaminating bacterial product derived from 
Bordella pertussis.
Pretreatment of MC with recombinant PT-B (50 to 1000 ng/ml) for 5 hours prior to the 
addition of IL-la had no significant effect on IL- 8  or IL- 6  production (Fig. 56a and b). 
These findings confirm the B oligomer of PT is not responsible for the inhibitory effects 
of PT on IL-la signalling events in MC.
Taken together, these results suggest that the inhibitory effects of non-recombinant PT- 
B, PTR9 E and PTR9 ENK may either be due to: (1) low level contamination of the 
preparations with active SI subunit, which is not detected by in vitro ADP-ribosylation 
assays (see results section 4.2.3 and Pizza et al (1989) and Loosemore et al (1990)) or
(2) the effects of a contaminating product of Bordella pertussis, which co-purifies with 
the toxin preparations.
5.2.5. Investigation of the ability of IL-1 or TNF to increase the cholera toxin 
ribosylation of a pertussis toxin-sensitive G protein
As the mechanism of pertussis toxin inhibition of IL-la induced IL- 8  and IL- 6  
production is unclear, and may be independent of G protein modification by ADP- 
ribosylation, a different method was employed to probe MC for a direct IL-la or TNFa 
receptor-Gj /o type protein interaction.
In the absence of guanine nucleotides in the ADP-ribosylation reaction mixture, CT 
additionally labels a -40 kDa protein in mesangial cell membranes, which normally 
only serves as a substrate for PT (Fig. 57). An ability of agonists to cause a specific 
increase in the CT labelling of the ~40 kDa protein has been shown to indicate a direct 
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Figure 56. Inability o f recombinant pertussis toxin B oligomer to modify IL-1 induced IL-8 and 
IL-6 peptide production. MC were pretreated with recombinant PT-B (50 - 1000 ng/ml) for 5 hours 
prior to the addition o f  IL -la  (3 ng/ml) to the drug containing media for 18 hours. Cell supernatants 
were quantitated for extracellular IL-8 (a) and IL-6 (b) peptide by ELISA. Results are expressed as a 
% o f the IL -la  control, where cells were stimulated with IL -la  alone for 18 hours, and are the mean ± 
SEM o f  n=3.
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et al 1989). The mechanism thought to account for this phenomena is that GDP must 
be released from the guanine nucleotide pocket of the Gi/o-type protein by the activated 
agonist/receptor complex to provide a form of the protein which is susceptible to CT 
ribosylation. Figure 58 shows 1 or 3 pg/ml IL-la (lanes 2 and 3), and 1 or 10 pg/ml 
TNFa (lanes 4 and 5) failed to cause any observable increase in the labelling of the ~40 
kDa band. Endothelin-1 (3 pM), included as a positive control was also without effect 
(Fig. 58, lane 6 ), which indicates the direct coupling of endothelin receptors to PT- 
sensitive G proteins in MC (Thomas et al. 1991) could not be detected under the
2"Fexperimental conditions employed. The inclusion of 2.5 mM Mg or 17 mM EDTA in 
the ADP-ribosylation assay had no effect on labelling of the ~40 kDa band in this study 
(data not shown). Both these conditions were tried due to contrasting reports in the
literature on the requirement for Mg2+ during the ADP-ribosylation assay. One study
2+
reported Mg was necessary for GDP release from the G protein (Iiri et al 1989), while
2+a separate study found Mg only served to increase background (agonist independent) 
labelling of the ~40 kDa substrate (Milligan et al 1991). Radiolabelled bands at ~60, 
~70 (Fig. 58) and ~21 kDa (not shown) are thought due to non-specific labelling. The 
~70 kDa band corresponds to the MW of BSA present in the IL-la vehicle, the intensity 
of labelling increased when higher doses of IL-la were used. Labelling of BSA present 
in the TNFa vehicle was not evident due to higher stock concentrations, which therefore 
required greater dilution for use. The ~21 kDa band corresponds to autoribosylation of 
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Figure 57. Ribosylation of a -4 0  kDa pertussis toxin-sensitive G protein in MC membranes 
following incubation with cholera toxin in the absence o f guanine nucleotides. Membranes were 
extracted from untreated MC cultured in 80 cm2 flasks. 60 pg o f membrane protein was exposed to PBS 
(lane 1), 10 pg/ml pre-activated PT (lane 2) or 50 pg/ml pre-activated CT (lane 3) in the presence o f  
[32P]-NAD for 15 mins at 30°C. Guanine nucleotides were omitted from the reaction mixture throughout. 
Membrane proteins were resolved on a 12.5% SDS-PAGE gel and autoradiographed. The relevant part 
o f  the autorad is shown, n = l.
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Figure 58. Inability o f IL-1, TNF or endothelin-1 to increase the cholera toxin ribosylation o f a 
~40kDa G protein. Membranes were extracted from untreated MC cultured in 80 cm2 flasks. 60 pg 
o f  membrane protein was exposed to 50 pg/ml pre-activated CT (lane 1-6) in the presence o f  media 
(lane 1), 1 or 3 pg/ml IL -la  (lanes 2 and 3 respectively), 1 or 10 pg/ml TNFa (lanes 4 and 5 
respectively) or 3 pM endothelin-1 (lane 6) for 1 hour at 30°C. Guanine nucleotides were omitted 
from the reaction mixture throughout. Membrane proteins were resolved on a 12.5% SDS-PAGE gel 




Pertussis toxin has become an important experimental tool for investigating G protein 
involvement in signal transduction mechanisms. However, its biological effects may 
not be solely due to its ability to modify G proteins.
The present study investigated the inhibitory effect of pertussis toxin on IL-1 induced 
IL- 8  and IL- 6  production in human MC. Treatment with the toxin resulted in partial 
inhibition of IL-1 induced IL- 8  (40%) and IL- 6  (27%) generation. No further inhibition 
of the IL-1 response was observed following treatment with higher doses of the toxin, 
which may reflect saturation with PT by 50 ng/ml. Furthermore, ADP-ribosylation 
studies demonstrate that 2 hours contact of MC with toxin resulted in almost complete 
ribosylation of the susceptible G protein pool, with no further ribosylation observed 
after 6  hours contact. It was therefore concluded that the conditions in which the toxin 
partially inhibited IL- 8  and IL- 6  production (5 hours) would have resulted in near total 
ADP-ribosylation and inactivation of Gj/ 0  type proteins. This latter finding is consistent 
with previous studies showing PT modified the susceptible pool of G proteins in 
cultured cells within a 4 hour incubation (Katada et al 1983). An inhibitory effect of 
PT on IL-1 induced IL- 8  generation has been previously reported in the human 
monocytic cell line, U937 (Pleass & Westwick, 1991), pretreatment with 100 ng/ml PT 
resulted in 80% inhibition of IL- 8  generation. In contrast, PT was found to have no 
inhibitory effect on IL-1 induced IL- 6  production in human gingival fibroblasts (O'Neill 
et al 1992). The inhibition of IL- 6  production by PT observed in the present study was 
not as marked as the effects on IL- 8  generation.
The characterized action of PT, the inactivation of G^ type proteins through ADP- 
ribosylation appeared not to be responsible for the observed inhibitory effect of PT on 
IL-1 induced IL- 8  or IL- 6  production in MC, as the purified B oligomer of PT (PT-B), 
which was devoid of ADP-ribosylating activity was found to be equally inhibitory. The 
partial inhibition of IL-1 induced IL- 6  production by PT-B was significant (P<0.01) at 
the level of ANOVA, but did not reach statistical significance when further analysed 
using the Dunnetts t test. The relatively small level of inhibition of IL-1 induced IL- 6  
production by both PT and PT-B treatment may account for these statistical findings.
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Possible contamination of the PT-B preparation with SI subunit is unlikely to account 
for its’ inhibitory effects on IL- 8  and IL- 6  production, as PT-B contained undetectable 
ADP-ribosyltransferase activity when incubated with MC membranes at 10 times the 
effective concentration of PT. These findings support the manufacturers claim that the 
PT-B preparation contained less than 0.02% contamination with holotoxin. The flat 
dose response curve for IL- 8  and IL- 6  inhibition by PT-B may reflect saturation by 50 
ng/ml. The similarity between the dose-response curves for holotoxin and B oligomer 
further suggest that contamination of the PT-B preparation with SI subunit was not 
responsible for its’ inhibitory activity, as PT-B was as effective as the holotoxin across 
the dose range employed. Unfortunately, the range of doses employed did not extend 
low enough to identify the minimum amount of PT or PT-B required for an inhibitory 
effect.
Of relevance to the present findings is a recent study by O'Neill et al (1992), which 
investigated the PT inhibition of IL-1 induced IL-2 secretion in EL4 cells and PGE2  
secretion in human gingival fibroblasts. In both these cells the purified B oligomer was 
as inhibitory as the holotoxin. Furthermore, the inhibition by PT and PT-B was found 
to be specific for the IL-1 pathway, as PT-B did not impair the ability of PMA to induce 
IL-2 or PGE2  generation in the respective cell types. PT-B appeared to be inhibiting at 
a later point in the IL-1 pathway, as the affinity or number of IL-1 receptors was not 
altered and PT-B did not inhibit an early response of EL4 cells to IL-1, induction of the 
transcription factor NFkB. These findings support the observations in MC that 
inhibition of certain IL-1 activities by PT is attributable to unknown actions of the toxin 
which appear independent of G protein modification by ADP-ribosylation. In direct 
contrast to the report by O’Neill et al is a study performed in a different subclone of 
EL4 cells which found the inhibition of IL-1 induced IL-2 secretion by PT was not 
mimicked by the purified B oligomer (Rollins et al 1991). The reason for the 
discrepancy between these two studies is at present unclear. Unfortunately other studies 
demonstrating an effect of PT on IL-1 signalling events, including PGE2  production in 
human synovial cells, klg light chain expression by 70Z/3 cells, IL-2R expression by 
YT cells and DAG production in EL4 cells, did not investigate the effects of purified 
PT-B (Chedid et al 1989; Dobson et al 1989).
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The study by O’Neill et al (1992) concluded that the ability of PT to inhibit certain IL-1 
activities was attributable to unknown actions of the B oligomer. Signalling properties 
of purified PT-B have been previously described. PT-B stimulated mitosis in murine 
splenocytes and human T lymphocytes, and enhance glucose oxidation in rat adipocytes 
(Tamura et al 1983; Stmad & Carchman, 1993). The mechanism of PT-B action 
appeared to involve a rapid and sustained elevation of cytosolic Ca^+ predominantly 
from extracellular stores (Stmad & Carchman, 1993). The lectin concanavalin A (con 
A) exhibited similar effects to PT-B in these studies. The activities of con A are thought
due to its’ multipoint attachment to cell surface glycoproteins resulting in the
2+aggregation of receptor proteins and subsequent changes in cytosolic Ca . Aggregation 
of receptor molecules by PT-B may therefore be important in mediating its effects, in 
an analogous manner to con A (Stmad & Carchman, 1993; Tamura et al 1983). The 
structural properties of PT-B are consistent with such a model, consisting of the two 
dimers, S2-S4 (dimer 1) and S3-S4 (dimer 2), connected by S5. Interaction of each 
dimer with an independent recognition site would result in a bivalent binding
phenomenon. The effects of PT or PT-B on lymphocyte proliferation, glucose oxidation
2+
and intracellular Ca levels were only observed when high doses of the toxin were 
employed (>0.5 pg/ml). The marked difference in the dose-response of PT-B inhibition 
of IL-1 induced IL- 8  and IL- 6  production in human MC, and IL-2 production in EL4
cells (where 100 ng/ml PT-B was used) (O'Neill et al 1992), indicates the mechanism
2+
of regulation may differ, and therefore elevation of intracellular Ca by PT-B may not 
be involved. Indeed, the results of the presents study obtained using a PT mutant, 
PTR9 ENK and a recombinant preparation of PT-B indicate that the properties of the B 
oligomer may not be important in mediating the inhibitory effects of the toxin on IL-1 
activity.
The PT mutant, PTR9ENK contained points mutations in the SI, S2 and S3 subunits. 
The mutations in the SI subunit consisted of substitution of arginine 13 and glutamine 
129, with leucine and glycine respectively. These substitutions in the SI subunit have 
been shown to result in undetectable levels of ribosylation of the G protein, transducin 
by pertussis toxin in ADP-ribosylation studies and to cause complete attenuation of the 
in vivo activities of the toxin in mice, which are known to be mediated by its ADP-
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ribosylating activity (Pizza et al 1989; Loosemore et al 1990). The mutations in the B 
oligomer were located in S2 and S3, as these subunits are thought to contain the 
receptor recognition sites, although the identity of the cellular receptors for PT have yet 
to be identified (Schmidt & Schmidt, 1989; Schmidt et al 1991; Kaslow & Bums, 
1992). Deletion of the asparagine residue 105 of S2 and the lysine residue 105 of S3 
resulted in complete inhibition of the ability of PT to induce agglutination of red blood 
cells, cytotoxicity in Chinese hamster ovary (CHO) cells and mitogenic effects in T 
lymphocytes (Lobet et al 1993), activities of PT that are known to be mediated by the B 
oligomer. These reports demonstrate the mutations in PTR9 ENK effectively inhibit 
activities of PT which are mediated by its’ ADP-ribosylating activity or by properties of 
the B oligomer, however my preliminary results indicate PTR9 ENK was as effective as 
the holotoxin in inhibiting IL-1 induced IL- 8  and IL- 6  production in MC. This suggests 
neither the ADP-ribosyltransferase activity of the toxin nor the properties of the B 
oligomer are involved in the inhibition of IL-1 induced IL- 6  and IL- 8  production. The 
similarity between the dose response curves for holotoxin and P T R g E N K  inhibition of 
IL- 8  and IL- 6  production, with both toxins being inhibitory between 50 and 500 ng/ml, 
while a 1 0 0 0  ng/ml dose was ineffective, argues against the possibility that residual SI 
activity is responsible for the effects of P T R g E N K .  In addition, the inability of a 
recombinant preparation of PT-B to modify IL- 8  or IL- 6  production confirms the 
inhibitory effects of PT are not mediated by the B oligomer.
Taken together the findings of this study suggest the inhibitory activity of PT, non­
recombinant PT-B and PTRgENK on IL-1 induced IL- 8  and IL- 6  production in MC may 
be due to contamination with a distinct product from B. Pertussis which co-purifies with 
the toxin, since only the recombinant form of PT-B, produced in a host other than B. 
Pertussis, showed no inhibitory activity. The mechanism of inhibition of IL-1 induced 
IL- 8  and IL- 6  production by pertussis toxin is therefore unknown, but appears 
independent of ADP-ribosylation and thus does not indicate a role for Gi/o type proteins 
in IL-1 signalling for IL- 8  and IL- 6  in MC. While the effects of pertussis toxin 
preparations on certain IL-1 signalling events may prove to be interesting, until the 
mechanism of action is understood, the involvement of any specific signalling 
component cannot be inferred.
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In the current literature, evidence for a G protein involvement in IL-1 and TNF signal 
transduction has also arisen from studies involving GTPyS binding experiments and 
GTPase assays (Chedid et al 1989; O'Neill et al 1990a; Imamura et al 1988). These 
methods detect a direct functional interaction between the agonist receptor and 
heterotrimeric G proteins in cell membrane preparations. The ability of PT to inhibit the 
IL-1 and TNF stimulated increases in GTP hydrolysis suggests, in this system, that PT- 
sensitive G proteins such as Gj or G0  isoforms may be involved (Chedid et al 1989; 
O'Neill et al 1990a; Imamura et al 1988).
A different experimental approach was therefore employed to probe mesangial cells for 
a direct IL-1 or TNF receptor-PT-sensitive G protein coupling. The novel technique 
used was based on the ability of an agonist to specifically increase the CT induced 
ADP-ribosylation of a ~40 kDa PT-sensitive G protein, if the agonist-receptor complex 
functionally coupled to that G protein (Milligan et al 1991; Gierschik & Jakobs, 1987; 
Iiri et al 1989). However, IL-1, TNF and endothelin-1 were found to have no 
observable effects in this system. Endothelin-1 was included as a positive control as its’ 
receptor is a member of the family of G protein-coupled receptors which possess 7 
membrane spanning domains, and endothelin is known to signal via a PT-sensitive G 
protein in MC (Thomas et al 1991). A number of reasons may account for the inability 
of IL-1, TNF or endothelin-1 to induce an observable effect in this system. Firstly, this 
technique may be unsuitable for detecting all types of receptor-PT-sensitive G protein 
interactions. To date, this novel method has been used to demonstrate 2 types of 
receptor G protein interactions: coupling of the human platelet a 2 -C10 adrenergic 
receptor to Gyi and G^ proteins in rat- 1  fibroblasts transfected with this receptor 
(Milligan et al 1991), and coupling of the formyl-methionyl-leucyl-phenylalanine 
(FMLP) receptor to Gj2  proteins in the neutrophil-like HL-60 cell line (Iiri et al 1989; 
Gierschik & Jakobs, 1987). A more recent study in HL-60 cells investigated the ability 
of both FMLP and LTB4  to specifically enhance the CT ribosylation of a PT-sensitive G 
protein (Schepers & McLeish, 1993). Both these agonists induce disparate second 
messengers and functional responses in HL-60 cells, but are thought to couple to a 
common pool of PT-sensitive G proteins, since both agonists increase GTP hydrolysis 
and GTPyS binding in cell membrane preparations, which was inhibitable by PT
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treatment (McLeish et al 1989). However only FMLP enhanced the CT ribosylation of 
a -40 kDa substrate, while LTB4  had no effect. It was therefore suggested that the PT- 
sensitive G proteins that couple to the FMLP and LTB4  receptors exist in different 
activated conformations which is determined by the receptor with which they interact, 
and not all activated conformations may be susceptible to CT ribosylation. Additional 
doubts on the ability of an IL-1 or TNF receptor-G protein interaction to be detected by 
this method rests on the fact that like endothelin, both the FMLP and LTB4  receptors 
belong to the family of classical G protein coupled receptors which possess the common 
structural feature of 7 membrane spanning domains. The nature of the G protein 
coupling occurring between receptors that do not belong to this family has yet to be 
established and may prove to be quite different (Ray et al 1992).
A further consideration is the relatively low number of IL-1 and TNF receptor expressed 
on cells (200 - 4000 IL-1 receptors (Saklatvala & Guesdon, 1992) and 100 - 10,000 
TNF receptors (Beyaert & Fiers, 1994)) compared to the number of high affinity FMLP 
receptors on HL-60 cells (>46,000) (Weisbart et al 1986), the model cell system for 
demonstrating the use of this method in showing a receptor-G protein interaction. It is 
therefore possible that the number of IL-1 and TNF receptors present on MC is 
insufficient, even if the majority are activated, to cause an observable increase in 
ribosylation over the relatively high basal labelling that occurs. The other cell system in 
which this method has been successfully employed is rat-1 -fibroblasts transfected with 
the a 2 -C 1 0  adrenergic receptor, and in this study, only clones showing high receptor 
expression were used (Milligan et al 1991). Furthermore, in the previous studies (Iiri et 
al 1989; Gierschik & Jakobs, 1987) high concentrations of FMLP (>100 nM), which 
far exceed the concentrations necessary to elicit a biological response (1 nM) (Cassatella 
et al 1992) were required to induce an observable effect, indicating that a large number 
of receptors need to be activated. The lack of effect in the MC system should not simply 
be a question of insufficient receptor occupancy with ligand, since high concentrations 
of all 3 agonists were tried (upto 3 pg/ml IL-la (180 nM), upto 10 pg/ml TNFa (590 
nM) and 3 pM endothelin-1).
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Finally, the possibility that the experimental conditions employed in this study were not 
correct for supporting an agonist dependent CT ribosylation of a PT-sensitive G protein 
cannot be ruled out, due to the absence of an appropriate positive control. Based on the 
points discussed above, the most appropriate positive control to use would be the HL- 
60/FMLP system, since there are no doubts concerning the ability of FMLP to induce an 
observable effect using this technique. Such a control would have confirmed viable 
membrane preparations with intact receptors were obtained after the extraction 
procedure, and that the conditions for ADP-ribosylation were correct.
The techniques employed in the present study proved to be unsuitable for determining 
whether IL-1 or TNF signal via PT-sensitive G proteins in human MC. The low 
number of IL-1 receptors present on cells is likely to pose a problem in many of the 
current techniques available for identifying a receptor-G protein interaction. GTPase 
assays and GTPyS binding studies are the most widely employed techniques for 
identifying G protein coupled receptors, and both methods were used to demonstrate an 
IL-1 receptor-G protein interaction in 70Z/3 cells (Chedid et al 1989) and an EL4 cell 
line (O'Neill et al 1990a). In contrast, a subsequent study using both the 70Z/3 and 
EL4 cell lines failed to demonstrate any such effects of IL-1 using these techniques (Ray 
et al 1992). Such discrepancy may be due to the fact a specific IL-1 receptor rich strain 
of EL4 cells (NOB-1) was used in the initial study (O'Neill et al 1990a), while the latter 
investigation employed a different strain of EL4 cells (EL4.6.1.dlO) (Ray et al 1992). 
Furthermore, problems in reproducing these findings may be due to the fact the number 
of IL-1 receptors present on cells is greatly exceeded by the number of GTP binding 
sites, and therefore unless agonist-bound IL-1 receptors can couple G proteins with an 
exceptionally high frequency, significant IL-1 induced changes in the rate of GTP 
binding or hydrolysis in membrane preparations will be difficult to measure above the 
high backgrounds observed when using these techniques (Ray et al 1992). Similar 
considerations concerning receptor number may apply to investigations into a TNF 
receptor-G protein coupling.
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6. DETERMINATION OF THE POTENTIAL OF HIJMAN MESANGIAL
CELLS TO GENERATE NITRIC OXIDE
6.1. RATIONALE FOR STUDY
At the time of starting this area of work, reports describing production of nitric oxide 
(NO) by any human cell type were very limited. In contrast, a number of studies had 
demonstrated activation of the NO pathway in rodent mesangial cells by 
proinflammatory stimuli such as IL-1 p, TNFa or LPS (Pfeilschifter & Schwarzenbach, 
1990; Shultz et al 1991). Previous studies in our laboratory had indicated the 
NO/cGMP pathway may play a role in the IL-1 regulation of IL- 8  production in human 
MC (Brown et al 1993b). These observations suggest that iNOS may be induced in 
cytokine activated human MC and may regulate chemokine expression via NO induced 
elevation of intracellular cGMP. Inorder to explore further the potential role of the NO 
pathway as a novel signal transduction mechanism for chemokine regulation, it was 
important to demonstrate NO production by cytokine activated human MC in vitro in 
the first instance.
6.2. RESULTS
6.2.1. Ability of cytokine activated human mesangial cells to generate nitrite
NO production by human mesangial cells was determined by measuring in cell 
supernatants the stable end-product nitrite using the Griess reaction. Incubation of 
growth-arrested MC in 24 multi-well tissue culture plates (~5xl04  cells/ml/well) with 
Waymouths medium alone for 72 hours resulted in undetectable nitrite levels (<0.8 
pM). The proinflammatory cytokines IL-la (10 ng/ml) or IFN-y (50 to 500 U/ml) 
added alone or in combination failed to induce detectable nitrite levels after 24, 48 or 72 
hours (n=2 , data not shown).
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A number of modifications were therefore introduced to improve the system for 
detecting nitrite levels in MC culture supernatants;
(1) Nitrite levels were quantitated using a fluorimetric nitrite assay, which has a 
lower detection limit of -100 nM. This compares to 0.8 pM, the detection limit 
of the Griess reaction.
(2) MC were grown in 25 cm2  tissue culture flasks (-8x105  cells/flask), and 
stimulated with cytokines in a final volume of 3 ml. This enhanced the 
sensitivity of the system by increasing the cell:volume ratio. Flasks were also 
employed as a larger volume of supernatant ( 2  ml) was required for the 
measurement of undiluted sample using the fluorimetric assay.
(3) MC were not growth-arrested prior to the start of the experiments, in case this 
reduced the magnitude of the cytokine induced NO response, as was previously 
observed for TNFa induced IL- 6  production in human MC (see chapter 1).
(4) IL-1 (3, as opposed to IL-la was employed, as the majority of published reports 
demonstrating nitrite generation by either animal or human cells in culture used 
this isoform of IL-1 (Nussler et al. 1992; Junquero et al. 1992; Pfeilschifter et al. 
1992).
The results obtained after the introduction of these modifications were as follows 
supernatants from mesangial cells incubated with media alone for 48 hours contained 
nitrite levels of 90 ± 22 nM (mean ± SEM, n=8 ) (data not shown). Stimulation of MC 
with IL-lp (0.3 to 10 ng/ml), IFN-y (100 U/ml) or TNFa (10 to 300 ng/ml) alone failed 
to increase nitrite generation above media control levels after 24 or 48 hours (n>3). 
Similarly, MC stimulated with a combination of IL-1 P (0.3 to 10 ng/ml) and IFN-y (10 
to 500 U/ml), or IL-lp (0.3 to 10 ng/ml ), IFN-y (10 to 500 U/ml) and TNFa (10, 30 
ng/ml) for 24 or 48 hours showed no generation of nitrite above basal levels (n>3). The 
addition of 10 pg/ml LPS or 100 pM Db-cAMP to a cytokine cocktail of IL-lp (1 
ng/ml), IFN-y (100 U/ml) and TNFa (10 ng/ml), or to IL-lp (1 ng/ml) alone had no 
effect on nitrite levels after 48 hour (n=2).
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Further changes to the methodology were tried;
(1) MC were stimulated with cytokines in the presence of 10% FCS to determine 
whether serum factors were required for the induction of iNOS activity.
(2) Experiments were performed on freshly isolated MC cultures at passage 2 and 
above, to assess whether long term culturing of MC or the storage of cultures in 
liquid nitrogen was leading to phenotypic changes which resulted in loss of the 
ability of MC to produce NO.
(3) Culture supernatants were assayed immediately after the experiment as opposed 
to storing at -20°C, to ensure that any nitrite present was not being broken down 
during storage.
(4) Experiments were performed in a different medium, Dulbecco’s Modified Eagles 
Medium (DMEM) without phenol red, as previous studies reported that phenol 
red interfered with both the Griess reaction and fluorimetric assay (Green et al 
1982; Misko et al 1993).
2 6(5) MC were grown in 80 cm tissue culture flasks (~2.5xl0 cells/flask) and
stimulated with cytokines in a final volume of 6  ml for 72 hours, to further 
enhance sensitivity by increasing the cell:volume ratio.
(6 ) The arginine content of Waymouths medium was increased from 360 pM to 2 
mM during the experiment, incase substrate levels were limiting.
The above changes to the system had no effect on the ability of the cytokines IL-lp, 
TNFa or IFN-y, alone or in combination, to increased nitrite levels in MC culture 
supernatants above basal levels after 24, 48 or 72 hours stimulation (n>2, data not 
shown).
As a positive control, rat kidneys were obtained from untreated male Sprague Dawley 
rats and mesangial cells were isolated and cultured in a similar manner to human 
mesangial cells. Rat MC grown in 25 cm tissue culture flasks were used at passage 2 
and 3, and the experiment was performed in serum-free Waymouths medium on cultures 
which were not growth-arrested prior to use. Supernatant from rat MC incubated with 
medium alone for 24 or 48 hours contained undetectable nitrite levels (<0.8 pM) using 
the Griess reaction. In comparison, stimulation of rat MC with IL-lp alone (0.3 to 10
150
ng/ml) for 24 or 48 hours resulted in dose-dependent nitrite generation, 22 pM and 33 
fiM nitrite was detected after 24 and 48 hours stimulation with 3 ng/ml IL-1 (3 
respectively (Fig. 59). The results indicate that the stock of IL-lp and the Griess assay 
were functional, and performing the experiments in Waymouths medium in the absence 
of FCS supported nitrite generation by cultured cells. The successful detection of 
increased nitrite levels in culture supernatants from the human colonic epithelial cell 
line HT-29 in our laboratory, following stimulation with a combination of IL-la, IFN-y 
and TNFa using the fluorimetric nitrite assay confirmed this latter assay and stock 
cytokines were also functional (Kolios et al 1995).
Together, these findings indicate that cytokine stimulation of human MC resulted in 
undetectable increases in nitrite levels of culture supernatants, using both the Griess 
(<0.8 pM) and fluorimetric (<100 nM) nitrite assays.
6.2.2. Ability of cytokine activated human mesangial cells to produce nitrate
Contrasting reports on the fate of NO in aqueous solution describe either oxidation of 
NO to nitrite and nitrate in a 2:1 ratio (Marietta et al 1988), or complete oxidation of 
NO to nitrite, with little or no nitrate formed (Ignarro et al 1993). Nitrate, however 
may be formed if FCS is present in the culture medium during the experiment, as small 
amounts of haemoglobin present in FCS will result in the conversion of NO to nitrate 
(Misko et al 1993). The ability of human MC to produce superoxide (0 2’) following 
cytokine stimulation (Radeke et al 1990) may also lead to nitrate rather than nitrite 
production, since NO and 0 2’ react with high affinity to form the peroxynitrite anion, 
which degrades to nitrate (Mulligan et al 1991). To determine whether the inability to 
detect increased nitrite levels in culture supernatants from cytokine stimulated MC was 
due to the oxidation of NO to nitrate as a result of superoxide generation or the presence 
of FCS in the system, nitrate levels in culture supernatants from the previous 
experiments (described in 6 .2 .1 ) were quantitated by incubating the sample with nitrate 
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Figure 59. Dose-dependent production o f nitrite by IL -l activated rat MC. Sprague Davvley rat MC 
cultured in 25 cm2 flasks were stimulated with increasing doses o f  IL-lp for 24 or 48 hours. Nitrite 
levels in cell supernatants were quantitated using the Griess reaction. A representative experiment is 
shown, similar nitrite production was observed in one other study.
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Results obtained using the Griess reaction showed supernatants from MC incubated 
with media alone for 48 hour contained undetectable nitrite/nitrate levels. MC 
stimulated with IL-1 p (0.3 to 3 ng/ml) or TNFa (300 ng/ml) alone, or IL-lp (0.3 to 3 
ng/ml), TNFa (10 ng/ml) and IFN-y (100 U/ml) in combination also failed to produce 
detectable nitrite/nitrate levels after 48 hours (n>3). The rate of conversion of nitrate to 
nitrite using nitrate reductase was assessed by using known standards of sodium nitrate 
which were within the range of the Griess reaction (i.e. 1 - 2 0  pM), conversion rates 
were ~60% with a lower detection limit of 2 pM nitrate, when performed using 
Waymouths medium in the absence of FCS. Results were obtained from the conversion 
of supernatants from experiments performed in either Waymouths medium or DMEM in 
the absence of FCS. The presence of FCS proved problematic as it contained relatively 
high levels of nitrate (>11 pM) which reduced the sensitivity of the conversions and 
caused large variations (>3 pM) across triplicates of the enzyme blank (i.e. nitrate 
reductase + NADPH + medium which has not been incubated with cells). Variation 
across triplicates of the enzyme blank within an experiment made result difficult to 
interpret. DMEM without phenol red also contains low levels of nitrate (1.6 pM) and 
subsequently the sensitivity of conversions performed in this medium were not as good 
as in Waymouths media, which contains no added nitrate.
Results obtained using the fluorimetric assay showed MC incubated with media alone, 
or stimulated with IL-lp (1, 3 ng/ml), TNFa (10, 300 ng/ml) or IFN-y (100 U/ml) alone, 
or in combination showed no production of nitrite/nitrate above media control levels 
after 48 hours (n>4). % conversion rates of nitrate to nitrite were generally 50 to 60%. 
However, the lower detection limit of the conversion was only 2 pM nitrate, despite the 
greater sensitivity of the fluorimetric assay (>100 nM nitrite). The poor detection limit 
for nitrate was due to high backgrounds (1 to 2 pM) obtained with the enzyme blank, 
despite the use of Waymouths medium which contains no added nitrate. The high 
background may therefore be due to nitrate present in water and absorbed from glass 
and/or plasticware. Furthermore, variations of up to 1 pM in the levels of background 
nitrate measured in triplicate samples of the enzyme blank made results difficult to 
interpret.
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6.2.3 Expression of mRNA for the inducible form of the NO synthase enzyme by 
cytokine activated human mesangial cells
Geller et al in 1993 were the first group to clone an inducible form of the NO synthase 
enzyme (iNOS) from human cells (hepatocytes) (Geller et al 1993). Subsequent to this 
study, probes to detect human iNOS gene expression became available. Due to 
difficulties in demonstrating NO production by cytokine stimulated MC using 
nitrite/nitrate measurements, MC were probed for iNOS mRNA expression.
MC incubated in Waymouths medium alone, in the presence of 10% FCS did not 
express detectable iNOS mRNA transcripts. Surprisingly, stimulation of MC with a 
combination of IL-1 P (1 ng/ml), TNFa (10 ng/ml) and IFN-y (50 U/ml) for 8 , 16 and 24 
hours in the presence of 10% FCS resulted in time-dependent iNOS mRNA expression 
(data not shown).
The effect of cell cycle, FCS and different cytokine combinations on iNOS expression 
in MC was determined, in order to allow optimum conditions to be employed in future 
experiments.
(i) Cell cycle and FCS:
Figure 60 shows that non-quiescent MC stimulated with a cocktail of IL-lp (1 ng/ml), 
TNFa (10 ng/ml) and IFN-y (100 U/ml) in the presence of 10% FCS (Fig. 60, C) 
express reduced levels of iNOS mRNA at 8 , 24 and 48 hours compared to non-quiescent 
cells stimulated in the absence of FCS (Fig. 60, B), a 34 ± 2% (mean ± SEM, n=2) 
decrease in mRNA expression was observed after 24 hours stimulation in the presence 
of 10% FCS. Furthermore, cocktail stimulation of non-quiescent MC in the absence of 
FCS (Fig. 60, B) resulted in reduced iNOS mRNA expression of 35 ± 4% (mean ± 
SEM, n=2) at 24 hours compared to cells which were made quiescent before use (Fig. 
60, A). All further experiments were therefore performed on quiescent MC, in the 
absence of FCS.
(ii) Cytokines:
The effect of different cytokines, either alone or in combination on iNOS mRNA 
expression was next assessed to determine the cytokine requirement for iNOS induction. 
iNOS mRNA transcripts were not detected in unstimulated MC. The proinflammatory
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Figure 60. Effect o f different culture conditions on iNOS mRNA expression in human MC 
stimulated with a cytokine cocktail. MC cultured in 25 cm2 flasks were either preincubated in serum 
free medium for 24 hours (A), or left in ‘complete’ Waymouths medium prior to stimulation with a 
cytokine cocktail o f  IL-1(3 (1 ng/ml), TNFa (10 ng/ml) and IFN-y (100 U/ml) for 48 hours, in either the 
absence (B) or presence (C) o f  10% FCS. Total cellular RNA was extracted and northern analysis carried 
out. Autoradiographs (i) were analysed by densitometry and the results plotted using the absorbance 
units (ii). The ethidium bromide stained gels showing the 18S and 28S ribosomal RNA were used to 
assess equal loading (iii). Representative blots are shown, n=2.
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cytokines IL-la, TNFa or IFN-y added alone to MC did not induce detectable iNOS 
mRNA expression (n=3, data not shown). The combination of IL-lp/IFN-y was the 
minimal requirement for iNOS mRNA expression, while other pairs of cytokines were 
ineffective (Fig. 61). The addition of TNFa did not significantly increase the IL-ip (1 
ng/ml) / IFN-y (100 U/ml) induced iNOS mRNA expression in MC (Fig. 61). 
Stimulation of MC with increasing doses of IL-lp (0.3 - 3 ng/ml) in the presence of 100 
U/ml IFN-y resulted in dose-dependent expression of iNOS mRNA (Fig. 62). No 
further increase in iNOS mRNA expression was observed with a higher dose of IL-1(3 
(10 ng/ml). Similarly, stimulation with 30 to 300 U/ml of IFN-y in the presence of IL- 
lp (1 ng/ml) resulted in dose-dependent iNOS mRNA expression at 48 hours in MC 
(Fig. 62). However, increasing concentrations of TNFa (3 to 30 ng/ml) in combination 
with IL-lp (1 ng/ml) and IFN-y (100 U/ml) had no effect on the level of iNOS mRNA 
expression in MC (Fig. 62).
The time course of iNOS mRNA expression in MC following stimulation with IL-lp (1 
ng/ml), TNFa (10 ng/ml) and IFN-y (100 U/ml) was examined. In unstimulated cells 
iNOS transcripts were not detected at any of the time points examined. The cocktail of 
cytokines induced iNOS expression which was first detected at 4 hours, peaked at 24 
hours and was still present at 72 hours (Fig. 63a). The levels of iNOS detected at 72 
hours varied, depending on how viable the culture remained during the longer 
incubation periods with the cocktail, in the absence of FCS.
iNOS mRNA transcripts were consistently expressed in all the MC cultures tested (n=7) 
after stimulation with IL-lp and IFN-y or IL-lp, IFN-y and TNFa. However, culture 
supernatants from these same experiments contained undetectable levels of nitrite ( < 1 0 0  
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Figure 61. Specificity of iNOS mRNA induction in human MC. Cells cultured in 25 cm2 flasks were 
stimulated with different combinations o f the cytokines IL-1 (3 (1 ng/ml), TNFa (10 ng/ml) and IFN-y 
(100 U/ml), as indicated. After 48 hours, total cellular RNA was extracted and northern analysis carried 
out. Autoradiographs (i) were analysed by densitometry and the results plotted using the absorbance 
units (ii). The ethidium bromide stained gels showing the 18S and 28S ribosomal RNA were used to 
assess equal loading (iii). Representative blots are shown, n=2.
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Figure 62. Dose-dependent expression of iNOS mRNA in cytokine stimulated MC. Cells were 
stimulated with either increasing doses o f IL-1 P (0.3 - 10 ng/ml) in the presence o f  100 U/ml IFN-y, 
IFN-y (30 - 300 U/ml) in the presence o f 1 ng/ml IL-1 P or with TNFa ( 3 - 1 0  ng/ml) in combination 
with both IL-1 P (1 ng/ml) and IFN-y (100 U/ml). Total cellular RNA was extracted after 48 hours and 
northern analysis carried out. Autoradiographs (i) were analysed by densitometry and the results plotted 
using the absorbance units (ii). Identical membranes were probed with the house-keeping gene P-actin 
(iii) to assess equal loading, together with the ethidium bromide stained gels showing the 18S and 28S 
ribosomal RNA bands (iv). Representative blots are shown, n=3.
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Figure 63. Time-dependent expression of iNOS mRNA in cytokine stimulated MC. Cells cultured 
in 25 cm2 flasks were stimulated with 1 ng/ml IL-ip, 100 U/ml IFN-y and 10 ng/ml TNFa for the times 
indicated.
(a) Total cellular RNA was extracted and northern analysis carried out. Autoradiographs (i) 
were analysed by densitometry and the results plotted using the absorbance units (ii). Identical 
membranes were probed with the house-keeping gene P-actin (iii) to assess equal loading, together 
with the ethidium bromide stained gels showing the 18S and 28S ribosomal RNA bands (iv).
(b) Nitrite and nitrate levels in 48 hour culture supernatants were measured using the 
fluorimetric assay.
A representative experiment is shown, similar results were obtained in 4 other experiments.
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6.2.4. Inducible NOS protein expression by cytokine activated human mesangial 
cells
To determine whether the iNOS mRNA expressed by cytokine stimulated MC was 
being translated into protein, MC were probed for iNOS protein by western blot using a 
specific anti-iNOS antibody (monoclonal, human). Figure 64 (a) shows MC incubated 
with media alone for 48 hours contained undetectable amounts of iNOS protein. The 
combination of IL-lp (1 ng/ml), IFN-y (100 U/ml) and TNFa (10 ng/ml) induced 
expression of a ~131 kDa protein after 24 and 48 hours. This protein corresponds to the 
molecular weight of the known form of human iNOS enzyme (Geller et al 1993). 
Specificity of the iNOS antibody was confirmed by incubating an identical membrane 
with antisera containing 50 nM of a peptide corresponding to the C-terminal sequence 
of human iNOS, against which the antibody was directed. Addition of the blocking 
peptide completely inhibited staining (Fig. 64b).
iNOS protein was not detected in cells stimulated for 48 hours with either IL-1 P (3 
ng/ml), TNFa (300 ng/ml) or IFN-y (100 U/ml) alone, or the combination of IL-1 p (1 
ng/ml) and TNFa (10 ng/ml) or TNFa (10 ng/ml) and IFN-y (100 U/ml) (Fig. 65).
6.2.5. Effect of inhibiting superoxide generation on nitrite production by cytokine 
activated mesangial cells
The ability of cytokine activated human MC in culture to generate superoxide is well 
established (Radeke et al 1990; Jones et al 1993) and may result in nitrate as the end 
product of NO degradation, through formation of the peroxynitrite anion (Mulligan et 
al 1991). However, the method used to assay nitrate levels in culture supernatants, 
using the enzyme nitrate reductase to convert nitrate to nitrite for quantitation using the 
Griess or fluorimetric nitrite assays had a poor lower detection limit (>2 pM nitrate). 
The effect of blocking 0 2’ production using an inhibitor of the NADPH-oxidase, 4- 
hydroxy-3-methoxyacetophenone (HMAP) (Suzuki et al 1992) and the effects of the 
0 2* scavengers, pyrrolidinedithiocarbamate (PDTC) and superoxide dismutase (SOD) 
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Figure 64. Production of iNOS protein by cytokine stimulated MC. Cells cultured in 25 cm flasks 
were stimulated with 1 ng/ml IL-1 (3, 100 U/ml IFN-y and 10 ng/ml TNFa for 24 or 48 hours. Control 
cells (C) were stimulated with media alone for 48 hours. Total cellular protein was extracted and 
resolved in a 7% SDS-polyacrylamide gel, prior to western blotting. iNOS protein was detected using a 
specific antibody directed against the human hepatocyte form o f the inducible NOS enzyme, in either the 
absence (a) or presence (b) o f  a blocking peptide which corresponds to the C-terminal sequence o f  iNOS. 
Representative blots are shown, n=4.
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Figure 65. Specificity of iNOS protein production by cytokine stimulated MC. Cells were stimulated 
with IL -ip  (1 ng/ml), TNFa (10 ng/ml) or IFN-y (100 U/ml) either alone or in combination, as indicated. 
After 48 hours, total cellular protein was extracted and resolved in a 7% SDS-polyacrylamide gel, prior to 
western blotting and immunodetection. Representative blots are shown, n=2.
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Pretreatment of MC with HMAP (3 to 300 fiM) for 1 hour, or PDTC (3 to 1000 pM) or 
SOD (10 to 300 U/ml) for 30 minutes, prior to stimulation with IL-1 p (1 ng/ml), IFN-y 
(100 U/ml) and TNFa (10 ng/ml) resulted in undetectable nitrite levels (<100 nM) after 
72 hours (data not shown, n=3).
6.2.6. Nitrite production by human MC: quantitation using chemiluminescence
The inability to detect increased nitrite production in culture supernatants from cytokine 
stimulated MC which positively express iNOS mRNA transcripts and protein may be 
due to lack of sensitivity of the fluorimetric assay. Chemiluminescence was therefore 
employed to quantitate nitrite levels in cell supernatants, the sensitivity of this assay is 
in the pM range. Figure 6 6  shows MC incubated with media alone generated 2.2 ± 0.2 
nM (mean ± SEM, n=3) nitrite after 48 hours. Stimulation of MC with IL-1 p (1 ng/ml), 
IFN-y (100 U/ml) and TNFa (10 ng/ml) resulted in increased nitrite production of 4.2 ± 
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Figure 66. Chemiluminescence measurement o f nitrite production by cytokine stimulated human
MC. Cells cultured in 25 cm2 flasks were stimulated with I ng/ml IL-I0, 100 U/ml IFN-y and 10 ng/ml 
TNFa for 24, 48 or 72 hours. Control cells (C) were stimulated with media alone for 48 hours. Cell 




The presence of an inducible NO/L-arginine pathway in human cell types in vitro has, 
until recently been difficult to demonstrate. Nussler et al in 1992 demonstrated freshly 
isolated human hepatocytes produced an L-NMMA inhibitable increase in nitrite 
production and elevation of cGMP after stimulation with a ‘cocktail’ of factors, IL-1, 
TNF, IFN-y and LPS (Nussler et al. 1992). The following year Geller et al (1993) 
cloned the human hepatocyte iNOS, which appeared to be a structurally distinct 
isoform, -80% homologous to murine macrophage NOS and -50% homologous to
human endothelial NOS at the amino acid level. Unlike murine macrophage NOS, the
2+activity of human hepatocyte NOS was partially inhibited by Ca chelation or treatment 
with a calmodulin inhibitor (Geller et al. 1993).
In the present study the ability of cultured human mesangial cells to express the 
inducible NO/L-arginine pathway was investigated. MC expressed mRNA transcripts 
and protein for the human hepatocyte isoform of iNOS following stimulation with a 
combination of cytokines. The minimum cytokine requirement for detectable iNOS 
mRNA and protein expression was stimulation with a combination of IL-1 and IFN-y. 
No other pair of cytokines, or individual cytokines tested proved to be effective for 
iNOS induction. These findings on cytokine specificity are consistent with reports in 
other human cell types which indicate that in contrast to animal tissues, induction of 
iNOS expression in human cells generally requires a combination of cytokines. The 
cytokine requirement for iNOS induction appears to vary across different cell types. 
Similar to our findings in MC, IL-1/IFN-y was an effective stimulus for iNOS induction 
in human colonic epithelial cells (Kolios et al 1995), human retinal pigmented 
epithelial cells (Goureau et al 1994), human osteoblast-like cells (Ralston et al 1994) 
and human lung epithelial cells (Asano et al 1994). Modest induction of iNOS 
expression and/or activity was also observed in human osteoblast-like cells (Ralston et 
al 1994) and human lung epithelial cells (Asano et al 1994) after stimulation with 
TNF/IFN-y, while human monocytes expressed iNOS mRNA following stimulation 
with IFN-y/LPS (Reiling et al 1994). The addition of TNF to the combination of IL-1 
and IFN-y was found to cause significant potentiation of nitrite production in these
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studies (Kolios et al 1995; Goureau et al. 1994; Ralston et al. 1994). However, 
stimulation of MC with increasing doses of TNF in the presence of sub-maximal doses 
of IL-l/IFN-y caused no enhancement of iNOS mRNA levels, while the effect on nitrite 
production was not determined in these experiments. This finding supports the previous 
suggestion of Kolios et al (Kolios et al 1995) that TNFa upregulates IL-l/IFNy 
induced iNOS activity at a posttranscriptional level. In marked contrast to the human 
MC study and reports in other human cell types, induction of iNOS activity has been 
observed in human vascular smooth muscle cells (Junquero et al 1992) and human 
chondrocytes (Charles et al 1993; Maier et al 1994) after stimulation with single 
cytokines, either IL-1, TNF or IFN-y. Cloning of the human chondrocyte iNOS showed
this isoform differed from the human hepatocyte iNOS by 7 amino acids, and unlike
2+human hepatocyte iNOS, was insensitive to Ca chelation and calmodulin inhibitors. It 
was therefore suggested that human hepatocyte iNOS and human chondrocyte iNOS 
may be distinct molecular forms, which are differentially regulated (Chartrain et al 
1994). In support of this, cloning of vascular smooth muscle, macrophage and 
hepatocyte iNOS isoforms from the same species (male Sprague Dawley rats) revealed 
some structural differences between the 3 isoforms which had previously been thought 
due to species variation (Mohaupt et al 1994). This indicates different cell types may 
express structurally and functionally unique isoenzymes of iNOS, which may be 
encoded by a family of distinct iNOS genes.
Recent studies by Brown et al (1993b) and Andrew et al (1995) have indicated a role for 
NO in IL-1 and TNF induced IL- 8  production, since NO donors and cGMP analogues 
upregulated, while L-arginine analogues partially inhibited IL- 8  production in IL-1 
stimulated human MC and TNF stimulated human melanoma cells. The role of NO in 
MC chemokine production was not investigated directly in the present study, but the 
findings of the cytokine requirement for expression of the human hepatocyte isoform of 
iNOS in MC indicate that this isoform is unlikely to play a role in IL-1 induced IL- 8  
generation, since single cytokines were not an effective stimulus for its induction. 
Recent studies have indicated an increasing number of human cell types (e.g. 
endothelial cells (Gross et al 1991), monocytes/macrophages (Reiling et al 1994) and 
lung epithelial cells (Asano et al 1994)) can express both a constitutive and inducible
165
form of the NOS enzyme. Furthermore, a novel report in cultured rat MC demonstrated 
an ability of these cells to express both a designated vascular smooth muscle and 
macrophage iNOS isoenzymes, which were shown to be differentially regulated by 
TNF/IFN-y stimulation (Mohaupt et al 1994). An ability of human MC to express a 
number of NOS isoforms which are differentially regulated, may explain the reported 
effects of L-NMMA on IL-1 induced IL- 8  production. In the present study, stimulation 
of MC with IL-1 alone did not induce a detectable increase in nitrite generation by MC 
using the fluorimetric nitrite assay, however any induced NO production may have been 
below the detection limit of the assay (<100 nM), and studies have shown 10 nM NO 
production is sufficient to induce elevation of intracellular cGMP and cause smooth 
muscle cell relaxation in vitro (Beckman & Tsai, 1994). Alternatively, the response 
may involve low output NO production by a constitutive NOS isoform. This area of 
work therefore requires further investigation.
Inducible NOS mRNA transcripts were first detected in MC 4 hours post-IL-l/IFN- 
y/TNF stimulation, levels peaked at 24 hours and remained elevated beyond 72 hours. 
A similar time course of iNOS mRNA expression was observed in human colonic 
epithelial cells (Kolios et al 1995), while human hepatocytes expressed peak mRNA 
levels 8  hours post-stimulation and levels had declined by 24 hours (Nussler et al 
1993). Stimulation of MC with cytokines in the presence of FCS was found to cause 
marked inhibition of iNOS mRNA expression. The inhibitory activity of FCS may be 
due, at least in part to platelet factors present in serum, since PDGF was previously 
shown to inhibit nitrite production in cytokine stimulated rat MC (Pfeilschifter, 1991a). 
Growth-arresting MC prior to cytokine stimulation in serum-free media may further 
increase iNOS mRNA expression by allowing sufficient time (24 hours) for the effects 
of serum factors to diminish prior to iNOS induction. Intriguingly, despite consistent 
detection of iNOS mRNA transcripts and iNOS protein in human MC isolated from 
different donors and at different passage numbers, the ability of MC to produce NO and 
thereby increase nitrite levels in cell supernatants was difficult to demonstrate, despite 
employing optimal experimental conditions by stimulating growth-arrested MC with a 
combination of IL-l/IFN-y/TNF, in the absence of FCS. Nitrite production by cytokine- 
stimulated MC was not detected using the Griess reaction or a fluorimetric assay which
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have lower detection limits of 0.8 pM and 100 nM nitrite respectively. Preliminary 
results obtained using a more sensitive chemiluminescence assay, which detects nitrite 
levels down to the pM range demonstrated stimulation of MC with IL-l/IFN-y/TNF 
produced a two-fold increase in nitrite production after 48 hour of 4.2 nM nitrite. The 
synthesis of such small amounts of nitrite by MC explains the inability to measure 
nitrite production using the Griess or fluorimetric nitrite assay, due to their limited 
sensitivity. The small levels of nitrite produced by MC following cytokine stimulation 
does not exclude a role for NO in mesangial cell signalling, since 10 nM NO increased 
cGMP and causes smooth muscle cell relaxation in vitro (Beckman & Tsai, 1994). 
However, the production of such low levels of NO are uncharacteristic of an inducible 
isoform of NOS and contrast with studies in other human cell types, which describe the 
production of pM amounts of nitrite following cytokine stimulation, measured using the 
Griess reaction (Nussler et al. 1992; Goureau et al 1994; Ralston et a l 1994; Asano et 
al 1994). These findings suggest some factor(s) may be interfering with the conversion 
of NO to nitrite or restricting the activity of iNOS in MC in our system.
The low nitrite levels produced by MC are unlikely to be due to the conversion of 
synthesized NO to nitrate, as the use of nitrate reductase to convert nitrate to nitrite for 
measurement failed to detect nitrate production (>2 pM) after 24, 48 or 72 hours 
stimulation with IL-l/IFN-y/TNF. Furthermore the use of agents to block potential 
superoxide production by MC (Radeke et al 1990) during the experiments, which can 
react with NO and lead to nitrate formation via the synthesis of the peroxynitrite anion 
(Mulligan et al 1991), had no effect on the ability of mesangial cells to produce 
detectable nitrite levels (>100 nM) after 72 hours.
The substrate for iNOS, L-arginine may also be metabolised to L-omithine and urea by 
the action of arginase. Some cells can express both NOS and arginase activity 
indicating competition for substrate may occur (Cattell & Cook, 1993). Competition 
between arginase and NOS for L-arginine has been demonstrated in vitro in rat 
macrophages and in glomeruli isolated from rats with experimental GN, as addition of 
the NOS inhibitor, L-NMMA increased arginase activity, measured by the generation of 
radiolabelled urea from 1 4 C-labelled L-arginine (Cattell & Cook, 1993; Jansen et al
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1992). Studies have indicated that cultured mesangial cells are a major source of 
arginase (Cattell & Cook, 1993). However, limiting substrate did not account for the 
poor nitrite production by human MC in the present study, as increasing the arginine 
concentration of Waymouths medium from 360 pM to 2 mM for the duration of the 
experiment had no effect on nitrite production (<100 nM) by cytokine stimulated MC 
after 72 hours.
The findings of the present study are not in isolation. Morris and Billar (1994) have 
reported similar observations in human pulmonary artery smooth muscle cells and 
human cardiac myocytes which express significant iNOS mRNA and protein in 
response to a combination of IL-l/IFN-y/TNF/LPS, while showing only minor increases 
in nitrite/nitrate production in cell supernatants. Human hepatocytes were found to 
generate significant nitrite/nitrate using the same experimental conditions. Furthermore, 
Reiling et al (1994) demonstrated iNOS mRNA expression in human monocytes 
stimulated with LPS/IFN-y, but failed to detect nitrite production using the Griess 
reaction. This latter study highlights the difficulties researchers have experienced in 
demonstrating iNOS activity in human monocytes/macrophages (Schneemann et al 
1993; Sakai & Milstien, 1993) despite the proposed role of iNOS as an antimicrobial 
system in these cells, which has been firmly established in murine macrophages. 
Intriguingly, a recent study by Nicholson et al (1993) demonstrated human MC in 
culture produced pM amounts of nitrite after 24 hours stimulation with IL-1/IFN-y or 
the more effective cytokine combination of IL-l/IFN-y/TNF in the presence of 10% 
FCS, using the Griess reaction for nitrite measurement. The reason for the discrepancy 
between the present findings and those of Nicholson et al is unknown, since to my 
knowledge identical experimental conditions were tried during this study.
The poor nitrite production by human cells which express significant levels of iNOS 
mRNA and protein following cytokine stimulation may be due to a posttranslational 
defect in NO synthesis in these cells. iNOS activity may be affected at a 
posttranslational level by cofactor availability, since NOS enzymes require an array of 
biochemical cofactors to express activity (Morris & Billiar, 1994). Of particular interest 
is tetrahydrobiopterin (BH4), a cofactor which may play a role in maintaining iNOS in
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an active configuration. Baek et al (1993) have shown BH4  to be important in forming 
active dimeric enzymes from inactive iNOS monomers. BH4  is synthesized by cells de 
novo from GTP or produced by the activities of a salvage (recycling) pathway. The de 
novo synthesis of BH4  was found to be co-induced with iNOS in a host of cells, 
including rat aortic smooth muscle cells (Gross & Levi, 1992) and rat mesangial cells 
(Muhl & Pfeilschifter, 1994) following cytokine stimulation, and de novo BH4  synthesis 
was found to be an absolute requirement for NO generation. Furthermore, addition of 
sepiapterin to increase intracellular BH4  levels via the salvage pathway dose- 
dependently augmented LPS or cytokine induced NO synthesis in these cells, indicating 
BH4  levels under normal culture conditions was limiting the rate of NO production 
(Gross & Levi, 1992; Muhl & Pfeilschifter, 1994). An inability of certain cells in 
culture to synthesize sufficient BH4, which may be acquired from other cell types in 
vivo, or be an artefact of cell culture, could therefore account for their inability to 
produce sufficient NO and thus nitrite in vitro. The effect on nitrite production of 
increasing BH4  levels in cultured human MC remains to be determined.
Some factor(s) produced by cytokine stimulated human MC may inhibit iNOS activity 
at a posttranslational level and thus effect nitrite production in this system. A number of 
cytokines have been shown to exert inhibitory effects on nitrite synthesis, including 
TGFP, IL- 8  and IL-10 (Ding et al 1990; Cunha et al 1992; McCall et al 1992). These 
factors however appear to inhibit an early event in the induction of iNOS activity, since 
the cytokines were only inhibitory when added prior to or simultaneously with the 
stimuli for iNOS expression, and were without effect if added 6  hours later. The ability 
of human MC to synthesize some of these cytokines may not therefore account for the 
low levels of nitrite production. In addition to the production of inhibitory cytokines, 
methylated arginine analogues which inhibit iNOS activity have been found in the 
plasma and urine of patients with end-stage chronic renal failure demonstrating 
endogenous production of these inhibitors (Vallance et al 1992). Cellular sources 
however, have yet to be identified.
The findings of the present study indicate complex regulation of iNOS activity in human 
MC. iNOS activity appears to be regulated both at the level of iNOS mRNA induction
169
(e.g. by FCS) and at a posttranslational level, since expression of significant iNOS 
mRNA and protein by MC was not sufficient for the synthesis of high levels of nitrite 
which is a characteristic of this isoform of NOS. Further studies into the regulation of 
human MC iNOS activity are therefore required, since experimental conditions in terms 
of the appropriate repertoire of cytokines, growth factors, cofactors, etc., which are 
necessary to support high output NO synthesis in vitro have not yet been fully defined.
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7. CONCLUSIONS AND IMPLICATIONS
Human MC are now recognised as a potentially important source of inflammatory 
mediators, including members of the recently identified chemokine superfamily. A 
novel finding of this study was the ability of cultured human MC to express and secrete 
the specific chemotactic factor for CD45RO/CD4+ T lymphocytes, RANTES, following 
stimulation with the proinflammatory cytokines IL-1 and TNF. MC-derived RANTES 
may play a potential role in the recruitment of specific T cell subsets during glomerular 
injury, since T lymphocytes have been detected in glomeruli at both an early and late 
stage of the disease process in animal models of immune complex mediated GN 
(Tipping et al. 1985; Radounikli et al. 1995). The infiltrating T lymphocytes were 
predominantly CD4+ positive. T lymphocytes of this subset may play an important role 
in both the initiation and perpetuation of the immune response (Holdsworth & Tipping, 
1991).
A recurrent finding throughout this work was that expression of the chemokines IL-8 , 
MCP-1 and RANTES by cytokine stimulated human MC was differentially regulated at 
several levels. Expression of the chemokines differed in terms of (a) kinetics of 
expression, (b) specificity of induction, (c) susceptibility to regulation by the 
intracellular second messenger, cAMP and (d) the involvement of secondary proteins in 
TNF induced chemokine gene expression. This ability of the chemokines to be 
differentially regulated may be important for the fine tuning of an immune response, and 
expression of each chemokine in vivo will be dependent on the net regulatory effects of 
local inflammatory mediators (e.g. IL-1, TNF, PGE2, IFN-y). Furthermore, these 
findings provide support for the suggestion that redundancy in the chemokine 
superfamily may be more apparent than real, since expression of members possessing 
overlapping chemotactic activities may be regulated temporally, as well as spatially and 
vary in potency for the given target cell (Schall, 1994).
The ability of IL-1 and TNF to induce expression and production of the same 
chemokines in MC, with different kinetics was a surprising finding. IL-1 induced IL-8 ,
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MCP-1 and RANTES gene expression was more tightly regulated than the TNF 
response, since mRNA levels declined rapidly after maximal expression of the mRNA 
transcripts. TNF induced chemokine expression, in comparison remained sustained. 
Interestingly similar differences in the kinetics of IL-1 and TNF induced chemokine 
expression have since been observed in human vascular smooth muscle cells (Dr N. 
Jordon, personnel communication). The significance of this finding is not yet clear, 
however tighter regulation of the IL-1 response in tissue cells, such as MC may be due 
to the fact that IL-1 can be expressed by a wide range of immune and non-immune cells 
following appropriate stimulation, while expression of TNF is limited mainly to 
macrophages and T lymphocytes (Akira et al 1990a). TNF may consequently only be 
present during a ‘developed’ inflammatory response.
The ability of agents that elevate intracellular cAMP to differentially regulate IL-6 , IL- 8  
and RANTES production in IL-1 or TNF stimulated human MC argues against a role 
for cAMP as a major second messenger in mediating IL-1 or TNF signal transduction. 
However these findings, together with other published studies indicate cAMP is an 
important regulator of IL-1 and TNF activity, and cytokine expression in general. The 
effects of cAMP elevation on MC cytokine production is summarized in table 8 , which 
includes the work presented in this thesis, together with the findings of Satriano et al
(1993) and Rovin and Tan (1994) relating to MCP-1 production. Similar studies have 
demonstrated differential regulation of T lymphocyte-derived cytokines by cAMP- 
elevating agents, production of IL-2 was downregulated, IL-3 and IL-4 were unchanged, 
while IL-5 was increased (Snijdewint et al 1993). Interestingly, a role for the guanine 
nucleotide, cGMP in regulating IL-1 induced IL- 8  production in human MC (Brown et 
al 1993b) and IL-3 production by T lymphocytes has also been suggested 
(Marcinkiewicz & Chain, 1993), although cGMP had opposing effects to cAMP. Thus 
a balance between the intracellular levels of these two nucleotides may be involved in a 
fine tuning of cytokine release. In vivo, the intracellular levels of cAMP and cGMP in 
human MC, and other cell types may be regulated by endogenous or exogenous PGE2  
and NO production.
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Effect o f  cAMP on IL-1 induced cytokine 
production
Effect o f cAMP on TNF induced cytokine 
production
IL-6 t IL-6 T
IL-8 — IL-8 —
RANTES — RANTES i
MCP-1 1 MCP-1 i
Table 8. Sum mary o f the effects o f elevation o f intracellular cAM P on IL-1 or TNF induced 
cytokine production in MC.
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The present study demonstrates an ability of human MC to express the inducible nitric 
oxide synthase enzyme. In comparison to rodent MC, iNOS mRNA and protein 
expression was only induced in human MC following stimulation with a combination of 
cytokines, IL-1 and IFN-y, or IL-1, IFN-y and TNF. The regulation of iNOS activity in 
human MC however, appears complex, since despite significant iNOS mRNA and 
protein expression, production of NO could not be readily detected using a range of 
nitrite assays. Intriguingly, my findings contrast with two recent reports which describe 
pM amounts of nitrite production by human MC following stimulation with a 
combination of IL-1, IFN-y and TNF (Nicolson et al 1993; Saura et al. 1996). Clearly, 
further investigations into the regulation of iNOS activity in human MC is required, and 
until the isoforms of NOS expressed by MC and their regulation has been characterised, 
the potential role of NO as an endogenous regulator of chemokine expression in human 
MC remains unresolved.
The bacterial agent, pertussis toxin was found to inhibit both IL-1 induced IL- 8  and IL- 6  
production in MC. This property of the toxin appeared to be unrelated to its ability to 
ADP-ribosylate and inactivate Gi/o type proteins. Furthermore, cholera toxin, the 
bacterial agent which activates the cAMP signal transduction pathway through 
modification of Gs by ADP-ribosylation was found to upregulate MC cytokine 
production by both cAMP dependent and independent mechanisms. Taken together, 
these findings suggest that while the toxins remain useful tools for investigating signal 
transduction pathways, their mechanism of action is not specific and thus care must be 
taken when interpreting their effects in a system. Use of the control reagent, the B 
oligomer is paramount in studies which employ these toxins to provide some indication 
whether their mechanism of action is G protein dependent.
Renewed interest in the use of phosphodiesterase inhibitors as a therapeutic approach to 
certain inflammatory disorders has stemmed from the observations that PDE inhibitors 
can effectively suppress TNF production in endotoxin stimulated human mononuclear 
cells (Semmler et al 1993b; Semmler et al 1993a; Schade & Schudt, 1993) and IL- 6  
production in IL-1 stimulated human lung fibroblasts (Zitnik et al 1993), via elevation 
of intracellular cAMP. The findings presented in this thesis support a pharmacological
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potential for PDE inhibitors, since agents which elevated intracellular cAMP selectively 
modified human MC cytokine production. These agents exerted antiinflammatory 
effects by suppressing expression of the C-C chemokines, RANTES and MCP-1 (Rovin 
& Tan, 1994; Satriano et al 1993) in cultured MC, thus these agents may act to reduce 
monocyte and T lymphocyte glomerular infiltration in vivo. In addition, the cAMP- 
elevating agents significantly upregulated MC IL- 6  production, a cytokine with both 
proinflammatory and antiinflammatory properties. The regulatory effects of cAMP on 
cytokine production however, appear to be cell specific, since cAMP-elevating agents 
had opposing effects on IL-1 induced IL- 6  production in human MC and human lung 
fibroblasts (Zitnik et al. 1993). Thus the beneficial effects of such treatment will be 
dependent upon the target cells, the importance of individual cytokines in the disease 
process and the net effect of cAMP elevation on the cytokine network.
The findings presented in this thesis lend support to the hypothesis that activated MC 
play a direct role in the initiation and propagation of inflammatory events within the 
glomerulus via the generation of inflammatory mediators. The release of chemokines 
by intrinsic glomerular cells may be important in initiating an influx of leukocytes into 
the injured tissue, as well as contributing to the progression of inflammatory renal 
injury. Since chemokines appear to be relatively selective in their actions compared 
with many other inflammatory mediators, they have been regarded as promising targets 
for the development of anti-inflammatory therapies. Understanding the intracellular 
mechanisms that regulate chemokine production in glomerular cells will enhance the 
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APPENDIX I. GENERAL BUFFERS
Unless otherwise stated all standard laboratory reagents were obtained from Fisons pic 
(Loughborough, UK), BDH Laboratory supplies (Poole, UK) or Sigma Chemical Co. 
(Poole, UK).





1 M Potassium phosphate buffer, pH 7.5
0.7 M K2HP04 
0.3 M KH2P04
0.15 M Potassium phosphate buffer, pH 7.5
0.105 M K2HP04 
0.045 M KH2P04
100 mM HEPES buffer, pH 8.5
1 M HEPES buffer solution (Gibco BRL, Paisley, UK) was diluted 1:10 in double­
distilled water.
2 0 2
APPENDIX TT. CELL CULTURE REAGENTS
All solutions for cell culture were prepared using Steripak sterile, pyrogen-free distilled 
water (Steripak Ltd, Cheshire, UK).
lx  PBS, pH 7.4
2+ 2+10x sterile PBS (without Ca and Mg ) (Gibco) was diluted 1:10 in water. No need to 
pH.
Hanks Balanced Salts Solution (HBSS), pH 7.4 (for MC isolation, see 2.4.1)
100 ml lOx Hanks’ balanced salts (Gibco)
6 ml 7.5% sodium bicarbonate (Gibco)
20 ml 1 M HEPES buffer solution (Gibco)
200 pi 40% (w/v) NaOH
500 pi 10 mg/ml Gentamicin (Gibco)
Make up to 1 L with distilled water. No need to pH.
Culture media
Way mouths medium MB752/1 (Gibco) was supplemented with penicillin-streptomycin 
(10 U/ml and 10 pg/ml, respectively) (Gibco) and fungizone (0.5 pg/ml) (Gibco) before 
use.
Dulbeccofs Modified Eagles Medium (DMEM), without phenol red (used during 
nitrite determinations) was supplemented with penicillin-streptomycin (10 U/ml and 10 
pg/ml, respectively), fungizone (0.5 pg/ml) and 2 mM glutamine (Gibco) before use.
Foetal Calf Serum (FCS)




2% gelatin solution, type B from bovine skin (cell culture grade) (Sigma) was diluted 
1:1 with water.
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APPENDIX TIT. ELISA BUFFERS





Carbonate coating buffer, pH 9.6 (For IL-8 and RANTES ELISA)
15 mM Na2C 03 
35 mMNaHC03
IL-6 wash buffer, pH 7.2
2.5 mM NaH2P04
7.5 mM Na2HP04 
0.5 M NaCl
0.1% (v/v) Tween-20




8.1 mM Na2HP04 
0.05% (v/v) Tween-20
0.1 M Citric acid-phosphate substrate buffer, pH 5 (For IL-6 and RANTES ELISA) 
34 mM citric acid 
66 mM Na2HP04
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Diethanolamine substrate buffer, pH 9.8 (For IL-8 ELISA) 
10% (v/v) diethanolamine (BDH)
1 mM MgCl2 
Store in the dark, at 4°C.
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APPENDIX TV. REAGENTS FOR NORTHERN ANALYSIS
DEPC-treated water or buffer
1 ml of diethyl pyrocarbonate (DEPC) (Sigma) was added per litre of double-distilled 
water or buffer and incubated overnight at 37°C. Autoclave (15-20 lb/in 2 for 20 
minutes at 121°C).
0.75 M Sodium citrate solution, pH 7.0
0.75 M trisodium citrate dihydrate 
in double-distilled water. Autoclave.
20% (w/v) SDS solution
20 g SDS dissolved in 100 ml sterile double-distilled water.
2 M TRIS-HC1 stock solution, pH 8
2 M Tris(hydroxymethyl)aminomethane (TRIS) 
in double-distilled water. Autoclave.
0.5 M EDTA stock solution, pH 8
0.5 M Ethylenediamine-tetraacetic acid, disodium salt (EDTA) 
in double-distilled water. Autoclave.
Nucleic acid extraction buffer
4 M guanidine thiocynate (Fluka, Gillingham, UK)
25 mM sodium citrate 
0.5% sarcosyl
in sterile double-distilled water.
Add 0.1 M 2-mercaptoethanol (0.36 ml/50 ml) prior to use. Use buffer containing 2- 
mercaptoethanol within 1 month. Store at 4°C.
(17.6 ml of 0.75 M stock/500 ml) 
(8.3ml of 30% stock (BDH)/500ml)
2 0 7
Phenol extraction buffer
100 mM TRIS (25 ml of 2 M stock/500 ml) 
(10 ml of 0.5 M stock/500 ml) 
(25 ml of 20% stock/500 ml)
10 mM EDTA
1% SDS
in double-distilled water. Autoclave.
3M Sodium acetate, pH 5.2
3 M sodium acetate dissolved in 250 ml double-distilled water.
Adjust pH to 5.2 using 3 M glacial acetic acid (requires approximately 200 mis) 
DEPC-treat and autoclave.
75% (v/v) Ethanol solution
75 ml absolute ethanol (Hayman Ltd, Witham, UK) in 25 ml DEPC-treated water 
20X MOPS running buffer
0.4 M 3-[N-morpholino]propane-sulphonic acid (MOPS)
0.02 M EDTA (4 ml of 0.5 M stock/100 ml)
0.2 M sodium acetate (6.64 ml of 3 M stock/100 ml)
Adjust volume to 100 ml with double-distilled water and pH with ~ 0.85 g solid NaOH. 
Filter sterilize.
lx  MOPS running buffer
50 ml 20x MOPS in 950 ml DEPC-treated water.
1 mg/ml Ethidium bromide solution
10 mg ethidium bromide (Sigma) in 10 ml DEPC-treated water
2 0 8
RNA Sample buffer (per sample)
7 pi formaldehyde 
4 pi 20x MOPS running buffer
2 pi 1 mg/ml ethidium bromide solution 
20 pi formamide (mol. biol. grade, BDH)
Made up fresh immediately before use.
Bromophenol blue solution
0.001 g bromophenol blue
3 ml glycerol
Adjust volume to 10 ml with DEPC-treated water.
20X SSC, pH 7 
3 M NaCl
0.3 M trisodium citrate dihydrate 
in double-distilled water. DEPC-treat and autoclave.
Buffer 1
0.1 M maleic acid 
0.15 M NaCl
Adjust to pH 7.5 with ~ 75 g solid NaOH. DEPC-treat and autoclave.
Blocking stock solution
10 g (w/v) blocking reagent (Boehringer Mannheim, Lewes, UK) in 100 ml of buffer 1. 





1% blocking buffer 
in DEPC-treated water.
(25 ml of 20X stock/100 ml) 
(0.33 ml of 30% stock/100 ml) 
(0.1 ml of 20% stock/100 ml) 
(10 ml of 10% stock/ 100 ml)
209
2X SSC , 0.1% SDS solution
50 ml of 20X SSC
2.5 ml of 20% SDS stock
Adjust volume to 500 ml with DEPC-treated water.
0.1X SSC, 0.1% SDS solution
2.5 ml of 20X SSC
2.5 ml of 20% SDS stock
Adjust volume to 500 ml with DEPC-treated water.
Washing buffer
0.3% (v/v) Tween-20 in buffer 1
Buffer 2
10% (v/v) blocking stock solution in buffer 1
Buffer 3, pH 9.5
0.1 MTRIS 
0.1 MNaCl
in sterile double-distilled water.
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APPENDIX V. REAGENTS FOR SDS-PAGE AND WESTERN BLOTTING
1.5 M TRIS-HC1, pH 8 . 8
1.5MTRIS
in double-distilled water.
0.5 M TRIS-HCI, pH 6 . 8
0.5 M TRIS
in double-distilled water.
10% (w/v) SDS solution
5 g of SDS in 50 ml double-distilled water.
10% (w/v) Ammonium persulphate solution
0 . 1  g ammonium persulphate in 1  ml double-distilled water. 
Made up fresh on day
Electrophoresis buffer
25 mM TRIS 
192 mM glycine 
0.1% SDS
IX Electrophoresis sample buffer
1 ml 1.5 M TRIS-HCI, pH 8 . 8  
0 . 8  ml glycerol
1.6 ml 10% SDS solution 
0.4 ml 2-mercaptoethanol
4.2 ml double-distilled water
0.01 g bromophenol blue (Bio-Rad)
Sample buffer was stored at room temperature for up to 1  week.
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Coomassie blue stain
40% (v/v) methanol 
7% (v/v) acetic acid




7% acetic acid 
in distilled water.
Transfer Buffer
25 mM TRIS 
192 mM glycine 
20% methanol
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APPENDIX VI- DRUG SOLUTIONS
CYTOKINES
g
Recombinant human IL -la  (specific activity 3x10 U/mg), a gift from Hoffman La 
Roche (Nutley, New Jersey) was diluted in sterile PBS + 0.25% (w/v) bovine serum 
albumin (BSA, low endotoxin) to 10 pg/ml and stored in aliquots at -20°C. 
Recombinant human IL-1B (specific activity 1.2xl07 U/mg), a gift from Glaxo 
(Greenford, UK) was diluted in PBS + 0.25% BSA to 1 pg/ml and stored in aliquots at - 
20°C.
Recombinant human TNFa (specific activity 6xl07 U/mg), a gift from Bayer (Slough, 
UK) was diluted in PBS + 0.1% BSA to 100 pg/ml and 500 pg/ml and stored in aliquots 
at -70°C.
Recombinant human IFN-y (specific activity >2.0x10 U/mg) was purchased from 
Boehringer Mannheim and stored in aliquots at -20°C.
Recombinant human IL-1 receptor antagonist (IL-lra) was supplied by Synergen 
INC (Boulder, Colorado, USA) and stored at 5 mg/ml in PBS + 0.25% BSA in aliquots 
at -20°C.
All cytokines were further diluted in Waymouths medium immediately prior to use.
COMPOUNDS WHICH ELEVATE INTRACELLULAR cAMP 
Forskolin (Sigma) was dissolved in dimethylsulphoxide (DMSO, cell culture grade, 
Sigma) to 100 mM and stored in the dark at room temperature. This stock was further 
diluted in Waymouths medium immediately prior to use. To prevent precipitation, it 
was necessary to initially add the forskolin to a few ml of Waymouths medium with 
agitation, before further diluting.
Dibutyryl cAMP (Db-cAMP) (Sigma) was dissolved in sterile distilled water to a 
concentration of 5 mg/ml and stored in aliquots at -20°C. Further dilutions were made 
in Waymouths medium immediately prior to use.
3-Isobutyl-l-methyl-xanthine (IBMX) (Sigma) was dissolved in warmed (37°C) 
Waymouths medium to a concentration of 1 mM on the day required. Further dilutions 
were made in Waymouths medium.
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RO 20-1724 (Calbiochem, Nottingham, UK) was dissolved in DMSO to a concentration 
of 200 mg/ml and stored in aliquots at -20°C. Further dilutions were made in 
Waymouths medium immediately prior to use.
BACTERIAL TOXINS
Cholera toxin (CT) (Gibco), cholera toxin B oligomer (CT-B) (Gibco and Sigma), 
pertussis toxin (PT) (Gibco) and pertussis toxin B oligomer (PT-B) (Gibco) were 
reconstituted in sterile distilled water to 1 mg/ml., 0.5 mg/ml, 0.1 mg/ml and 1 mg/ml 
respectively and stored at 4°C for either 2 months (PT, PT-B) or 6 months (CT, CT-B). 
Recombinant pertussis toxin (55 pg/ml stock in PBS) was a gift from Dr Luke 
O’Neill, Trinity College, Dublin and was made by Sclavo Ltd (Sienna, Italy).
Mutated pertussis toxins, PT/R9 E and PT/R9 ENK (300 and 150 pg/ml in PBS 
respectively) were a gift from Dr Yves Lobet, SmithKline Beecham, Rixensart, 
Belgium. All toxins were further diluted in Waymouths medium immediately prior to 
use.
MISCELLANEOUS COMPOUNDS
Lipopolysaccharide (LPS) (serotype 0111 :B4) (Sigma) was reconstituted in sterile 
PBS and stored in aliquots at -20°C
Indomethacin (Sigma) was dissolved in absolute ethanol to a concentration of 10 
mg/ml on the day required. Further dilutions were made in Waymouths medium . 
Actinomycin D (AcD) (Sigma) was dissolved in DMSO to 5 mg/ml and stored in 
aliquots at -20°C for a maximum of 1 month. Further dilutions were made in 
Waymouths medium immediately prior to use. Aliquots were then discarded. 
Cycloheximide (CHX) (Sigma) was dissolved in Waymouths medium immediately 
prior to use.
Phalloidin-FITC conjugated (Sigma) was dissolved in PBS to 0.5 mg/ml and stored in 
aliquots at -20°C. Further dilutions were made in PBS immediately prior to use.
4-hydroxy-3-methoxyacetophenone (HMAP or acetovanillone) (Aldrich chemical Co. 
Ltd, Gillingham, UK) was dissolved in warmed (37°C) Waymouths medium to 1.2 mM 
on the day required. Further dilutions were made in Waymouths medium.
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Superoxide dismutase (SOD) (Sigma) was dissolved in PBS to 15,000 U/ml and stored 
in aliquots at -20°C. Further dilutions were made in Waymouths medium immediately 
prior to use.
Pyrrolidinedithiocarbamate (PDTC) (Sigma) was dissolved in Waymouths medium to 
0.1 M on the day required. Further dilutions were made in Waymouths medium.
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